Improving Outcomes in Hypertrophic Cardiomyopathy by Vriesendorp, P.A. (Pieter)
Improving Outcomes in 
Hypertrophic Cardiomyopathy
Pieter Adriaan Vriesendorp
Improving outcomes in hypertrophic cardiomyopathy
Copyright © P. A. Vriesendorp, Rotterdam, the Netherlands 2016
ISBN 978-94-6299-403-4
Layout and printing: Ridderprint b.v., Ridderkerk, the Netherlands
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or 
transmitted, in any form or by any means, without the written permission of the author, or, 
when appropriate, of the publishers of the publications.
Financial support for this thesis was generously provided by:
Cardialysis BV
Biotronik Nederland BV
Servier
ABN AMRO
Astra Zeneca
Boehringer Ingelheim
St. Jude Medical
Erasmus Universiteit Rotterdam
TomTec Imaging Systems
Financial support by the Dutch Heart Foundation for the publication of this thesis is grate-
fully acknowledged
Improving Outcomes in 
Hypertrophic Cardiomyopathy
Verbeteren van uitkomsten in hypertrofische 
cardiomyopathie
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
dinsdag 6 september 2016 om 13.30 uur
door
Pieter Adriaan Vriesendorp
geboren te Groningen
PrOmOtIeCOmmIssIe
Promotor
prof.dr. F. Zijlstra
Overige leden
prof.dr. A.J.J.C. Bogers
prof.dr. R.J.M. van Geuns
prof.dr. J. van der Velden
Copromotoren
dr. M. Michels
dr. A.F.L. Schinkel
ἄλλος γάρ τ᾽ ἄλλοισιν ἀνὴρ ἐπιτέρπεται ἔργοις.
Homer, the Odyssey (14:228)

7Table of Contents
tABLe OF CONteNts
I – Introduction
 General introduction and outline of the thesis 11
II – Invasive treatment of symptomatic left ventricular outflow tract obstruction
1 Long-term outcome after medical and invasive treatment in patients with 
hypertrophic cardiomyopathy 23
 JACC Heart Fail. 2014
 editorial:
 Revisiting arrhythmic risk after alcohol septal ablation: is the pendulum finally 
swinging…back to myectomy? 38
2 A systematic review and meta-analysis of long-term outcomes after septal 
reduction therapy in patients with hypertrophic cardiomyopathy 45
 JACC Heart Fail. 2015
3 Long-term benefit of myectomy and anterior mitral leaflet extension in 
obstructive hypertrophic cardiomyopathy 71
 Am J Cardiol. 2015
4 Completely percutaneous repair of a failing surgical mitral valve repair 85
 Eur Heart J. 2015
5 Combining myectomy and mitral leaflet extension in the treatment of a true 
obstructive cardiomyopathy patient 89
6 Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in 
patients with hypertrophic cardiomyopathy 95
 Catheter Cardiovasc Interv. 2016
7 Long-term outcome of alcohol septal ablation for obstructive hypertrophic 
cardiomyopathy in the young and the elderly 111
 JACC Cardiovas Interv. 2016
8Table of Contents
 editorial:
 Patient selection for alcohol septal ablation: does age matter? 124
8 Microsphere embolisation as an alternative for alcohol in percutaneous 
transluminal septal myocardial ablation 129
 Neth Heart J. 2013
III – Prediction and prevention of sudden cardiac death
9 Validation of the 2014 ESC guidelines risk prediction model for the primary 
prevention of sudden cardiac death in hypertrophic cardiomyopathy 139
 Circ Arrhythm Electrophysiol. 2015
 editorial:
 Prophylactic implantable defibrillators for hypertrophic cardiomyopathy: disarray 
in the era of precision medicine. 155
10 Impact of adverse left ventricular remodeling on the risk of sudden cardiac death 
in patients with hypertrophic cardiomyopathy 163
 Clin Cardiol. 2014
11 Outcome and complications after implantable cardioverter defibrillator therapy in 
hypertrophic cardiomyopathy: systematic review and meta-analysis. 175
 Circ Heart Fail. 2012
12 Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient 
outcomes, rate of appropriate and inappropriate interventions, and complications. 191
 Am Heart J. 2013
IV – Clinical implications of sarcomeric mutations
13 Incremental value of genetic testing for the prediction of outcome in in patients 
with hypertrophic cardiomyopathy 209
 Am J Cardiol. 2016
14 Follow-up of adult patients with preclinical hypertrophic cardiomyopathy 229
15 Positive correlation between contractile dysfunction of the sarcomere and 
impaired regional systolic strain in hypertrophic cardiomyopathy. 243
9Table of Contents
V – Discussion
 Discussion 259
 Nederlandse samenvatting 275
VI – Epilogue
 List of publications 293
 Dankwoord 295
 About the author 299
 COEUR PhD Portfolio 301

12
3
4
5
6
7
8
9
10
11
12
13
14
15
I – Introduction

13
Introduction
GeNerAL INtrOduCtION
Hypertrophic cardiomyopathy (HCM) is the most common (prevalence of 0.2%-0.5%) in-
heritable myocardial disease[1, 2], and is defined by left ventricular hypertrophy that is not 
explained by other conditions such as hypertension or aortic valve stenosis (figure 1). HCM 
is a heterogeneous disease with a diverse spectrum of clinical manifestations. Patients may 
remain asymptomatic and have a normal life expectancy. A small subgroup of patients with 
HCM however may suffer from sudden cardiac death (SCD) as the first presentation. Other 
common symptoms are exertional dyspnea, chest pain, syncope and palpitations. The under-
lying pathophysiology exists of several components: left ventricular outflow tract obstruction, 
diastolic dysfunction, mitral regurgitation, myocardial ischemia, and atrial and ventricular 
arrhythmias.
First description of HCm
The modern description of this disease is credited to Donald Teare, a London pathologist 
who published his observations in 1958 in the British Heart Journal[3], and the compre-
hensive report by Eugene Braunwald in 1964 in Circulation.[4] However the concept of a 
hypertrophic heart disease was not new. Already in the Renaissance, several pieces of the 
puzzle were described.[5] William Harvey (1578-1657), the physician of the King of England, 
demonstrated in 1628 that the heart is a pump which causes blood to circulate through the 
body, an important breakthrough in the history of medicine. He also described a nobleman 
who was troubled by palpitations, chest pain, syncope and:
[…] the circulation of the blood being obstructed from the left ventricle in the artery.[6]
figure 1 – Parasternal long and short axis 2D echocardiogram illustrating asymmetrical hypertrophy 
in a patient with HCM.
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Other important contributions came from two Italian physicians: Giovanni Lancisi (1654-
1720) and Giovanni Morgagni (1682-1771). Lancisi, the physician of Pope Clement XI, 
reported deaths due to left ventricular hypertrophy in his work on sudden death: De subitaneis 
mortibus, and was the first to mention a hereditary component in the disease.[7] Morgagni, 
celebrated as the father of modern anatomical pathology, continued on this work and in De 
sedibus et causis morborum per anatomen indigatis he wrote:
 A coachman died suddenly in his carriage whose heart was larger than that of any bullock, 
another sudden death of a heart far exceeding its natural bulk.[8]
Further groundwork was laid in the 18th and 19th century by several French and German physi-
cians[5], and with each description of the disease a new or alternative name was proposed. 
After the reports by Teare and Braunwald, >80 different terms had been used, varying from 
‘primary muscular left sided conus stenosis?’, ‘asymmetrical hypertrophy of the heart’ (by 
Teare), idiopathic hypertrophic subaortic stenosis (by Braunwald), and ‘hypertrophic (ob-
structive) cardiomyopathy’. After its introduction in 1979 HCM has become the predominant 
formal term to describe this disease.[9, 10]
diagnosis of HCm
In the following ±35 years the clinical perception of HCM has changed. It appeared to be an 
exotic disease with high mortality, and “no method of management that can specifically and 
favorably influence the course of a patient”.[11, 12] But in these last 3 decades, scientific and 
technical advancements have altered the clinical course of patients with HCM.[12]
Improvement in imaging techniques facilitated a better and more early diagnosis. Until 
the development of echocardiography, diagnostic left ventricular catheterization was neces-
sary to diagnose HCM. Electrocardiograms (ECG) in suspected patients showed signs of 
left ventricular hypertrophy, and ST- and T-wave abnormalities. It remained a sensitive but 
not-specific test, and the diagnosis could not be based on an abnormal ECG alone. When 
echocardiography came available, the diagnosis of HCM could be established safe and 
painless, but it could also characterize HCM much more precise. The asymmetry of the 
ventricular hypertrophy was easily demonstrated, in M-mode echocardiography. [13, 14] 
The ease of use of echocardiography, especially after development of 2D echocardiography 
led to its prominent position in the diagnosis and follow-up of patients with HCM. (figure 
1) It could also be used in asymptomatic family members to assess if they also had HCM.
[14] Because a familial association with HCM was already suspected, and in 1961 Pare et al 
published a report describing a large family with HCM (in the report the disease is called he-
reditary cardiovascular dysplasia), and its transmission appeared to be autosomal dominant.
[15] In 1989 the first pathogenic mutation was identified in the myosin heavy chain gene by 
Seidman et al.[16] Subsequent research had led to the discovery of >1500 mutations in > 20 
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genes and has increased the understanding of the complexity as well as the diversity of the 
disease.[17]
therapeutic strategies
Initially therapeutic options were limited, but advancement in invasive techniques have also 
given us the possibility to treat patients diagnosed with HCM, especially in patients with 
extensive left ventricular outflow tract obstruction. Most symptoms related to this obstruc-
tion can be relieved by abolishing the obstruction, either by medical therapy or invasive septal 
reduction therapy. Medical therapy should be the first step in management of symptoms, and 
beta-blockers are the first line drugs to treat symptomatic LVOT obstruction. Alternatives 
such as verapamil and disopyramide are useful if beta-blocker therapy is causing side-effects 
or is ineffective. Invasive septal reduction therapy should only be considered for patients with 
severe, drug-refractory symptoms despite optimal medical therapy.[1]
Surgical myectomy was developed in 1961, a high risk procedure then, and only reserved 
for very symptomatic patients. Improvement of surgical techniques and periprocedural 
care made surgical myectomy a safe and effective procedure.[18-20] However, myectomy is 
open-heart surgery with relatively long rehabilitation, so in 1995 alcohol septal ablation, a 
percutaneous alternative, was developed. [21] This strategy was quickly adopted all over the 
world and the numbers of patients who received alcohol septal ablation quickly outnumbered 
the patients who underwent myectomy.[21-26] Concerns about alcohol septal ablation remain 
however, especially about the arrhythmogenic effect of the ablation scar in patients already at 
an increased risk of life-threatening arrhythmias.(figure 2)[27-30]
Finally, the breakthrough of implantable cardioverter defibrillators (ICD) have further 
improved the prognosis of patients with HCM. In the 1980’s the first report on ICDs by 
Mirowski et al. [31] was published. Interestingly, 3 of the 5 patients described herein, were 
patients with HCM and had survived 2 (!) cardiac arrests. The initial development of the de-
vice was focused on patients with ischemic heart disease, but in the last two decades more and 
more evidence demonstrated the efficacy of the ICD in patients with HCM in both primary 
and secondary prevention of SCD.[32-34] Nowadays the ICD is recommended in a selected 
group of HCM patients with increased SCD risk, a mere 300 years after the first description 
of this problem.[1, 10]
figure 2 – An example of ventricular fibrillation.
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OutLINe OF tHe tHesIs
Several important questions in the management of the patient with HCM remain. The aim 
of this thesis is to approach these questions in a similar manner as we approach a patient with 
HCM. After a newly diagnosed patient presents itself, it is important to discuss the charac-
teristics of the disease, the prognosis, and avoidance of competitive sports; and if necessary, 
medication can be started to treat symptoms. If optimal medical therapy remains insufficient, 
and patients remain severely symptomatic, an invasive approach should be considered. The 
next step is to improve the prognosis and prevent SCD in our patient. Finally, it is important 
to realize that behind every HCM patient is a potential HCM family; clinical and genetic 
screening can be used to identify family members at risk.
In part II, we consider the invasive treatment of symptomatic left ventricular outflow 
tract obstruction. Although a large subset of patients will remain asymptomatic during their 
lifetime, in most cases HCM will be diagnosed when a symptomatic patient visits the out-
patient clinic. These symptoms, such as dyspnea on exertion, chest pain, or syncope can 
be related to left ventricular outflow tract obstruction (figure 1). The obstruction can be 
present during rest or after provocation, and 70% of the HCM population has obstructive 
physiology.[35] The first step is to alleviate symptoms by using beta-receptor antagonists, 
calcium channel blockers or disopyramide. If optimal medical therapy fails, an invasive ap-
proach is indicated. This can be a surgical or a percutaneous procedure. In chapter 1 and 
chapter 2 we evaluated and compared the long-term outcomes of both surgical myectomy 
and alcohol septal ablation. If there is concomitant mitral valve dysfunction, surgical myec-
tomy can be combined with anterior mitral leaflet extension. This approach was developed in 
the Erasmus MC by van Herwerden, ten Cate, and de Jong,[36, 37] and the long term results, 
complications and examples of this surgical approach are described in chapter 3 – 5. Alcohol 
septal ablation was developed 20 years ago, but concerns of increased risk of life-threatening 
arrhythmias remain. In chapter 6 we evaluate the effect of high and low alcohol dosages 
used during the procedure. chapter 7 describes the outcomes of alcohol septal ablation in 
the young and elderly. In chapter 8 we explore the possibility of an alternative for alcohol, in 
this case septal microsphere embolization, to reduce procedure related arrhythmias.
The prevention and prediction of SCD in HCM is discussed in part III. SCD is a devastat-
ing expression of HCM, but the annual risk is low (<1%). There is a subset of patients with 
HCM at increased risk of sudden cardiac death, but identification of these patients may be 
challenging. In chapter 9 we evaluate and validate the most recent risk prediction model, 
and the role of adverse left ventricular remodeling is analyzed in chapter 10. ICDs can be 
used to prevent SCD, but this protection comes at a price of inappropriate shocks and device 
related complications. Our own results and a systematic review of ICD studies are discussed 
in chapter 11 and 12.
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Part IV considers the clinical implications of sarcomeric mutations. Genetic testing is 
used to identify family members at risk. In chapter 13 we determine the incremental value 
of genetic testing, and to see if presence of a pathogenic sarcomere mutation affects outcome. 
The increased access to genetic screening has revealed family members with a pathogenic 
mutation, but without left ventricular hypertrophy. Follow-up of individuals with preclinical 
HCM is described in chapter 14. Finally, in chapter 15 we set out to improve our under-
standing of genotype-phenotype relations.
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Chapter 1
Long-term outcome after medical and invasive 
treatment in patients with hypertrophic 
cardiomyopathy
Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel 
AF, Willems R, Ten Cate FJ, van Cleemput J, Ten Berg JM, 
Michels M
JACC Heart Fail. 2014 Dec;2(6):630-6
Chapter 1
24
ABstrACt
Objectives
The aim of this study is to determine the long-term outcomes (all-cause mortality and sudden 
cardiac death (SCD)) after medical therapy, alcohol septal ablation (ASA) or myectomy in 
patients with hypertrophic cardiomyopathy (HCM).
Background
Therapy-resistant obstructive hypertrophic cardiomyopathy (HCM) can be treated both 
surgically and percutaneously. But there is no consensus on the long-term effects of ASA, 
especially on SCD.
methods
This study included 1047 consecutive HCM patients (age 52 ±16 years, 61% male) from 3 
tertiary referral centers. A total of 690 patients (66%) had a left ventricular outflow tract 
gradient ≥30 mmHg, of them 124 (12%) were treated medically, 316 (30%) underwent ASA 
and 250 (24%) underwent myectomy. Primary endpoints were all-cause mortality and SCD. 
Kaplan-Meier graphs and Cox-regression models were used for statistical analyses.
results
Follow-up was 7.6 ± 5.3 years. The 10-year survival was similar in medically treated patients 
(84%), ASA patients (82%), myectomy patients (85%), and non-obstructive HCM patients 
(85%, log-rank p=0.5). Annual SCD-rate was low after invasive therapy: 1.0%/year in the ASA 
group, and 0.8%/year in the myectomy group. Multivariable analysis demonstrated that the 
risk of SCD was lower after myectomy compared with the ASA group (HR 2.1 [1.0-4.4], 
p=0.04), and the medical group (HR 2.3 [1.0-5.2], p=0.04).
Conclusions
Patients with obstructive HCM that are treated in referral centers for HCM care have a good 
survival and low SCD risk, similar to that of non-obstructive HCM patients. The SCD risk of 
patients after myectomy was lower than after ASA or in the medical group.
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INtrOduCtION
Hypertrophic cardiomyopathy (HCM) is the most prevalent inheritable myocardial disease, 
and (provocable) left ventricular outflow tract (LVOT) obstruction is present in the majority 
of HCM patients (±70%).[1] Not only is LVOT obstruction associated with symptoms such 
as dyspnea on exertion, fatigue, chest pain or syncope, but previous studies have also demon-
strated that the presence of obstruction increases all-cause mortality and the occurrence of 
sudden cardiac death (SCD) in these patients,[2, 3] and it is included as a risk factor in the 
novel clinical risk prediction model presented by the HCM Outcomes Investigators.[4]
Therapy-resistant obstructive HCM can be treated both surgically and percutaneously 
and during the last years there is an intense and polarizing debate to define the best strategy.
[5-8] Surgical approaches have been used for over 5 decades, and in experienced centers 
relief of obstruction can be achieved with minimal perioperative morbidity and mortality.
[9-11] However, myectomy is open-heart surgery with relatively long rehabilitation, so in 1995 
alcohol septal ablation (ASA), a percutaneous alternative, was developed. [12] This strategy 
was quickly adopted all over the world and the numbers of patients who received ASA quickly 
outnumbered the patients who underwent myectomy.[5-8, 12, 13] In some European coun-
tries ASA has fully replaced myectomy.[7] Concerns about ASA remain however, especially 
about the arrhythmogenic effect of the ablation scar in patients already at an increased risk of 
life-threatening arrhythmias.[14-17]
Although a randomized controlled trial does not seem feasible[18], and recent meta-
analyses[19, 20] only evaluated short-term SCD rate and survival, there is no consensus on the 
long-term outcomes of ASA.[17, 21-24] The aim of the current study is therefore to determine 
the long-term effects of medical treatment, ASA and myectomy on all-cause mortality and SCD.
metHOds
study design and population
An international multi-center, observational cohort design was used. The study conforms to 
the principles of the Helsinki Declaration. All patients gave informed consent for the inter-
vention, and local institutional review board approval was obtained.
The study population consisted of 1065 consecutive HCM patients from the University 
Hospital Leuven, Leuven, Belgium (n=200), St. Antonius Hospital Nieuwegein, Nieuwe-
gein, the Netherlands (n=318), and the Thoraxcenter, Erasmus Medical Center, Rotterdam, 
the Netherlands (n=547). Each patient had an established diagnosis of HCM, based on 
unexplained left ventricular hypertrophy of ≥15 mm, assessed by echocardiography.[25, 26] 
Patients with HCM linked to Noonan’s syndrome, Fabry’s disease, mitochondrial disease or 
congenital heart defects were excluded.
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The LVOT gradient was measured in all patients using continuous wave Doppler-echo-
cardiography, in rest and after provocative maneuvers. Patients were considered obstructive if 
LVOT gradient was ≥ 30 mmHg, at rest or after provocation. Invasive therapy was indicated if 
peak LVOT gradient was ≥ 50 mmHg, ventricular septal thickness ≥ 15 mm and persistent New 
York Heart Association (NYHA) class III/IV dyspnea, or Canadian Cardiovascular Society 
class III/IV angina despite optimal medical therapy.[26] Patients without an LVOT gradient 
≥30 mmHg after provocation were considered non-obstructive and used as a control group.
Patients with obstructive HCM were classified in three groups based on the clinical treat-
ment strategy: a medically treated group, an ASA group, and a myectomy group. Surgical 
septal myectomy was performed throughout the study period and as described previously[27, 
28] and the postoperative care was in accordance with local protocols. ASA was performed 
starting from 1999 as described previously.[28, 29] Afterwards, all patients were monitored 
for at least 24 hours at the intensive coronary care unit.
endpoints
The primary endpoints of this study were all-cause mortality and SCD-related events. The 
SCD endpoint was a composite endpoint, and consists of (1) instantaneous and unexpected 
death within 1 hour of a witnessed collapse in patients who were previously in a stable clini-
cal condition, or nocturnal death with no antecedent history of worsening symptoms; (2) 
successful resuscitation after cardiac arrest; (3) appropriate internal cardioverter defibrilla-
tor (ICD) intervention for ventricular fibrillation (VF) or for fast VT (>200 bpm); and (4) 
unknown cause of death. Unknown death was included in the SCD endpoint to estimate the 
maximal occurrence of SCD in the population. We also evaluated periprocedural arrhythmic 
events and mortality, re-interventions, LVOT gradient reduction, and implantation of ICDs.
Mortality and adverse events were retrieved from hospital patient records at the center 
where follow-up occurred, from civil service population registers, and from information 
provided by patients themselves or their general practitioners. Cardiac transplantation was 
considered a HCM-related death, and patients were censored at the time of transplantation. 
All ICD interventions were evaluated by an experienced electrophysiologist.
data collection and follow-up
Follow-up started at the time of intervention. In the medically treated cohort, follow-up 
started at the first outpatient clinic contact after January 1st, 1990. At baseline, all patients 
were evaluated for the following characteristics: NYHA class, maximum left ventricular 
wall thickness (LVWT), maximum (provocable) LVOT gradient, systolic and diastolic left 
ventricular function, and medication used. During follow-up, the established risk factors for 
SCD were evaluated.[25, 26] Other potential modifiers of SCD risk were also examined: atrial 
fibrillation and coronary artery disease. In patients treated with ASA, the dose of alcohol used 
was also collected.
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If no endpoints occurred during follow-up, final censoring date was set at November 1st, 
2012. If alternative septal reduction therapy was necessary (e.g. ASA after myectomy or vice 
versa) follow-up was censored at the date of the second intervention, due to the difficulty to 
attribute any later event to any intervention.
statistical Analysis
SPSS version 20 (IBM, Armonk, NY, USA) and Microsoft Excel 2010 (Microsoft Corpora-
tion, Redmond, WA, USA) were used for all statistical analyses. Categorical variables were 
summarized as percentages. Normality was assessed using the Shapiro-Wilk test combined 
with visual inspection of histogram and Q-Q plots. Normally distributed continuous data are 
expressed as mean ± standard deviation and non-normally distributed data are expressed as 
median (interquartile range). To compare continuous variables Student t test, Mann-Whitney 
U-test and 1-way ANOVA were used. When appropriate, post-hoc comparisons were carried 
out using Bonferroni correction. To compare categorical variables, the χ2-test was used. To 
identify clinical predictors of SCD mortality univariable and multivariable Cox regression 
analyses were used. Variables were selected for multivariable analysis if univariable p-value 
was < 0.10 and were expressed as hazard ratio (HR) with 95% confidence interval. The final 
number of variables was restricted according to the number of endpoint events to avoid 
overfitting the multivariable model. All tests were 2-sided and a p-value <0.05 was considered 
statistically significant.
resuLts
Baseline characteristics
table 1 lists the baseline characteristics of all patients. Of the 1065 patients (mean age 52 ± 16 
years, 61% male) included in this study, 716 (67%) had obstructive HCM; in 269 (25%) LVOT 
obstruction was only present after provocation. Of these 716 patients, 142 (20%) were treated 
medically, 321 (45%) underwent ASA and 253 (35%) underwent myectomy. Patients in the 
ASA group were older (58 ± 14 years) than in the surgery group (52 ± 16 years, p<0.001) and 
in the medical group (53 ± 15 years, p=0.001). The majority of medically treated patients (124, 
87%) reported no symptoms or mild (NYHA class I/II) symptoms at baseline, despite a mean 
LVOT gradient of 70 ± 32 mmHg. The other 18 patients (13%) had an indication for invasive 
treatment but were considered not eligible due to severe comorbidities (e.g. one patient had 
liver cirrhosis due to alcohol abuse and kidney failure) or patient refusal (several patients 
refused further invasive treatment, mostly because they were at old age, and preferred no 
further interventions). In this group mortality was high (8 deaths, 44%) and these patients 
were excluded from further analysis.
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The distribution of established risk factors for SCD, among the 3 intervention groups and 
controls, is shown in table 1. Complete risk stratification was not available for all patients: 
blood pressure response during exercise testing was available in 645 patients (61%), and docu-
mented rhythm information was available in 656 patients (62%). Significantly more patients in 
the myectomy group (44 patients (17%)) had ≥2 established risk factors for SCD than those in 
ASA group (32 patients (10%) p=0.009).
table 1 – Baseline characteristics of 1065 HCM patients.
n=
Medical
group ASA group
Myectomy
group
Control (non-
obstructive) group
142 321 253 349
Age, y 53 ± 15*** 58 ± 14*** 52 ± 16*** 46 ± 16
Female 54 (38)* 143 (45)*** 117 (46)*** 98 (28)
NYHA III/IV 18 (13) 249 (78)*** 165 (65)*** 40 (11)
Atrial fibrillation 21 (15)** 76 (24) 62 (25) 103 (30)
Coronary artery disease 4 (3) 18 (6)** 25 (10)** 12 (3)
Maximum LVWT, mm 20 ± 5 21 ± 5*** 21 ± 5*** 20 ± 5
LVOT gradient, mmHg 70 ± 32*** 102 ± 52*** 92 ± 39*** 9 ± 6
Systolic dysfunction (EF<50%) 17 (12) 18 (6)*** 18 (7)*** 63 (18)
Diastolic dysfunction 99 (70)** 130 (40)*** 105 (42)** 190 (54)
Medication
β-receptor antagonist 83 (58)* 218 (68)*** 167 (66)*** 166 (48)
Calcium-channel blocker 47 (33)*** 116 (36)*** 90 (36)*** 49 (14)
Risk factors
Survivor of sudden cardiac death 4 (3)* 7 (2)*** 8 (3)* 29 (8)
Sudden death in family history 23 (16) 24 (7)*** 42 (17) 81 (23)
Abnormal BP response 9 (6) 31 (10) 37 (15) 29 (8)
Maximum LVWT > 30 mm 9 (6) 22 (7) 18 (7) 19 (5)
Non-sustained VT 22 (15)** 41 (13)*** 37 (15) 98 (28)
Syncope 10 (7) 52 (16) 41 (16) 45 (12)
0 risk factors 87 (61)** 188 (59)** 136 (54)* 158 (45)
≥ 2 risk factors 15 (11)* 32 (10)** 44 (17) 66 (19)
* = P < 0.05; ** = P < 0.01; *** = P < 0.001 (compared with controls). Data represented as n (percentage) 
unless stated otherwise. ASA: alcohol septal ablation, BP: blood pressure, EF: ejection fraction, HCM: 
hypertrophic cardiomyopathy, LVWT: left ventricular wall thickness, LVOT: left ventricular outflow 
tract, NYHA: New York Heart Association, VT: ventricular tachycardia
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Procedural data
Invasive therapy was performed in 574 obstructive HCM patients. Periprocedural mortality 
was similar in ASA (5 patients, 1.6%) and myectomy (3 patients, 1.2%, p=0.7). In the first 30 
days post-procedure, ventricular arrhythmias occurred more frequently in the ASA group (11 
patients, 3.1%) than in the myectomy group (1 patient, 0.4%, p < 0.001). Cardiac resuscita-
tion was necessary in 7 ASA patients (2.2%). Residual LVOT gradient was measured after 3 
months, and was reduced after both ASA and myectomy: from 97 (66-130) mmHg to 10 (1-24) 
mmHg after ASA, and from 90 (70-100) mmHg to 9 (0-16) mmHg after myectomy. In 31 ASA 
patients (9.7%) additional septal reduction therapy was necessary, and this was higher than 
after myectomy (6 patients, 2.3%, p < 0.001; table 2)
table 2 – Invasive therapy in 574 HCM patients
n=
ASA group Myectomy group
321 253
Center
Leuven 18 (6) 28 (11)
Nieuwegein 209 (65) 109 (43)
Rotterdam 94 (29) 116 (46)
Procedural details
Volume of alcohol injected, median (IQR), mL 2.0 (1.0)† NA
Residual LVOT gradient, median (IQR), mmHg 10 (24) 9 (16)**
Reduction in LVOT gradient, % 87 ± 30 90 ± 19**
Redo septal reduction therapy 31 (9.7) 6 (2.3)***
Periprocedural arrhythmic event
Total 11 (3.1) 1 (0.4)***
Sudden cardiac death 3 (0.9) 1 (0.4)
Sustained VT 1 (0.3) 0 (0)
Resuscitated cardiac arrest 7 (2.2) 0 (0)
Periprocedural mortality
Total 5 (1.6) 3 (1.2)
Sudden cardiac death 3 (0.9) 1 (0.4)
Heart failure death 0 (0) 2 (0.8)
Cardiac tamponade 2 (0.6) 0
* = P < 0.05; ** = P < 0.01; *** = P < 0.001. † In 53 patients (16.5%) the dose of alcohol could not be 
retrieved. Data are represented as n (percentage), unless stated otherwise. ASA: alcohol septal ablation, 
HCM: hypertrophic cardiomyopathy, IQR: interquartile range, LVOT: left ventricular outflow tract.
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mortality
In 1047 patients follow-up duration was 7.5 ± 5.3 years (maximum 22.8 years). There were 156 
deaths in the entire cohort (table 3): 8 (5%) were procedure-related, 80 (51%) were HCM-
related, 56 (36%) patients died of non-cardiac causes, and unknown cause of death in 12 (8%). 
Twelve patients underwent cardiac transplantation, and were considered as HCM-related 
death. Kaplan-Meier estimates of survival are shown in figure 1a. The 5-year and 10-year 
survival was similar after ASA, myectomy, medically treated patients in NYHA class I/II 
and non-obstructive HCM patients (table 3). Independent predictors for all-cause mortality 
were: age (HR 1.05 95% CI 1.0-1.1, p<0.001); systolic dysfunction, with ejection fraction < 50% 
(HR 1.8 95% CI 1.2-2.6, p=0.005); and a trend towards diastolic dysfunction (HR 1.4 95% CI 
0.98-1.88, p=0.07; table 4).
table 3 – Mortality and sudden cardiac death in 1047 HCM patients.
n=
Medical
group ASA group
Myectomy 
group
Control (non-
obstructive) group
124 321 253 349
Follow-up, mean (±SD), years 7.1 ± 4.8* 6.3 ± 3.6*** 7.9 ± 6.1 8.7 ± 5.7
Mortality
Periprodecural death - 5 (1.6) 3 (1.2) -
HCM-related death 11 (8.9) 12 (3.7)** 21 (8.4) 36 (10.3)
Non-cardiac death 8 (6.5) 23 (7.2)* 12 (4.8) 13 (3.7)
Unknown death 0 (0) 3 (0.9) 6 (2.4) 3 (0.8)
Total 19 (15.3) 38 (11.8) 39 (15.6) 52 (14.9)
5-year survival, % 89 91 92 95
10-year survival, % 84 82 85 85
Sudden cardiac death
Sudden cardiac death 5 (4.0) 6 (1.9) 6 (2.4) 9 (2.6)
Resuscitated CA 1 (0.8) 2 (0.6)* 2 (0.8) 9 (2.6)
Appropriate ICD shock 5 (4.0) 8 (2.5) 1 (0.4) 12 (3.4)
Unknown death 0 (0) 3 (0.9) 6 (2.4) 3 (0.8)
Total 11 (8.9) 19 (6.0) 15 (6.0) 31 (8.9)
Annual SCD rate, %/year 1.26 0.96 0.75 1.02
ICD recipients 14(11.3)** 41 (13.0)*** 29 (11.6)** 83 (23.8)
* = P < 0.05; ** = P < 0.01; *** = P < 0.001 (compared with controls). Data are represented as number 
(percentage) unless stated otherwise. CA: cardiac arrest, HCM: hypertrophic cardiomyopathy, ICD: 
implantable cardioverter-defibrillator, SD: standard deviation.
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sudden cardiac death
The SCD-endpoint occurred in 76 patients in 8003 patient-years (0.9%/year. Annual SCD 
rate was 0.96%/y after ASA, 0.76%/y after myectomy, 1.26%/y in medically treated groups, 
and 1.02%/y in non-obstructive HCM patients (p= 0.4). Appropriate ICD shocks were more 
common after ASA (in 8/41 patients (20%) than after myectomy (in 1/29 patients (3.4%, 
p=0.03). Other characteristics of SCD are described in table 3. Kaplan-Meier estimates of 
survival free from SCD are shown in figure 1b. Multivariable analysis identified the follow-
ing independent predictors of SCD: patients who survived VF or sustained VT (HR 6.0 95% 
CI 3.4-10.6, p < 0.001); patients with ≥2 established risk factors (HR 2.7 95% CI 1.6-4.4, p < 
0.001); patients with atrial fibrillation (HR 1.7 95%CI 1.1-2.8, p = 0.03); and when compared 
with myectomy: ASA (HR 2.1 95% CI 1.0-4.4, p = 0.04), and medically treated patients (HR 
2.3 95% CI 1.1-5.1, p=0.04; table 4).
figure 1 – Survival in 1047 HCM patients. Kaplan-Meier graphs of survival (A) and sudden cardiac 
death free survival (B) in 1047 hypertrophic cardiomyopathy (HCM) patients.
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dIsCussION
The purpose of this investigation was to compare the long-term effects of medical treatment, 
ASA and myectomy on all-cause mortality and SCD in patients with obstructive HCM. There 
were two important results. First, the mortality rates in patients with prior ASA or myectomy, 
and medically treated patients in NYHA functional class I/II were similar to those of non-
obstructive HCM patients. Second, the long-term risk of SCD is low both after myectomy 
(0.8%/year) and ASA (1.0%/year), a small but significant difference (HR for SCD after ASA 
vs myectomy: 2.1, p=0.04).
table 4 – Analysis of clinical variables associated with sudden cardiac death and all-cause mortality in 
1047 hypertrophic cardiomyopathy patients.
Univariable Multivariable
HR CI 95% p HR CI 95% p
Mortality (n=156)
Age, y 1.05 1.03-1.06 < 0.001 1.05 1.04-1.06 < 0.001
Female 1.8 1.27-2.43 0.001 1.3 0.93-1.79 0.1
Atrial fibrillation 1.6 1.18-2.29 0.003 1.2 0.89-1.78 0.2
Coronary artery disease 1.9 1.25-2.74 0.002 1.4 0.94-2.08 0.1
Systolic dysfunction (EF < 50%) 2.2 1.51-3.22 < 0.001 1.4 1.19-2.59 0.005
Diastolic dysfunction 1.5 1.08-2.07 0.02 1.8 0.98-1.89 0.07
Myectomy (reference) 1.0 … 1.0 …
Alcohol septal ablation 1.3 0.79-2.02 0.3 1.0 0.65-1.61 0.9
Medical therapy NYHA I/II 1.3 0.73-2.20 0.4 1.2 0.68-2.13 0.5
Sudden cardiac death (n=76)
Age, y 1.00 0.98-1.01 0.7
Male 1.6 0.98-2.68 0.06 1.6 0.97-2.73 0.06
Left ventricular wall thickness, mm 1.03 0.98-1.08 0.2
Atrial fibrillation 1.8 1.14-2.87 0.01 1.7 1.06-2.75 0.03
Coronary artery disease 1.8 1.06-3.20 0.03 1.7 0.98-3.04 0.06
Sudden cardiac death survivor 6.5 3.82-10.9 < 0.001 6.0 3.43-10.7 < 0.001
≥2 established risk factors 3.3 2.04-5.23 < 0.001 2.7 1.65-4.44 < 0.001
Myectomy (reference) 1.0 … 1.0 …
Alcohol septal ablation 2.0 0.99-4.25 0.05 2.1 1.02-4.39 0.04
Medical therapy NYHA I/II 2.2 0.99-4.91 0.05 2.3 1.03-5.19 0.04
Backwards multivariable Cox regression analysis was used. CI: confidence interval; EF: ejection frac-
tion; HR: hazards ratio; NYHA: New York Heart Association.
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Low mortality in obstructive HCm patients
The observed survival after both myectomy (10-year survival of 85%) and ASA (82%, p=0.5), 
was similar to that of non-obstructive patients (85%, p=0.7 and p=0.2 respectively). This 
demonstrates that the survival disadvantage associated with LVOT obstruction can be ef-
fectively annulled by appropriate invasive therapy and management in referral centers for 
HCM care.[2] ASA was performed in carefully selected patients who were older and with 
more co-morbidities (61% of the deaths was due to non-cardiac causes), but despite this, 
the observed mortality after ASA was not significantly higher than in the other groups. The 
observed survival after invasive therapy in this study confirms other studies evaluating long-
term outcomes for the individual approaches.[21-24]
The good survival of obstructive HCM patients who remain in NYHA I/II on optimal 
medical therapy (10-year survival of 84%) could imply that earlier intervention in asymptom-
atic or mildly symptomatic patients with obstructive HCM is not indicated, despite the low 
procedural mortality and morbidity of both invasive therapies.
Mortality, not surprisingly, was high (44%) in a limited group of patients (n=18, 13%) with 
an indication for invasive treatment (NYHA class III/IV despite optimal medical therapy), 
but who were deemed to be ineligible due to severe comorbidities.
sudden cardiac death after alcohol septal ablation
Since the introduction of ASA there have been concerns regarding the arrhythmogenic effect 
of the ablation scar in patients already at an increased risk of life-threatening arrhythmias. 
Studies of short-term follow-up after ASA have described frequent episodes of sustained VT 
and VF.[14-17] Our findings confirm this, and show that although arrhythmic events were 
more frequent after ASA (3.1%) than after myectomy (0.4%, p<0.001), this had no effect on 
procedure-related mortality (1.6% vs. 1.2%, p= 0.7). The aim of this study was to assess the 
long-term effects of the different treatment modalities, especially because the long-term ef-
fect of ASA on SCD is unclear.
Two meta-analyses showed that the risk of SCD was not higher in ASA patients than 
in patients who underwent myectomy. These studies did not focus on long-term outcomes: 
average follow-up period across the cohorts in the study by Argawal et al.[19] was < 3 years, 
and in the study by Leonardi et al.[20] there was a significant difference in follow-up duration 
between the ASA and myectomy cohorts, with a median follow-up of 1266 patient-years in the 
myectomy studies and 51 patient-years in the ASA studies. Other concerns, especially about 
the calculated SCD risk have already been illustrated by Nishimura and Ommen.[30] The 
risk of SCD after myectomy has generally been low,[11] and the study by McLeod et al. even 
suggests that myectomy could decrease the risk of SCD.[31]
Our study found that the annual SCD rate (excluding periprocedural events) in patients 
who underwent ASA was 1.0%/year, which was similar to that of non-obstructive HCM 
patients and medically treated patients. The study by Ten Cate et al.[17], which included 
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a subset of the patients from the present study, reported a higher SCD rate than this study. 
The reason for this is twofold: (1) a separate endpoint for SCD (instead of a composite of 
cardiac mortality and SCD) was used, and (2) we excluded the periprocedural events from 
the final analysis to focus on the long-term effects of ASA. Two recently published studies 
with long-term follow-up, found that the risk of SCD was not high after ASA. Jensen et al.[23] 
examined 470 ASA patients, with an average follow-up of 8.4 years, and found an annual SCD 
rate of 0.5%/year. Sorajja et al.[24] examined 177 ASA patients and 177 age- and sex-matched 
myectomy patients, with an average follow-up of 5.7 years. They found annual SCD rates 
(including unknown death) of 1.3%/year after ASA and 1.1%/year after myectomy. The results 
of this study are in line with these findings, but the SCD risk after ASA is still higher than 
after myectomy (0.8%/year, HR for SCD after ASA vs myectomy: 2.1, p=0.04).
Patient selection and specialized care
The current findings may have implications for the clinical management of patients with 
obstructive HCM, who are considered for septal reduction therapy. Patient who underwent 
myectomy had a statistically significantly lower risk of SCD as compared with patients who 
underwent ASA.This, combined with a lower need for additional septal reduction therapy and 
lower periprocedural arrhythmic events, favors surgical myectomy over ASA when an invasive 
strategy is chosen, for example in younger and otherwise healthy patients. In older patients or 
patients with co-morbidities and drug-refractory symptoms, and appropriate septal anatomy, 
the expected survival after ASA is excellent, and in these patients ASA is a valuable therapy. 
Open heart surgery can be avoided and rehabilitation is much faster. We recommend that a 
multidisciplinary heart team (consisting of at least a cardiothoracic surgeon, an interventional 
cardiologist and a cardiologist specialized in the care of HCM patients) determines the op-
timal strategy for septal reduction. Also, in line with the 2003 ESC/ACC and 2011 ACCF/
AHA guidelines,[25, 26] the procedure should be performed by experienced operators and 
confined to centers having substantial and specific experience with HCM care.
study limitations
This study has several limitations. The 3 centers are all tertiary referral centers for the diagnos-
tic and therapeutic care of HCM, and the patient population might not represent the general 
HCM population. This referral and selection bias could have influenced current results. Data 
collection was limited to variables that were routinely collected. As rhythm documentation of 
the event was not available for all SCD cases, it was not possible to ascertain that all deaths 
were arrhythmic in nature. Neither was it possible to correct for individual or local alterations 
of surgical or percutaneous technique, however all procedures were performed by experi-
enced interventional cardiologist or cardiothoracic surgeons. This implies that our findings 
are more generalizable than those of single-center investigations.
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CONCLusION
Patients with obstructive HCM that are treated in referral centers for HCM care have a good 
survival and low SCD risk, similar to that of non-obstructive HCM patients. The SCD risk of 
patients after myectomy was lower than after ASA or in the medical group.
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edItOrIAL
revisiting Arrhythmic risk After Alcohol septal Ablation : Is the Pendulum 
Finally swinging…Back to myectomy?
Maron BJ, Nishimura RA
JACC Heart Fail. 2014 Dec;2(6):637-40.
For the past 10 years, a debate has raged within the international cardiovascular medicine 
community regarding treatment options for severely symptomatic and drug-refractory 
patients with obstructive hypertrophic cardiomyopathy (HCM) [1-21]. Surgical myectomy 
has been the gold-standard treatment for this relatively small HCM subset since the early 
1960s, with proven efficacy in abolishing left ventricular (LV) outflow gradients and heart 
failure symptoms, enhancing quality of life associated with long-term survival equivalent to 
the general population, and recently with low operative mortality (<1%) when performed by 
highly experienced surgeons [1- 6,20-22] (figure 1).
Catheter-based alcohol septal ablation entered the therapeutic arena for HCM about 10 
years ago, also with the capability for reducing gradient and symptoms, and became widely 
available, performed by many interventional cardiologists trained in standard percutaneous 
coronary interventions. [7-18] This introduction of alcohol ablation triggered a polarized and 
sometimes contentious debate focused on defining the most practical and effective strategy 
for severely symptomatic patients with obstructive HCM. [1-22] Advocates for septal ablation 
have underscored the less invasive nature of the technique, the shorter recovery time, as well 
figure 1 – Number of surgical myectomies versus alcohol ablation procedures performed at the mayo 
clinic (Rochester, Minnesota) by year, after an informed discussion of both options and shared decision-
making.
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as its widespread availability. However, concern has been raised regarding the extensive use 
of alcohol ablation, given that it produces a sizable transmural myocardial infarction (on aver-
age 10% of LV mass and 30% of septum), potentially leading to increased arrhythmogenicity 
[23] (figure 2). In addition, ablation is associated with an increased risk for complications 
such as heart block (requiring permanent pacing), generally less efficacious relief of gradient 
and symptoms, and the limited length of follow-up available for comparison with surgical 
myectomy.
Proponents of each strategy have argued their respective positions, and an extensive lit-
erature of almost 500 published papers has emerged. Notably, international consensus panels 
of the American Heart Association, the American College of Cardiology, and the European 
Society of Cardiology have weighed in on the debate by interrogating the assembled data, 
unanimously judging septal myectomy to be the primary treatment option for most patients 
with HCM (particularly the young) experiencing unrelenting symptoms due to marked 
LV outflow tract gradients at rest and/or with physiologic (exercise) provocation, despite 
maximal medical management. [1-6,19,20,22,24] Alcohol septal ablation is regarded as a 
selective alternative to myectomy reserved for patients at unacceptable operative risk because 
of comorbidities, advanced age, or with strong aversion to surgery. [1-3]
Despite these recommendations, selection of patients for these management options has 
varied considerably in geographic terms. Surgical myectomy has been virtually abolished 
and replaced by alcohol ablation in much of Europe, including countries such as Germany 
and Switzerland, where myectomy programs had previously been robust. There is, however, 
figure 2 – Post-contrast CMR images show the distinctly different morphologic consequences of al-
cohol septal ablation and surgical myectomy. Alcohol ablation (left) produces a bright dense transmural 
scar (arrow), whereas intramyocardial scarring is absent after surgical myectomy and muscular resection 
(right). CMR = cardiovascular magnetic resonance; LV = left ventricular wall; VS = ventricular septum. 
Adapted with permission from Valeti et al.[23]
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recent evidence of a resurgence in surgery for obstructive HCM in Italy, United Kingdom, 
and the Netherlands. [25] In the United States, alcohol septal ablation has been performed by 
interventional cardiologists at many institutions across the country, some of whom learn the 
technique from attending a conference. This is in contrast to septal myectomies performed 
primarily by the highly trained surgeons at HCM centers of excellence. The decision regard-
ing which procedure a patient will undergo may depend more on the location, referral pattern, 
and current knowledge of the managing cardiologist rather than scientific evidence and shared 
decision-making.
In the report by Vriesendorp et al. [26] in this issue of JACC: Heart Failure, investigators 
from 3 tertiary institutions have joined together to describe their experience with HCM in 
>1,000 patients, including 566 with either myectomy or ablation: Thoraxcenter in Rotterdam, 
St. Antonius Hospital Nieuwegein (also in the Netherlands), and University Hospital Leuven 
in Belgium. This ambitious analysis focuses on the sudden death risk associated with both 
septal reduction procedures. Because HCM is characteristically a low–event-rate disease, 
it is not surprising that the investigators observed that the sudden death rate was generally 
low in patients with either surgery or ablation, as well as in a medically treated group with 
nonobstructive HCM.
However, most importantly, there are several novel observations in the Vriesendorp et 
al. [26] report regarding the arrhythmogenic potential of alcohol septal ablation compared to 
myectomy. First, on the basis of a multivariate analysis, there was a 2-fold increase in sudden 
death risk with alcohol ablation (hazard ratio: 2.1; 95% confidence interval: 1.0 to 4.4; p = 
0.04) over the duration of the study, which could have been much higher if the investigators 
had included early life-threatening periprocedural arrhythmic complications (i.e., 11:1 for 
ablation to myectomy). The sudden death rate per year associated with alcohol ablation was 
25% greater than with myectomy (1.0% vs. 0.8%). In terms of individual patients, sudden death 
events were 80% more common with ablation (16 vs. 9 with myectomy), including appropriate 
implantable cardioverter-defibrillator shocks for ventricular tachycardia or ventricular fibril-
lation that were 8:1 more frequent post-ablation. Finally, myectomy patients had a greater 
number of independent risk markers for sudden cardiac death but paradoxically fewer events 
than in the septal ablation patients.
Taken together, these observations support a level of arrhythmogenicity that is a direct 
consequence of the alcohol-induced transmural myocardial infarct. In addition, such a 
significant sustained occurrence of ventricular tachyarrhythmias after alcohol ablation in 
the Vriesendorp et al. [26] study is consistent with prior data from important centers at the 
Massachusetts General Hospital [15] and the Thoraxcenter [14,18], as well as in a study by 
Cuocco et al. [16] in which a large alcohol ablation population implanted with cardioverter-
defibrillators is reported. In addition, a particularly low risk for sudden death and potentially 
lethal ventricular tachyarrhythmias has been reported after septal myectomy from the Mayo 
Clinic. [21,27] Indeed, the arrhythmogenic risk associated with alcohol septal ablation has 
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been an issue of concern since the inception of this procedure, [28,29] repeatedly raised by 
many clinicians and HCM experts, as well as by guideline and consensus panels.
The 250 patients with myectomy reported here from 3 institutions in the Netherlands and 
Belgium could reflect an emerging profile for this surgery in parts of Europe, although this is 
difficult to assess in precise terms because the investigators do not specify the period of time 
over which the procedures were performed. Nevertheless, myectomy was 2-fold more com-
mon in the Leuven group, and also constituted the majority of septal reduction procedures in 
Rotterdam. Indeed, in the United States, paradoxically, myectomy operations appear to have 
increased concomitant with the introduction of alcohol septal ablation [30] (figure 1).
Furthermore, myectomy versus alcohol ablation decisions must be made weighing the 
risk with alcohol ablation for permanent pacemakers (10% to 15%), therapeutic failures with 
multiple procedures (12%), ineffective results in patients with particularly substantial LV 
hypertrophy (in whom adequate septal thinning cannot be achieved), and the potential for 
post-procedural arrhythmic risk, particularly in younger patients, against the inconvenience 
and post-operative rehabilitation required after open-heart surgery. [1-23] Also important, the 
heterogeneous and complex LV outflow tract morphology characteristic of obstructive HCM 
is often most amenable to the myectomy operation, for which the skilled and experienced 
surgeon has the distinct advantage of direct anatomic visualization, thereby increasing the 
likelihood of an optimal hemodynamic and symptomatic result. [1-6,19-21,28-31] In contrast, 
alcohol ablation is a “blind” approach restricted by the size and distribution of the septal 
perforator artery and its fixed anatomic relationship to the target site of outflow obstruction 
(where the anterior mitral leaflet contacts the septum in systole). [1-4,19, 20,28,29,31] There-
fore, there will be patients in whom the optimal hemodynamic benefit will not be obtained by 
alcohol ablation because of these anatomic considerations.
Finally, Vriesendorp et al. [26] appropriately underscore the value of HCM subspecialty 
multidisciplinary teams at dedicated clinics and centers (e.g., with myectomy surgeons, inter-
ventional cardiologists, and cardiologists specialized in the care of patients with HCM) [32], 
creating an environment in which decisions between myectomy and alcohol ablation can be 
made effectively and in cooperation with fully informed patients [1,5,19].
In conclusion, the Vriesendorp et al. [26] data revisit the important issue of arrhythmoge-
nicity associated with alcohol septal ablation and offer support to the consensus and guideline 
recommendations from the United States (2003 and 2011) [2,3] and Europe (2003) [2] panels 
that septal myectomy should be considered the treatment of choice for most patients with 
HCM and severe drug-refractory heart failure symptoms attributable to LV outflow obstruc-
tion. Although the myectomy–versus-ablation pendulum may be swinging back toward septal 
myectomy, the controversy will undoubtedly continue, although perhaps now in a more bal-
anced environment, permitting greater repenetration of surgical myectomy into contempo-
rary care for patients with HCM. This would represent a much anticipated adjustment in the 
management armamentarium of HCM, in the best interests of this patient population.
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ABstrACt
Objectives
The aim of this meta-analysis is to compare long-term mortality and SCD rates after myec-
tomy and ASA in patients with HCM.
Background
Surgical myectomy and percutaneous alcohol septal ablation (ASA) are both accepted 
treatment options for medical therapy resistant obstructive hypertrophic cardiomyopathy 
(HCM). Questions remain however about the long-term outcomes, especially concerning the 
long-term risk of sudden cardiac death (SCD) after ASA.
methods
A systematic review was conducted for eligible studies with a follow-up of at least 3 years. 
Primary outcomes were all-cause mortality and (aborted) SCD. Secondary outcomes were 
peri-procedural complications, LVOT gradient and NYHA class after ≥ 3 months, and re-
intervention. Pooled estimates were calculated using a random effect meta-analysis.
results
Sixteen myectomy cohorts (2791 patients, mean follow-up 7.4 years) and 11 ASA cohorts 
(2013 patients, mean follow-up 6.2 years) were included. Long-term mortality was found to 
be similarly low after ASA (1.5% per year) as compared to myectomy (1.4% per year, P=0.78). 
The rate of (aborted) SCD, including appropriate implantable cardioverter defibrillator 
shocks, was 0.4% per year after ASA and 0.5% per year after myectomy (P=0.47). Permanent 
pacemaker implantation was performed following ASA in 10% of the patients, compared to 
4.4% after myectomy (P<0.001). Re-intervention was performed in 7.7% of the patients who 
underwent ASA, compared to 1.6% after myectomy (P=0.001).
Conclusion
Long-term mortality and (aborted) SCD rates after ASA and myectomy are similarly low. 
Patients who undergo ASA have over twice the risk of permanent pacemaker implantation 
and a 5 times higher risk of necessity for additional septal reduction therapy, as compared to 
those who undergo myectomy.
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INtrOduCtION
Hypertrophic cardiomyopathy (HCM) is the most prevalent inheritable myocardial disease, 
and (provokable) left ventricular outflow tract (LVOT) obstruction is present in the majority 
of HCM patients (±70%).(1) If patients with LVOT obstruction remain severely symptomatic 
despite optimal medical therapy, septal reduction therapy should be considered. This can be 
done, either by surgical myectomy or alcohol septal ablation (ASA).(2-4) Myectomy has been 
used for over 5 decades and in experienced centers relief of obstruction can be achieved with 
minimal perioperative morbidity and mortality.(5) In 1995 ASA was developed as a percuta-
neous alternative by Sigwart et al(6) and was quickly adopted all over the world. Now, after 
20 years since its introduction the debate about the safety of ASA still continues, especially 
concerning the arrhythmogenic effect of the ablation scar in patients already at an increased 
risk of life-threatening arrhythmias. The two most recent meta-analyses date back to 2010, 
and only evaluated short-term outcomes.(7,8) The aim of this meta-analysis is to compare 
long-term outcomes after myectomy and ASA.
metHOds
search strategy
Specific search terms were constructed, containing all synonyms for HCM in combination 
with all synonyms for myectomy and/or ASA, for the following databases: Embase, Medline, 
Cochrane, Web-of-science, Pubmed-publisher and Google Scholar. Search terms and amount 
of hits per database are shown in table 1. Predetermined inclusion and exclusion criteria 
(table 2) were applied by two independent reviewers. Because of our primary interest in 
long-term outcomes, a minimal mean follow-up was set on 3 years. Observational studies 
were included, in lack of randomized controlled trials.
data extraction
Continuous variables were extracted as means or medians, and dichotomous variables were 
extracted in absolute numbers or percentages for each cohort.
Baseline patient characteristics of interest included age, sex, New York Heart Association 
(NYHA) functional class, maximal left ventricular wall thickness (LVWT), maximal LVOT 
gradient, a history of syncope, implantable cardioverter defibrillator (ICD), amount of alcohol 
used (ASA studies), and concomitant mitral valve surgery (myectomy studies).
Primary outcomes of interest were mortality, cause of death (cardiac/non-cardiac/
unknown), sudden cardiac death (SCD), aborted SCD and appropriate ICD shocks. Cardiac 
death (syn. HCM related mortality) was defined as death due to heart failure, SCD, or death 
due to stroke associated with atrial fibrillation; SCD was defined as instantaneous and unex-
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pected death; and aborted SCD was defined as successful resuscitation after cardiac arrest. 
Secondary outcomes of interest were peri-procedural complications (death, permanent pace-
maker implantation, stroke, tamponade, sustained ventricular tachycardia and ventricular 
fibrillation), days of hospitalization, LVOT gradient after ≥ 3 months, NYHA functional class 
after ≥ 3 months, and re-intervention (ASA or myectomy).
table 1 – Search terms for systematic review per database with amount of corresponding hits.
Database Hits Search term
Embase.com 1052
(‘hypertrophic cardiomyopathy’/de OR ‘familial hypertrophic 
cardiomyopathy’/de OR ‘hypertrophic obstructive cardiomyopathy’/de 
OR (((hypertroph* OR obstruct*) NEAR/3 (cardiomyopath* OR ‘subaortic 
stenosis’ OR Asymmetric*)) OR hcm OR hocm OR ihss):ab,ti) AND 
(‘muscle resection’/exp OR myotomy/de OR myomectomy/de OR (((septal 
OR alcohol) NEAR/3 ablat*) OR ((muscle OR septal) NEAR/3 (resect* 
OR cut* OR excis* OR extirpat* OR reduct*)) OR myectom* OR myotom* 
OR myomectom* OR morrow OR tash OR ASA OR PTSMA):ab,ti) AND 
[english]/lim NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/
lim OR [Conference Paper]/lim OR [Editorial]/lim)
Medline 
(OvidSP)
910
(exp Cardiomyopathy, Hypertrophic/ OR (((hypertroph* OR obstruct*) 
ADJ3 (cardiomyopath* OR subaortic stenosis OR Asymmetric*)) OR hcm OR 
hocm OR ihss).ab,ti.) AND ((((septal OR alcohol) ADJ3 ablat*) OR ((muscle 
OR septal) ADJ3 (resect* OR cut* OR excis* OR extirpat* OR reduct*)) OR 
myectom* OR myotom* OR myomectom* OR morrow OR tash OR ASA OR 
PTSMA).ab,ti.) AND english.la. NOT (letter OR news OR comment OR 
editorial OR congresses OR abstracts).pt.
Cochrane 24
((((hypertroph* OR obstruct*) NEAR/3 (cardiomyopath* OR ‘subaortic 
stenosis’ OR Asymmetric*)) OR hcm OR hocm OR ihss):ab,ti) AND 
((((septal OR alcohol) NEAR/3 ablat*) OR ((muscle OR septal) NEAR/3 
(resect* OR cut* OR excis* OR extirpat* OR reduct*)) OR myectom* OR 
myotom* OR myomectom* OR morrow OR tash OR ASA OR PTSMA):ab,ti)
Web-of-
science 706
TS=(((((hypertroph* OR obstruct*) NEAR/3 (cardiomyopath* OR “subaortic 
stenosis” OR Asymmetric*)) OR hcm OR hocm OR ihss)) AND ((((septal 
OR alcohol) NEAR/3 ablat*) OR ((muscle OR septal) NEAR/3 (resect* 
OR cut* OR excis* OR extirpat* OR reduct*)) OR myectom* OR myotom* 
OR myomectom* OR morrow OR tash OR ASA OR PTSMA)) ) AND 
LA=(english) AND DT=(Article)
PubMed 
publisher
26
((((hypertroph*[tiab] OR obstruct*[tiab]) AND (cardiomyopath*[tiab] OR 
subaortic stenosis OR Asymmetric*[tiab])) OR hcm OR hocm OR ihss)) 
AND ((((septal OR alcohol) AND ablat*[tiab]) OR ((muscle OR septal) 
AND (resect*[tiab] OR cut*[tiab] OR excis*[tiab] OR extirpat*[tiab] OR 
reduct*[tiab])) OR myectom*[tiab] OR myotom*[tiab] OR myomectom*[tiab] 
OR morrow OR tash OR ASA OR PTSMA)) AND english[la] AND 
publisher[sb]
Google 
Scholar 200
“hypertrophic cardiomyopathy”|”hypertrophic * cardiomyopathy” 
“septum|septic|alcohol resection|ablation”|myotomy|myomectomy|tash|
ASA|PTSMA
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statistical Analysis
Descriptive statistics of patients before the intervention are described with weighted medians 
and interquartile ranges. Standard errors for the differences in weighted medians between 
the ASA and myectomy group were estimated by 10.000 bootstraps of the weighted medians 
differences. P-values for the pooled incidence rate differences and weighted medians were 
calculated using the Wald test. Random-effect meta-analysis was conducted using “metan” 
function with “randomi” option in Stata version 12.1 (StataCorp LP, College Station, TX), 
which derives the estimates of heterogeniety from an inverse-variance fixed-effect model. 
Heterogeneity among studies was estimated by Chi-squared test and the I2 statistics. Potential 
sources of heterogeneity were explored by meta-regression analysis, using “metareg” func-
tion in STATA. In all analyses, a P value of < 0.05 was considered significant.
resuLts
systematic review
The search strategy retrieved 2918 references. After elimination of double hits, a total of 
1317 unique references remained (figure 1). After applying the predetermined inclusion and 
exclusion criteria (table 2) during the initial review, a total of 50 studies were selected for 
further evaluation. Twenty-two studies were subsequently excluded because of overlapping 
study periods with cohorts containing more patient-years of follow-up.(9-30) For the same 
reason only the ASA cohort from the study by Sorajja et al(31) was included. A study(32) on 
the outcome of patients who underwent myectomy between 1960 -1981, wasn’t found eligible 
table 2 – Inclusion and exclusion criteria for meta-analysis.
Inclusion
Reporting on outcome of at least 5 patients undergoing ASA and/or surgical myectomy for treatment 
of medically refractory symptoms of obstructive HCM
Mean follow-up of at least 3 years
Exclusion
Use of ablative media other than ethanol (eg, cyanoacrylate, polyvinyl alcohol foam particles)
Enrolment primarily of patients undergoing rescue ablation after failed surgical myectomy or 
previous ASA, or vice versa of patients undergoing rescue myectomy after failed ASA or previous 
myectomy
Enrolment primarily of patients undergoing combined procedures (eg, simultaneous percutaneous 
coronary intervention or coronary bypass grafting for epicardial coronary disease, simultaneous 
percutaneous or surgical valve repair or replacement), patients selected for their high risk of sudden 
death (eg, patients with ICDs), or children
Publication in a non-English language without an available English translation
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because 47% of the surgical procedures were performed using a transventricular or combined 
approach, unlike the myectomy techniques as described by Morrow(5) in the other studies. 
Two studies were excluded because of insufficient baseline characteristics,(33) and the exclu-
sion of patients with a complete atrioventricular block after ASA.(34) Lastly, the study by 
Sathyamurthy et al(35) was excluded, in lack of an accurate description of the follow-up dura-
tion. Twenty-four studies were selected for inclusion, containing 11 ASA cohorts(31,36-45) 
and 16 myectomy cohorts.(42,43,45-58)
study characteristics
The characteristics of the studies and their cohorts are shown in table 3. The myectomy 
cohorts contain a total of 2791 patients, with a mean follow-up of 7.4 years. The ASA cohorts 
contain a total of 2013 patients, with a mean follow-up of 6.2 years. The median age in the 
ASA cohorts was 56 years, compared to 47 years in the myectomy cohorts (P = 0.009). Other 
baseline characteristics did not differ significantly between the ASA and myectomy cohorts.
Peri-procedural outcomes
Peri-procedural (< 30 days) outcomes are shown in table 4. There were 61 peri-procedural 
deaths in the myectomy cohorts and 20 in the ASA cohorts. Weighted for cohort size, peri-
procedural mortality was 1.3% (CI: 0.7-1.8) after ASA and 2.5% (CI: 1.4-3.6) after myectomy 
(P = 0.051). Cardiac mortality approximated all-cause mortality (1.1% vs. 2.5%; P = 0.035). Per-
manent pacemaker implantation was necessary after ASA in 10.0% (CI: 7.8-12.1) of patients 
compared to 4.4% (CI: 2.6-6.2) after myectomy (P < 0.001). The incidence of tamponade and 
stroke was similar and ≤ 1% after both ASA and myectomy (P = 0.50 and P = 0.15, respec-
tively). Peri-procedural adverse arrhythmic events (AAE), comprising sustained ventricular 
figure 1 – Selection of studies for meta-analysis.
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tachycardia and ventricular fibrillation, were similar after ASA compared to myectomy (2.2% 
vs. 1.0%; P = 0.091). Hospitalization duration was only reported for two myectomy cohorts, 
and was therefore disregarded.
In light of potentially less developed peri-procedural care in the 20th century, when we 
excluded studies from before 2000, the peri-procedural mortality rate of myectomy further 
approximated that of ASA (1.1% vs. 1.3%, respectively; P = 0.75). Similarly, the rates of pace-
maker implantation (4.0% vs 10.0% after ASA, P = <0.001) and peri-procedural AAE (0.6% vs 
2.2% after ASA, P = 0.055) following myectomy were lower.
Long-term outcomes
Long-term outcomes per study are shown in table 5. In the myectomy cohorts there were 
302 all-cause deaths during follow-up (i.e., after 30 days post-procedure), of which 175 were 
HCM related. In the ASA cohorts 191 patients died, of which 76 were HCM related. Pooled 
all-cause mortality rates after myectomy and ASA were similar (1.44% per year vs. 1.52% per 
year; P = 0.78; figure 2). The rate of HCM related mortality was 0.50% per year after ASA 
.
.
Alcohol septal ablation:
de la Torre Hernandez 2014
Fernandes 2008
Guo 2007
Jensen 2013
Klopotowski 2010
Lyne 2010
Samardhi 2014
Sedehi 2014
Sorajja 2012
Veselka 2014
Vriesendorp 2014
Subtotal  (I−squared = 51.7%, p = 0.023)
Surgical myectomy:
Cohn 1992
Desai 2013
Gol 1997
Havndrup 2000
Heric 1995
Krajcer 1989
Lisboa 2011
Merrill 2000
Minami 2002
Ommen 2005
Samardhi 2014
Schonbeck 1998
Schulte 1993
Sedehi 2014
Vriesendorp 2014
Woo 2005
Subtotal  (I−squared = 61.1%, p = 0.001)
Study
45
629
26
470
61
12
47
52
177
178
316
31
699
69
11
178
127
34
22
75
289
23
110
364
171
250
338
Patients,(n)
1.63 (0.88, 3.13)
1.76 (1.34, 2.32)
0.64 (0.04, 10.25)
1.06 (0.79, 1.44)
0.51 (0.16, 1.58)
2.12 (0.68, 6.57)
1.18 (0.30, 4.73)
1.20 (0.30, 4.81)
2.38 (1.59, 3.55)
1.99 (1.24, 3.20)
1.91 (1.39, 2.62)
1.52 (1.12, 1.91)
2.48 (1.03, 5.96)
0.95 (0.70, 1.28)
0.20 (0.01, 3.17)
7.62 (2.46, 23.62)
2.73 (1.72, 4.34)
0.88 (0.49, 1.60)
0.92 (0.30, 2.85)
1.38 (0.34, 5.51)
1.23 (0.51, 2.97)
1.37 (0.91, 2.06)
4.58 (1.72, 12.19)
2.33 (1.63, 3.33)
1.27 (0.93, 1.75)
1.02 (0.69, 1.53)
1.97 (1.44, 2.70)
2.15 (1.66, 2.80)
1.44 (1.13, 1.76)
rate (95% CI)
Incidence
8.01
17.10
0.58
20.08
13.24
1.66
2.78
2.69
9.52
9.52
14.83
100.00
1.48
12.62
3.13
0.09
4.14
9.85
4.30
1.36
4.52
9.64
0.36
7.01
11.42
11.31
9.06
9.69
100.00
Weight
%
Pooled estimates difference: P = 0.78 
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figure 2 – Forest plots and pooled estimates of all-cause mortality rates after surgical myectomy and 
alcohol septal ablation.
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and 0.74% per year after myectomy (P = 0.013). There were significantly more unknown 
causes of death in the ASA cohorts (P = 0.002). Moderate heterogeneity was present for 
all-cause mortality in both the ASA (I2 = 52%; P = 0.023) and the myectomy (I2 = 61%; P = 
0.001) groups. Meta-regression showed that ASA cohorts with older patients had higher all-
cause mortality rates (P = 0.02), hence age explained some of the heterogeneity in this group 
(I2 residual = 28%, P for heterogeneity = 0.19; figure 3). None of the remaining study-level 
covariates depicted in table 3 showed significant association with mortality across the ASA 
cohorts, nor were there any of the investigated covariates significantly related to mortality 
across myectomy cohorts.
The rate of (aborted) SCD during long-term follow-up was 0.41% per year after ASA, 
and 0.49% per year after myectomy (P = 0.47; figure 4). The description of appropriate 
ICD shocks was incomplete and unevenly distributed over the two groups (8/11 of the ASA 
cohorts vs. 4/16 of the myectomy cohorts). In part, this can be explained by the fact that half 
of the myectomy cohorts are from the year 2000 or earlier, when ICD implantation was less 
common. When appropriate ICD shocks were excluded from the (aborted) SCD endpoint, 
the event rates were 0.34% per year after ASA, and 0.47% per year after myectomy (P = 0.16; 
figure 5). Heterogeneity was present for SCD only in the myectomy cohorts when ICD 
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figure 3 – All-cause mortality bubble plot for mean age in myectomy cohorts (left) and ASA cohorts 
(right), with fitted regression lines in red, and estimates from each cohort in green with the circles size 
being proportional to the inverse of each study variance. The myectomy study by Havendrup et al. was 
censored from the plots, but included in the estimates.
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shocks were included (I2 = 43%; P = 0.038). In meta-regression analysis this heterogeneity was 
not explained by any of the investigated study-level covariates.
Clinical efficacy
Improvement of functional status, LVOT gradient reduction, and need for re-intervention 
are depicted in table 6. NYHA class during follow-up was reported either as mean class or 
in percentage of patients remaining in class III/IV, making comparisons difficult. The median 
reduction in NYHA class was 45% after both ASA and myectomy. The median amount of 
patients remaining in NYHA class III/IV was 8% after ASA and 5% after myectomy (P = 0.43). 
The reduction in LVOT gradient was 71% after ASA and 77% after myectomy (P = 0.63). The 
number of re-interventions (either ASA or myectomy) was significantly higher after ASA (n = 
165) as compared to myectomy (n = 45). Weighted for cohort size this translated in a need for 
re-intervention in 7.7% (CI: 4.2-11.1) of the patients who underwent ASA, compared to 1.6% 
(CI: 0.6-2.6) after myectomy (P = 0.001).
.
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Pooled estimates difference: P = 0.16 
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figure 4 – Forest plots and pooled estimates of (aborted) SCD rates after surgical myectomy and 
alcohol septal ablation, including ICD shocks.
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dIsCussION
This is the first systematic review that considers the long-term outcomes after ASA and surgi-
cal myectomy. The most important finding of this analysis is that after ASA and myectomy, 
both mortality and SCD risk were found to be similarly low. Furthermore, we saw that patients 
who undergo ASA have a significantly higher risk of permanent pacemaker dependency and 
need for additional septal reduction therapy, as compared to those who undergo myectomy.
sudden cardiac death after AsA and myectomy
Since the introduction of ASA there have been concerns regarding the arrhythmogenic effect 
of the ablation scar in patients already at an increased risk of life-threatening arrhythmias. 
Studies of short-term follow-up after ASA have described frequent episodes of AAE.
(29,59,60) Our findings do not confirm this by showing a peri-procedural AAE rate of just 
2%, similar to myectomy.
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figure 5 – Forest plots and pooled estimates of (aborted) SCD rates after surgical myectomy and 
alcohol septal ablation, excluding ICD shocks.
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table 6 – Clinical efficacy of ASA and myectomy.
Study NYHA,%RED
NYHA
III/IV, %
LVOT,
%RED Re-intervention
ASA
de la Torre Hernandez 
201436
- 13 74 0
Fernandes 200837 - - 67 100
Guo 200738 53 - - 0
Jensen 201339 - 8 90 -
Klopotowski 201040 - - 79 -
Lyne 201041 63 0 80 2
Samardhi 201442 - 5 63 8
Sedehi 201443 50 - 66 0
Sorajja 201231 - - - 15
Veselka 201444 45 - 71 9
Vriesendorp 201445 - - 90 31
Weighted median: (IQR): 45 (45-50) 8.0 (8.0-8.0) 71 (67- 90) Total: % (CI): 165 7.7 (4.2–11.1)
Surgical myectomy
Cohn 199246 45 19 95 0
Desai 201347 - 5 69 8
Gol 199748 38 5 77 0
Havndrup 200049 38 9 83 0
Heric 199550 50 6 77 22
Krajcer 198951 34 27 74 0
Lisboa 201152 55 - 77 0
Merrill 200053 - - - 0
Minami 200254 33 - 82 2
Ommen 200555 48 6 96 -
Samardhi 201442 - 0 83 0
Schonbeck 199856 - 12 99 3
Schulte 199357 45 4 - 3
Sedehi 201443 44 - 66 0
Vriesendorp 201445 - - 90 6
Woo 200558 - 17 - 1
Weighted median: (IQR): 45 (44-48) 4.5 (4.5-12) 77 (69-90) Total: % (CI): 45 1.6 (0.6-2.6)
P: 0.94 0.43 0.63 0.001
Values are n unless otherwise indicated; ASA – alcohol septal ablation; CI – confidence interval; IQR – 
interquartile range; LVOT – left ventricular outflow tract; NYHA – New York Heart Association; RED 
– reduction; P = P-value for difference between ASA and myectomy groups.
63
Meta-analysis of septal reduction therapy for obstructive HCM
2
Several meta-analyses comparing ASA and myectomy have been performed be-
fore,(7,8,61,62) but were only able to compare short-term results. Even the 2 meta-analyses 
published in 2010 did not reach a long enough cumulative follow-up time to make a definitive 
statement on long-term outcomes of ASA. The analysis by Agarwal et al.(7) had a mean 
follow-up period across the cohorts of 2.7 years, and the study by Leonardi et al(8) had a 
significant difference in follow-up duration between the ASA and myectomy cohorts, with a 
median follow-up of 1266 patient-years in the myectomy studies and 51 patient-years in the 
ASA studies.
There are two large studies in our analysis which compare the SCD risk of ASA to myec-
tomy. Sorajja et al(31) examined 177 ASA patients and 177 age- and sex-matched myectomy 
patients, with an average follow-up of 5.7 years. They found annual SCD rates (including 
unknown deaths) of 1.3% per year after ASA and 1.1% per year after myectomy. Vriesendorp et 
al(45) examined 321 ASA patients and 253 myectomy patients, and compared their outcomes 
to 349 non-obstructive HCM patients, with an average follow-up of 7.6 years. They found 
annual SCD rates (including unknown deaths) of 1.0% per year after ASA and 0.8% per year 
after myectomy. The present meta-analysis confirms these findings that the long-term risk of 
SCD after both myectomy and ASA is low.
Peri-procedural complications and re-intervention
The main differences between the two interventions were found in the secondary endpoints. 
The most frequent peri-procedural complication was an atrioventricular block requiring 
permanent pacemaker implantation. This was performed in 10% of patients following ASA, 
compared to 4% after myectomy. Surgical myectomy was not significantly more effective in 
reducing NYHA functional class and LVOT gradient at ≥ 3 months. We think however that 
the need for re-intervention is the best clinical parameter for determining the overall efficacy 
of the procedures. Our results show that re-intervention was necessary after ASA in 7.7% of 
patients, compared to only 1.6% after myectomy.
We think these findings are important to discuss with patients when they are being in-
formed about the possibilities and limitations of septal reduction therapy. Surgical myectomy 
is open heart surgery with relatively long rehabilitation. On the other hand, patients who 
undergo ASA have over twice the risk of permanent pacemaker implantation and a 5 times 
higher risk of necessity for additional septal reduction therapy (ASA or myectomy, depending 
on the presence of an additional suitable septal perforator). For these reasons, myectomy 
might be more suitable for younger patients. However, our results show that there is no 
elevated long-term risk for life-threatening arrhythmias after ASA, and that ASA is still ef-
fective for relief of symptoms in the majority of patients (92%) without need for pacemaker 
implantation in most (90%).
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Patient selection and specialized care
Important developments in imaging and new procedural techniques have improved the effi-
cacy and safety of both procedures. Guidance by myocardial contrast echocardiography made 
better predictions of the effect of ASA possible,(63) and recently developed peri-procedural 
image guidance does the same for myectomy.(64) Furthermore, new surgical techniques such 
as transatrial and transmitral myectomy (with or without robot-assistance), as alternatives to 
the traditional trans-aortic approach, make better visualization of the septum possible.(65,66) 
These advances reduce risks for both ASA and myectomy. In line with the 2011 American 
College of Cardiology(3) and the 2014 European Society of Cardiology(4) guidelines, we 
recommend that all patients considered for septal reduction therapy are assessed by a multi-
disciplinary heart team (consisting of at least one cardiothoracic surgeon, an interventional 
cardiologist, and a cardiologist specializing in the care of patients with HCM) to determine 
the most optimal therapy, by taking into account factors like mitral valve anatomy, septal 
thickness, age and comorbidities. Since the studies that were included in the systematic 
review were performed in centers with extensive experience in the treatment of HCM, the 
results from the meta-analysis primarily apply to such centers. We therefore recommend that 
surgical myectomy and ASA should be performed by experienced operators and confined to 
centers with substantial and specific expertise in HCM care.
study limitations
As shown in table 1 the patients who underwent ASA and myectomy are inherently differ-
ent. The direct comparisons as drawn by meta-analysis are thereby harder to interpret. Most 
importantly the patients from the ASA cohorts were older than those from the myectomy 
cohorts (median age 56 vs. 47 years). In fact, in the meta-regression analysis ASA cohorts 
with older patients had higher all-cause mortality rates. Therefore, unmeasured, age-related 
confounders, such as comorbid illness, may have been more prevalent in ASA cohorts and 
may have increased all-cause mortality after ASA.
Another important limitation is the great dispersion in study periods between the my-
ectomy and ASA cohorts, with half of the myectomy studies from the year 2000 or earlier. 
Although meta-regression analysis found no significant association between study period and 
all-cause mortality, the higher peri-procedural mortality of the myectomy cohorts might be 
explained by the less developed peri-procedural care in the early days of surgical myectomy. 
Indeed, the myectomy studies before 2000 all but one had above average peri-procedural 
mortality rates (Heric 6.2%, Schulte 4.9%, Krajcer 4.7%, Gol 4.3%, Schonbeck 3.6%). When 
we excluded studies from before 2000, the peri-procedural mortality rate of myectomy ap-
proximated that of ASA (1.1% vs. 1.3%, respectively). In doing so, the long-term mortality rate 
of myectomy was still similar to ASA (i.e., 1.42% per year after myectomy vs. 1.52% per year 
after ASA; P = 0.73).
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Finally, because analyses were applied on cohort data instead of individual patient charac-
teristics, the results of the regression models apply to cohorts rather than individual patients. 
The data shown here are therefore mainly descriptive, and conclusions should be drawn with 
caution.
CONCLusION
Long-term mortality and (aborted) SCD rates after ASA and myectomy are similarly low. 
Patients who undergo ASA have over twice the risk of permanent pacemaker implantation 
and a 5 times higher risk of necessity for additional septal reduction therapy, as compared to 
those who undergo myectomy.
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ABstrACt
Severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HC) may 
benefit from surgical myectomy. In patients with enlarged mitral leaflets and mitral regurgita-
tion, myectomy can be combined with anterior mitral leaflet extension (AMLE) to stiffen 
the mid-segment of the leaflet. The aim of this study was to evaluate the long-term results 
of myectomy combined with AMLE in patients with obstructive HC. This prospective ob-
servational single-center cohort study included 98 patients (49 ±14 years, 37% female) who 
underwent myectomy combined with AMLE between 1991 - 2012. Endpoints included all-
cause mortality and change in clinical and echocardiographic characteristics. Mortality was 
compared with age-and gender matched non-obstructive HC patients and subjects from the 
general population. Long-term follow-up was 8.3 ±6.1 years. There was no operative mortality 
and NYHA class was reduced from 2.8 ±0.5 to 1.3 ±0.5 (p<0.001); left ventricular outflow 
tract gradient from 93 ±25 to 9 ±8 mmHg (p<0.001); mitral valve regurgitation from grade 
2.0 ±0.9 to 0.5 ±0.8 (p<0.001); and systolic anterior motion of the mitral valve from grade 2.4 
±0.9 to 0.1 ±0.3 (p<0.001). The 1-, 5 -, 10-, and 15-year cumulative survival was 98%, 92%, 86%, 
and 83%, respectively; and did not differ from the general population (99%, 97 %, 92%, and 85%, 
respectively; p=0.3) or non-obstructive HC patients (98%, 97%, 88%, and 83%, respectively, 
p=0.8). In conclusion, in selected obstructive HC patients myectomy combined with AMLE 
is a low risk surgical procedure. It results in long-term symptom relief and survival similar to 
the general population.
73
Outcome after myectomy and AMVL extension
3
INtrOduCtION
The aim of this study was to evaluate the long-term results of myectomy combined with 
anterior mitral leaflet extension (AMLE) in patients with obstructive hypertrophic cardio-
myopathy (HC). In the current report long-term outcome after myectomy combined with 
AMLE was compared with age and gender matched patients with non-obstructive HC and 
subjects from the general Dutch population.
metHOds
The study conforms to the principles of the Helsinki Declaration. All patients gave informed 
consent for the intervention and prospective inclusion in a registry, and local institutional re-
view board approval was obtained. A total of 139 obstructive HC patients underwent surgical 
myectomy between 1991 and December 2012. Myectomy with AMLE was performed in 98 
patients (71%), isolated myectomy in 24 patients (17%), and myectomy combined with mitral 
valve replacement in 14 patients (12%).
Patients are selected for surgery at our HC center on the basis of the following indications: 
(1) peak left ventricular outflow tract (LVOT) gradient ≥ 50 mmHg at rest or on provoca-
tion and (2) presence of unacceptable symptoms despite maximally tolerated medications 
consisting of ß-blocking agents and/or calcium channel blockers. The decision to perform 
surgery was made after consensus of a heart team consisting of a cardiothoracic surgeon, an 
interventional cardiologist, and a cardiologist specialized in HC care.
Myectomy combined with AMLE is performed in patients with enlargement of the anterior 
mitral valve area (> 12 cm2), calculated with the formula previously validated by Klues et 
al [1-3]. The surgical technique has been described previously [2,3]. In brief, an autologous 
pericardial patch is harvested, trimmed of fat and extraneous tissue, immersed for 6 minutes 
in 0.4 % glutaraldehyde, and then placed in a normal saline bath. After opening the ascending 
aorta by an oblique incision, myectomy is performed to the left of an imaginary line through 
the nadir of the right coronary cusp in the beginning with a locally designed electrocautery 
device [4], later by excision with scissors and a rongeur or surgical knife. After myectomy 
AMLE is performed. A gap is created in the anterior mitral leaflet by a longitudinal incision, 
starting at the sub aortic hinge point and ending just before the rough zone. Then, an oval 
autologous pericardial patch, of about 2.5 cm wide and 3 cm long, is grafted across the bend-
ing point of the mitral valve where the systolic anterior motion (SAM) is maximal to stiffen 
the buckling anterior mitral valve leaflet (AMVL). The patch extends the width but not the 
length of the AMVL, which shifts the centrally attached chordae laterally. As a result, the 
chordae are stretched and erected, which will enhance leaflet coaptation. Finally, because 
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force produced by blood flow against the leaflet is proportional to its area, the increased leaflet 
will be pressed posterior, with a decrease in SAM and MR. The surgical results were assessed 
with transoesophageal echocardiography immediately after weaning from cardiopulmonary 
bypass and at a systolic blood pressure of ≥ 100 mmHg.
The clinical characteristics collected before the intervention included assessment of symp-
toms, New York Heart Association (NYHA) functional class and prescribed drugs. Physical 
examination and baseline laboratory studies were performed, including electrocardiography, 
transthoracic echocardiography, and cardiac catheterization. The echocardiographic data 
were reviewed by a physician unaware of the patient’s medical history. Echocardiography 
was performed in the month prior to surgery and after surgery repeated at 1 week, 3 months 
and at yearly intervals. Ventricular septum thickness was calculated at the site of myectomy 
from the septal width in diastole from both the parasternal short-axis and long-axis views. 
The severity of the mitral valve regurgitation (MR) was graded on a 0 to 4 scale by color flow 
Doppler echocardiography [5]. The severity of the SAM of the anterior mitral valve leaflet 
was determined from the 2D images and was graded on a scale from 0 to 3 depending on the 
mitral-septal distance (grade 0 indicating no SAM and grade 3 indicating prolonged contact 
between mitral valve and septum) [6]. The length of the anterior mitral valve leaflet was 
noted. Peak LVOT gradient was estimated with Doppler echocardiography by the modified 
Bernoulli equation (P = 4v2), where P is the pressure gradient and v is Doppler-determined 
blood velocity.
The primary endpoint was all-cause mortality. Follow-up information was obtained at 
routine visits at the HC outpatient clinic. For 7 patients follow-up information was collected at 
their referring cardiologist. Follow-up vital status and cause of death was obtained by review-
ing the hospital records, from general practitioners and civil registries. Sudden cardiac death 
(SCD) was defined as instantaneous and unexpected death within 1 hour after a witnessed 
collapse in patients who previously were in stable clinical condition, or nocturnal death with 
no antecedent history of worsening symptoms. Follow-up data were complete for all patients.
All statistics were performed using the SPSS 21 (IBM, Armonk, NY, USA) and Microsoft 
Excel 2010 (Microsoft Corporation, Redmond, WA, USA). Data are expressed as mean ± SD 
or number (percentage). The normal distribution for continuous data was examined with the 
Shapiro–Wilk test. Comparison of numerical variables was performed using the two-sided 
Student’s t-test or Wilcoxon rank-sum test or ANOVA test, and the chi-square or Fisher’s 
exact tests were used to compare qualitative variables. The p-values are two-sided; p < 0.05 
was considered statistically significant. The survival analysis model used proportional haz-
ards regression methodology; Kaplan-Meier survival curves were compared using log-rank 
statistics. Long-term survival of patients who underwent myectomy combined with AMLE 
was compared with age- and gender matched patients with non-obstructive HC and with the 
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expected survival curve for the general Dutch population. This expected survival curve was 
generated from the database of Statistics Netherlands, which incorporates all-cause mortality 
(www.cbs.nl). The administrative censoring date was set at August 1 2013. The authors had 
full access to the data and take responsibility for its integrity. All authors have read and agree 
to the manuscript as written.
resuLts
A total of 343 patients with obstructive HC (LVOT gradient > 50 mmHg) were evaluated at our 
center. Of these patients, 139 (41%) underwent myectomy, 97 (28%) underwent ASA, and 107 
table 1 – Clinical and demographic characteristics of 98 hypertrophic cardiomyopathy patients who 
received combined myectomy, 24 patients who underwent isolated myectomy, and 98 non-obstructive 
hypertrophic cardiomyopathy patients (controls).
Variable
Combined
myectomy
Isolated
Myectomy
Non-
obstructive
(n=98) (n=24) (n=98)
Age (years) 49 ± 14 48 ± 18 49 ± 15
Female 36 (37%) 10 (42%) 36 (37%)
NYHA III/IV 73 (74%) 19 (79%) 10 (10%)***
LV wall thickness (mm) 22 ± 5 20 ± 3 20 ± 5*
LV outflow tract gradient (mmHg) 93 ± 25 83 ± 20 8 ± 5***
Anterior mitral leaflet length (mm) 34 ± 4 29 ± 3*** 28 ± 4***
Mitral regurgitation 2.0 ± 0.9 1.3 ± 0.9*** 0.5 ± 0.7***
Medication
β-receptor antagonist 67 (68%) 19 (79%) 38 (39%)***
Calcium-channel blocker 48 (49%) 13 (54%) 12 (12%)***
Follow-up
Duration, y 8.3 ± 6.1 5.0 ± 6.0* 10.6 ± 5.5*
Cause of death
Heart failure 6 (6%) 0 4 (4%)
Sudden death 3 (3%) 0 3 (3%)
Non-cardiac 1 (1%) 1 (4%) 6 (6%)
* = P < 0.05; ** = P < 0.01; *** = P < 0.001 (compared with combined myectomy). Data represented as 
n (percentage) unless stated otherwise. HC: hypertrophic cardiomyopathy, LV: left ventricular; NYHA: 
New York Heart Association
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(31%) were treated medically. The majority of medically treated patients (91, 85%) reported no 
symptoms or mild (NYHA class I/II) symptoms at baseline, despite a mean LVOT gradient of 
70 ± 24 mmHg. The other 16 patients (15%) had an indication for invasive treatment but were 
considered not eligible due to severe comorbidities (e.g. one patient had liver cirrhosis due to 
alcohol abuse and kidney failure) or patient refusal (several patients refused further invasive 
treatment, mostly because they were at old age, and preferred no further interventions).
The baseline characteristics of the 98 combined surgery patients, 24 isolated myectomy 
patients are listed in table 1. Myectomy with additional coronary bypass grafting was per-
formed in 3 patients (3%). In 14 patients, myectomy and MVR was performed directly, instead 
of AMLE. Reasons for direct mitral replacement were (among others): chordal rupture or 
prolapse of posterior leaflet, severe calcification of the valvular apparatus, and infective 
endocarditis with valvular destruction. In most of these cases, MVR was planned prior to 
surgery, but the final decision to perform AMLE was made intraoperatively by the surgeon 
after epicardial and/or transesophageal beating heart echocardiography and visual inspection 
of the arrested heart. In 8 patients (8%) myectomy and AMLE was performed after failed 
alcohol septal ablation (ASA) or embolization using coils.
Because advanced symptoms refractory to pharmacologic therapy represent the standard 
indication for operation, patients who underwent myectomy (both isolated and combined 
with AMLE) expectedly showed more severe functional disability at study entry than patients 
with non-obstructive HC; 74-79% in NYHA class III or IV compared with 7% in the non-
obstructive group (p<0.001). The length of the anterior mitral valve leaflet prior to surgery 
was longer in patients who underwent combined surgery, compared with the isolated myec-
figure 1 – NYHA functional class at baseline and at latest follow-up in patients with obstructive 
hypertrophic cardiomyopathy treated with myectomy and mitral leaflet extension.
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tomy and non-obstructive patients. Mitral valve regurgitation (prior to surgery) was also more 
severe in patients who underwent combined surgery (table 1).
The myectomy combined with AMLE group experienced substantial symptomatic and 
hemodynamic improvement after surgery; 73 (74%) patients were in NYHA functional class 
III or IV before operation, whereas only 2 of 89 (2%) remaining patients at latest follow-up 
were in NYHA class III. (figure 1). Compared with preoperative data, there were significant 
changes in peak LVOT gradient, MR severity and presence of systolic anterior motion of the 
mitral valve at latest follow-up compared with pre-operative state (table 2).
Long-term follow-up was 8.3 ±6.1 years or 809 patient-years. Four patients (2 of those were 
operated after failed ASA) developed complete heart block during surgery. Three patients 
received a permanent pacemaker, in the remaining patient combined with an implantable 
cardioverter defibrillator (ICD) because of a high risk status for SCD. An ICD was implanted 
in 17 more patients for primary prevention of SCD. One patient received appropriate ICD-
shocks during follow-up. Paroxysmal or persistent atrial fibrillation occurred in 36 (37%) 
patients during follow-up. Of these patients, in 21 (21%) AF occurred during follow-up, and 
15 (15%) patients only had an episode of post-operative AF (6 of these had a prior history of 
AF). Electric cardioversion during post-operative recovery was necessary in 7 patients (7%).
None of the patients had an indication for reinstitution of cardiopulmonary bypass. Perfect 
mitral competence (grade 0 MR) was present in 57 (58%) of patients and only 2 (2%) had grade 
3+ MR at latest follow-up. In 1 patient (1%) early valve repair failure, due to rupture of the 
new chordae (13 days after initial surgery), leading to mitral valve replacement was necessary. 
Other indications of re-surgery are shown in table 3.
None of the patients died during surgery or in hospital. Twelve (12 %) patients died during 
follow-up; 3 suffered SCD, respectively after 1.9, 2.8, and 16.9 years. Six (6%) patients died 
of end-stage heart failure, after a median of 5.1 years (table 3). Three patients (3%) died of 
non-cardiac causes. The shortest time to death after the procedure was 3 months after surgery 
table 2 – Long-term echocardiographic follow-up in 98 obstructive hypertrophic cardiomyopathy 
patients treated with myectomy combined with anterior mitral valve leaflet extension.
Variable
Baseline Follow-up
(n=98) (n=86) P
Ventricular septum (mm) 22 ± 5 16 ± 4 < 0.001
LV end diastolic diameter (mm) 44 ± 6 49 ± 7 < 0.001
LV outflow tract gradient (mmHg) 93 ± 25 9 ± 8 < 0.001
Left atrial size (mm) 48 ± 8 49 ± 11 0.5
Systolic anterior motion (grade) 2.4 ± 0.9 0.1 ± 0.3 < 0.001
Mitral valve regurgitation (grade) 2.0 ± 0.9 0.5 ± 0.8 < 0.001
LV: left ventricular
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in the patient with LVEF of 30% and grade III diastolic dysfunction. In the isolated myectomy 
group, 1 (4%) patient died due to a non-cardiac cause.
As seen in figure 2; the 1-, 5 -, 10-, and 15- year cumulative survival after myectomy 
combined with AMLE was 98%, 92%, 86%, and 83%, respectively and did not differ from the 
general population (99%, 97 %, 92%, and 85%, respectively; log-rank p = 0.3). Likewise, the 1-, 5 
-, 10-, and 15- year cumulative survival (98%, 97%, 88%, and 83%, respectively, log-rank p = 0.8) 
of age- and gender-matched non-obstructive HC patients was not different from the patients 
who underwent myectomy combined with AMLE. The number of cardiac related deaths in 
both groups was identical; however in the non-obstructive HC group more patients died from 
non-cardiac causes during long-term follow-up.
dIsCussION
This study shows that myectomy combined with AMLE, which stiffens the mid-segment of 
the anterior leaflet, is an effective procedure to remove the LVOT obstruction in selected HC 
table 3 – Events during 20-year follow-up in 98 obstructive hypertrophic cardiomyopathy patients 
treated with myectomy and mitral valve leaflet extension
Latest Follow-up
Total mortality 12 (12%)
Operative mortality 0
Sudden cardiac death 3 (3%)
End-stage heart failure 6 (6%)
Non-cardiac 3 (3%)
Atrial fibrillation 36 (37%)
Pacemaker 4 (4%)
Implantable cardioverter-defibrillator 18 (18%)
Re-operation 17 (17%)
Mitral valve replacement 3 (3%)
Pericardial effusion 3 (3%)
Heart transplantation 2 (2%)
Patch-dehiscence 2 (2%)
Bleeding 4 (4%)
Mediastinitis 2 (2%)
Residual obstruction 1 (1%)
Data represented as n (percentage).
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patients. The operation can be performed at the cost of acceptable morbidity and very low 
operative mortality. It leads to long-term symptom relief and comparable survival to age and 
sex-matched patients with non-obstructive HC and subjects from the general Dutch popula-
tion.
LVOT obstruction is an important pathophysiological component of HC. Clinical studies 
performed in large HC populations have identified a consistent relationship between LVOT 
gradients at rest and heart failure symptoms and cardiovascular events; including overall 
probability of death due to heart failure, stroke and progression to NYHA functional class III 
or IV [7,8]. Severely symptomatic drug-refractory obstructive HC patients are candidates for 
invasive septal reduction interventions as surgical myectomy or ASA.
The current study consisted of consecutive patients with enlarged anterior mitral leaflets 
and typical SAM as described in previous reports from our institute treated with myectomy 
combined with AMLE [3] (figure 3). The immediate reduction of the LVOT gradient after 
surgical myectomy (with AMLE) has positive effects on LV filling pressures, heart failure 
symptoms and exercise capacity in patients with drug-refractory obstructive HC [9-11]. In 
this study there was a clear improvement in hemodynamics and NYHA class, and these 
benefits continue in 74% up to 20 years.
figure 2 – Kaplan-Meier event-free survival comparison between patients with obstructive hypertro-
phic cardiomyopathy treated with myectomy and mitral leaflet extension, non-obstructive hypertrophic 
cardiomyopathy patients, and the general population.
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The procedure was without operative mortality in this cohort, with an excellent long-term 
cumulative survival equal to general Dutch population of age-and gender matched patients 
and comparable with non-obstructive HC patients. This outcome is comparable with the 
reported long-term survival benefit of obstructive HC patients who underwent isolated my-
ectomy in the Mayo Clinic and Toronto General Hospital [12,13]. In the larger Mayo Clinic 
series 10-year overall survival was 83%, which was equivalent to expected in the matched 
general U.S. population. In the latter study, patients who underwent myectomy combined 
with concurrent operative procedures were excluded [13].
However, obstructive HC can also be associated with a variety of intrinsic abnormalities of 
the mitral valve, including increased mitral leaflet area [1,14]. These abnormalities may pre-
dispose to residual SAM and result in suboptimal outcome after isolated myectomy [15,16]. 
Our results show a post-operative reduction of SAM from 2.4 ±0.9 to 0.1 ± 0.3, and in only 1 
patient re-resection of the septum to further reduce the LVOT gradient was necessary. In the 
study performed by Wan et al [17], mitral valve repair was performed instead of AMLE. In 6 
of the 32 patients (19%) SAM was present post-operatively. In our study, only 7 patients (7%) 
had SAM after surgery. Balaram et al. performed mitral plication in 132 patients, and showed 
a similar reduction in MR severity (from 2.3 ± 0.9 to 0.5 ± 0.6), and need for re-resection (2 
figure 3 – Preoperative and postoperative 2D Parasternal long-axis view (top) and Continuous Wave 
Doppler (bottom) echocardiograms in patient treated with combined myectomy and mitral valve leaflet 
extension with successful reduction of the left ventricular outflow tract gradient. Left arrow shows sys-
tolic anterior motion of the mitral leaflet. Right arrow indicates the patch in the mitral leaflet (Ao: Aorta; 
LA: left atrium; LV: left ventricle; PRE: preoperative; POST: postoperative).
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patients, 1.5%) [18]. We do not propose myectomy combined with AMLE to be performed 
in all obstructive HC patients, but this technique can be a safe and valuable addition in the 
treatment of LVOT obstruction, especially in patients with enlarged mitral leaflets.
Other studies with patients who underwent myectomy and mitral valve repair with differ-
ent techniques show similar survival and improvement in functional class, LVOT gradient, 
SAM and mitral valve regurgitation at follow-up [19,20]. A study by Kaple et al. reports overall 
survival after myectomy combined with a number of repair techniques at 1-, 5 - and 10 years 
of respectively 91%, 81% and 66%; the patients in this study were however significantly (59±14 
versus 49±14, p<0.001) older than those in the current study [14]. The current study is to our 
knowledge the first to describe equivalent survival to the general population in obstructive 
HC patients undergoing a myectomy combined with AMLE. During long-term follow-up 88% 
patients were free of reoperation, which is comparable with the results of combined surgery 
in obstructive HC reported by others at 3 years follow-up [14].
In comparison with the age-and gender matched patients with non-obstructive HC car-
diac related mortality in both groups was similar. The annual mortality rate of the operated 
patients (1.4%/year) was similar to previously reported mortality rates in HC patients during 
long-term follow-up [12,21,22]. We did find that end-stage heart failure was the most com-
mon cause of death after myectomy with AMLE, but it was similar to non-obstructive patients 
(p=0.5), and median time to death was >5 years after surgery.
The majority of the patients were in NYHA class III/IV prior to surgery, and mortality 
related to end-stage heart failure in these patients is high and patients suffer from debilitating 
symptoms [7]. The outcome of this study, in line with aforementioned literature concerning 
isolated myectomy or surgical plication of the AMVL, shows that myectomy (with AMLE) 
delays or even averts the onset of heart-failure in patients with obstructive HC, and improves 
quality of life in these patients.
This is a single institution’s consecutive experience with myectomy combined with 
AMLE in a relatively small number of selected obstructive HC patients. These patients were 
deemed not acceptable candidates at our institution for isolated myectomy or ASA because 
of mitral valve abnormalities. We included a third group of obstructive HC patients treated 
by isolated myectomy, however this group was relatively small because between 1999 and 
2007 almost all patients (> 90 patients) suitable for isolated myectomy underwent ASA at our 
center, mostly because of patient preference [23]. Due to small sample size further analysis on 
comparing isolated and combined myectomy in our population was not appropriate. Based on 
the experience in our center with this specific technique there is also a referral bias; especially 
obstructive HC patients with enlarged mitral valve leaflets are being referred for surgery. 
Despite the lack of a statistically significant difference in the Kaplan-Meir survival analysis 
between patients who underwent myectomy combined with AMLE and the general Dutch 
population, the study may not be powered enough to detect such a difference.
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Completely percutaneous repair of a failing 
surgical mitral valve repair
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A 70-year-old female patient with hypertrophic cardiomyopathy was admitted 18 months after 
surgical septal myectomy, venous bypass of the left circumflex artery, and mitral valve repair 
using an autologous pericardial patch extension of the anterior mitral leaflet. Echocardiogram 
revealed severe mitral insufficiency with a central regurgitation based on malcoaptation of the 
mitral leaflets and an additional leak due to a perforation in the anterior leaflet patch (Panel A). 
The heart team agreed upon Mitraclip implantation and plug closure of the patch perforation.
Panel B demonstrates the mitraclip opening in the left ventricle before leaflet grasping. 
The mitral double orifice after Mitraclip implantation as seen by three-dimensional by 
transoesophageal echocardiography (TOE) is shown in Panel C. Panels D and E display the 
residual leak through the patch (red arrow) after mitraclip (arrowhead) implantation. The 
patch perforation is crossed by a 6-French multipurpose diagnostic catheter (Panel F—TOE, 
Panel G Fluoroscopy, note mitraclip (*) in situ). A 8 × 6 mm AMPLATZER™ Duct Occluder 
(St Jude Medical, St Paul, MN, USA) is deployed in the patch perforation with initially 
mild residual patch leakage (Panel H—TOE). Transthoracic echocardiography 4 days later 
confirms mild central mitral regurgitation with no residual patch leakage (Panel I). Panel J 
(TTE) and K(fluoroscopy) illustrate the mitraclip (*) and duct occluder within the patch 
(arrow) in situ.
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Combining myectomy and mitral leaflet 
extension in the treatment of a true obstructive 
cardiomyopathy patient
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ABstrACt
Left ventricular outflow tract obstruction is an important pathophysiological component of 
hypertrophic cardiomyopathy, and can be treated with surgical septal myectomy, with or 
without papillary muscle repositioning and mitral valve repair. In this report we describe 
the treatment of a patient with severe LVOT obstruction and grade 3 mitral regurgitation, 
but without hypertrophy: a case of true obstructive cardiomyopathy. The procedure, myec-
tomy combined with mitral leaflet extension, resolved the mitral regurgitation and no LVOT 
obstruction was present afterwards. This illustrates the value of mitral leaflet extension in 
selected patients, especially when there is only borderline hypertrophy.
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5
rePOrt
Obstruction of the left ventricular outflow tract (LVOT) is present in the majority of the 
patients with hypertrophic cardiomyopathy (HCM) and is a major determinant of outcome.1 
The obstruction is caused by a combination of muscular hypertrophy of the ventricular 
septum, systolic anterior motion (SAM) of the anterior mitral valve leaflet (AMVL) and 
anomalous papillary muscle insertion. The first step in the treatment of LVOT obstruction is 
to alleviate symptoms by using β-receptor antagonists, verapamil or disopyramide. If this is 
not sufficient and patients remain in NYHA or CCS class III/IV, and have an LVOT gradient 
of >50 mmHg, patients are eligible for invasive therapy. This can be surgical septal myectomy 
or alcohol septal ablation. The 2011 ACCF/AHA guidelines 2 recommend transaortic septal 
myectomy as the most appropriate treatment for these patients. This procedure was devel-
oped by Morrow over 5 decades ago, and initially a 3-cm long resection was performed. Cur-
rently, a more extended myectomy is performed, with a resection of about 7 cm. In addition 
to the myectomy, papillary muscles can be repositioned and at the Thoraxcenter in patients 
with elongated AMVL, a mitral valve extension, made from autologous pericardial tissue, is 
performed.3 Long-term outcome after surgical myectomy are excellent and the procedure 
plays a central role in the treatment of obstructive HCM.However, in this report we describe 
the treatment of a patient with severe LVOT obstruction and grade 3 mitral regurgitation, but 
without hypertrophy: a case of true obstructive cardiomyopathy.
A 44-year old man was referred to our hospital with invalidating symptoms of dyspnea on 
exertion in NYHA class III. Family history was inconclusive. On clinical examination there 
was a systolic ejection murmur grade 3/6, which increased during Valsalva-maneuver. The 
electrocardiogram was slightly abnormal: a sinusbradycardia, with a normal QRS-complex, 
and a negative T-wave in aVF. Echocardiography revealed a normal systolic and diastolic 
function with a wall thickness of 9-10 mm, except a borderline hypertrophy of the basal 
ventricular septum (14 mm). However, there was a clear SAM of the AMVL with mitral-
septal contact, and a grade III mitral regurgitation. The LVOT obstruction increased from 
55mmHg at rest to 75 mmHg after Valsalva (figure 1). The patient was already treated 
with metoprolol and verapamil by his referring cardiologist at maximal tolerable dosages, 
and was accepted for surgery. Cardiac surgery was performed with standard techniques of 
cardiopulmonary bypass with moderate hypothermia and myocardial preservation. After 
aortotomy, myectomy was attempted, but the septum was minimally resected, due to the 
lack of evident hypertrophy. Next, all abnormal papillary muscles were resected from the 
anterior wall, and a mitral leaflet extension, as described above, was performed. Postopera-
tive results were assessed by transesophageal echocardiography and demonstrated a mild 
MR (grade I) and LVOT gradient of ±10 mmHg. The further recovery was uneventful, and 
the patient was discharged without any complications. The patient continued to visit the 
outpatient clinic, and in the following 7 years the patient remained asymptomatic. Latest 
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echocardiographic control showed no SAM and minimal MR. There was no LVOT obstruc-
tion (figure 2).
dIsCussION
This case of obstructive cardiomyopathy, with only borderline hypertrophy of the basal septal 
wall, illustrates the role of the mitral valve apparatus and abnormal papillary muscle anatomy 
in LVOT obstruction. And although LVOT obstruction without hypertrophy is not a com-
figure 1 – Preoperative 2D and doppler echocardiography, demostrating a clear systolic anterior mo-
tion (SAM, left panel), severe mitral regurgitation (middle panel) and high left ventricular outflow tract 
obstruction (right panel). LA: left atrium; LV: left ventricle; RV: right ventricle.
figure 2 – Post-operative 2D and doppler echocardiography, in which no SAM or mitral regurgation 
is present. Left ventricular outflow tract gradient is not increased.
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mon finding, even in the absence of muscular hypertrophy it can still cause invalidating and 
drug-refractory symptoms. This case also shows that an isolated myectomy, or alcohol septal 
ablation, would not have been sufficient to relieve symptoms in this patient. The additional 
advantages of myectomy combined with mitral leaflet extension (MLE) are gained by the 
insertion of the pericardial patch on the central part of the AMVL. This stiffens the lax leaflet 
and thus prevents SAM, also the greater leaflet area reduces the mitral regurgitation.3
There is a certain controversy around this procedure. Other groups, for example the Mayo 
Clinic series, have excellent results without touching the mitral valve, and advocate that if the 
myectomy is sufficiently extended, there will be no remaining LVOT obstruction.4 But in pa-
tients with not a very thick septum, such as the patient in this case, there might not be enough 
muscle to remove. At our center there is ± 20 years of experience with myectomy combined 
with MLE, and long-term outcome is comparable to the non-obstructive HCM population.5 
On the other hand, myectomy combined with MLE should not be performed in all obstructive 
HCM patients. If there is limited (or no) hypertrophy, and the presence of enlarged mitral 
leaflets, MLE can be a safe and valuable addition to treat the LVOT obstruction.
In conclusion, myectomy combined with mitral leaflet extension, resolved the mitral 
regurgitation, and no LVOT obstruction was present afterwards. This illustrates the value of 
mitral leaflet extension in selected patients, especially when there is only borderline hyper-
trophy.
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ABstrACt
Objectives
The aim of this study is to assess the long-term effects of alcohol dosage in alcohol septal 
ablation (ASA) on mortality and adverse arrhythmic events (AAE).
Background
ASA can be performed to reduce left ventricular outflow tract (LVOT) obstruction in patients 
with hypertrophic cardiomyopathy (HCM). However, the effect of alcohol dosage on long-
term outcomes is unknown.
methods
This retrospective cohort study includes 296 HCM patients (age 60 ± 22 years, 58% male) 
who underwent ASA because of symptomatic LVOT obstruction. 29 patients (9.8%) were 
excluded because the alcohol dosage could not be retrieved. Primary endpoints were all-cause 
mortality and AAE.
results
During 6.3 ± 3.7 years of follow-up all-cause mortality and AAE rates were similar in patients 
who received ≤2.0 mL (n= 142) and >2.0 mL (n= 121) alcohol during ASA. Age was the only 
independent predictor of mortality (HR 1.1 95% CI 1.0-1.1, p< 0.001). Predictors of AAE 
were maximum CK-MB >240 U/L (HR 3.3 95% CI 1.5-7.2, p= 0.003), and sudden cardiac 
death survivor (HR 5.9 95% CI 1.7-20.3, p= 0.004). There was a mild to moderate correlation 
between CK-MB levels and amount of alcohol (Spearman’s ρ 0.39, p< 0.001), cross-sectional 
area of the target septal branch ostium/ostia (Spearman’s ρ 0.19, p= 0.003), and maximum 
ventricular wall thickness (Spearman’s ρ 0.17, p= 0.006).
Conclusions:
Alcohol dosage appears not to have a long-term effect on mortality and AAE. A larger infarct 
size created by ASA increases the risk of AAE, and extended monitoring of these patients is 
advised.
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INtrOduCtION
Hypertrophic cardiomyopathy (HCM) is an inheritable myocardial disease present in one 
in 500 of the general population (1). HCM is characterized by left ventricular hypertrophy 
and is often associated with (provocable) left ventricular outflow tract (LVOT) obstruction 
(2). Symptoms such as dyspnea (on exertion), syncope and angina due to LVOT obstruction 
can be alleviated by the use of β-receptor antagonists, verapamil or disopyramide. If patients 
remain severely symptomatic despite optimal medical therapy, septal reduction therapy 
should be considered, either by surgical myectomy or alcohol septal ablation (ASA) (3-6). 
ASA was introduced as a percutaneous alternative to surgical myectomy, and has shown to 
be effective in reducing LVOT obstruction and associated symptoms (7-9). In the 20 years 
since its introduction, ASA has become a valuable alternative in the management of HCM 
patients, and important developments (e.g. the use of intramyocardial ultrasound contrast 
agents) have improved the safety and efficacy of the technique (8-10). Concerns about ASA 
remain however, especially regarding the possible arrhythmogenic effect of the ablation scar 
in patients already at an increased risk of life-threatening arrhythmias (11). The effect of the 
dosage of intracoronary alcohol in this context remains controversial, and long-term results 
are scarce (12-15). The aim of this study is to evaluate the long-term effects of alcohol dosage 
in ASA on mortality and adverse arrhythmic events (AAE).
mAterIALs ANd metHOds
study design and patient population
A two-center, observational cohort design was used. The study population consisted of 296 
consecutive HCM patients who underwent ASA in the St. Antonius Hospital Nieuwegein, 
Nieuwegein, the Netherlands (n = 209), and the Thoraxcenter, Erasmus Medical Center, 
Rotterdam, the Netherlands (n = 87). All patients met the criteria for invasive treatment: (i) 
ventricular septal thickness ≥ 15 mm, (ii) (provocable) LVOT gradient ≥ 50 mmHg, and (iii) 
persistent New York Heart Association (NYHA) class III/IV dyspnea or Canadian Cardio-
vascular Society class III/IV angina despite optimal medical therapy (3-5). The choice of ASA 
instead of surgical myectomy was based on patient profile (age, comorbidities, etc.) and pa-
tient preference. Patients were divided in 2 groups, based on the amount of alcohol received: 
a high dose group (> 2.0 mL) and a low dose group (≤ 2.0 mL). A 2.0 mL cut-off was chosen 
because this was the median amount of intracoronary alcohol used in the entire cohort (range 
0.75-8 mL), and because this was in line with previous studies (12-13). Patients where the 
alcohol dosage could not be retrieved were excluded. The study conforms to the principles of 
the Helsinki Declaration. All patients gave informed consent prior to the procedure, and local 
institutional review board approval was obtained.
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the procedure
ASA was performed as described previously (16-17). After placement of a temporary right 
ventricular pacing lead, a double lumen pigtail catheter was advanced in the left ventricle 
allowing for simultaneous pressure recordings in the left ventricle and ascending aorta. Coro-
nary angiography was then performed and after visual assessment of the septal perforator 
branches of the left anterior descending artery the first or second septal perforator was wired 
with a 0.014” coronary guidewire introduced into an over-the-wire (OTW) balloon. After 
removal of the coronary guidewire, 2 mL of echo contrast agent (Sonovue, Bracco Diagnos-
tics, Milan, Italy) was selectively injected into the septal perforator through the inner lumen 
of the OTW balloon to allow for echocardiographic identification of the basal left ventricular 
septum as appropriate anatomical target. If the area of perfusion on the septum was not the 
area of contact by systolic anterior motion of the anterior leaflet of the mitral valve, another 
septal perforator was cannulated. Subsequent dosages of 0.5 mL of absolute alcohol were 
injected slowly over 1-15 minutes in the septal perforator under continuous echocardiographic 
guidance, after which the balloon remained in place for 10 more minutes. After the balloon 
was deflated, gradient reduction was assessed, and coronary angiography was repeated to con-
firm the occlusion of the septal branch and patency of the left anterior descending coronary 
artery. If significant LVOT gradient would remain afterwards, additional septal perforators 
could be treated. The temporary pacemaker lead was kept in place for at least 24 hours. All 
patients were monitored for at least 24 hours at the intensive coronary care unit afterwards.
Follow-up and endpoints
Follow-up started at the time of ASA, and the first procedures were performed in 1999. 
Baseline patient characteristics of interest included age, sex, NYHA class, maximum left 
ventricular wall thickness (LVWT), maximum (provocable) LVOT gradient, left ventricular 
ejection fraction, atrial fibrillation, coronary artery disease, medication used, conventional 
risk factors for sudden cardiac death (SCD) (3-5), amount of intracoronary alcohol used 
during the procedure and the cross-sectional area of the ostium/ostia of the target septal 
perforator(s).
The primary endpoints were all-cause mortality and AAE during long-term follow-up. 
AAE consisted of SCD, resuscitated cardiac arrests due to ventricular fibrillation
(VF) or tachycardia, and appropriate implantable cardioverter-defibrillator (ICD) firing. 
Secondary endpoints were periprocedural (< 30 days) mortality and AAE, LVOT gradient 
reduction, maximum CK-MB, temporary atrioventricular (AV) block, permanent pacemaker 
implantation, re-intervention (ASA or myectomy) and HCM-related death (death due to 
heart failure, stroke or SCD).
Mortality and adverse events were retrieved from hospital patient records at the center 
where follow-up occurred, from civil service population registers, and from information pro-
vided by patients themselves and/or their general practitioners. All ICD shocks were evalu-
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ated by an experienced electrophysiologist, unaware and independent of the study purpose 
and endpoints. If no events occurred during follow-up, the administrative censoring date was 
set at November 1st, 2012.
statistical Analysis
SPSS version 20 (IBM, Armonk, NY, USA) and Microsoft Excel 2010 (Microsoft Corpora-
tion, Redmond, WA, USA) were used for all statistical analyses. Categorical variables were 
summarized as percentages. Normally distributed continuous data are expressed as mean ± 
standard deviation and non-normally distributed data are expressed as median ± interquartile 
range. To compare continuous variables Student t test or Mann-Whitney U-test were used, 
and to compare categorical variables the χ2-test was used. To identify clinical predictors 
of all-cause mortality and AAE univariable and multivariable Cox regression analysis was 
used. Variables were selected for multivariable analysis if the univariable p-value was < 0.10 
and were expressed as hazard ratio (HR) with 95% confidence interval. The final number of 
variables was restricted according to the number of endpoint events to avoid overfitting the 
multivariable model. For correlation analysis, spearman’s ρ was calculated in case of a non-
linear relationship between the variables, or if the variables were non-normally distributed. A 
p-value ≤ 0.05 was considered statistically significant.
resuLts
Clinical characteristics
In the cohort of 296 patients, 29 (9.8%) were excluded because no alcohol dosage could be 
retrieved. Of these 29 patients (age 60 ± 22, 44% male), 1 experienced periprocedural VF 
and 3 patients died (none in the first 30 days). The cause of death was SCD in 1 patient, and 
non-cardiac in the others.
The baseline characteristics of the remaining 267 patients (age 61 ± 14, 58% male) are 
found in table 1. Patients in the low dose group (n = 143) were older (63 ± 24 years) than 
those from the high dose group (n = 124, age 58 ± 22 years, p = 0.005). Conversely, fewer 
patients from the low dose group were in NYHA class III/IV (76% vs. 85%, p = 0.05) or had 
systolic dysfunction on echocardiography (2% vs. 9%, p = 0.03).
Procedural outcomes
Over time a reduction of the mean amount of alcohol used for ASA was seen (figure 1, 
p < 0.001). This was irrespective of the pre- and post-procedural LVOT gradient (figure 2). 
The infarct size after a high amount of alcohol was greater than after a low dose (maximum 
CK-MB levels 213 ± 137 U/L vs. 152 ± 91 U/L, p < 0.001), which resulted in a slightly greater 
reduction in LVOT gradient (95% vs. 86%, p < 0.001). The NYHA class post-procedure was 
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similar in both groups though (p = 0.08), and more re-intervention (ASA or myectomy) was 
necessary in patients who received a high dose compared with the low dose group (15% vs. 
6%, p = 0.01) (table 2). The maximum CK-MB level was correlated with amount of alcohol 
(Spearman’s ρ 0.39, p < 0.001), cross-sectional area of the target septal branch ostium (Spear-
man’s ρ 0.19, p = 0.003), and maximum LVWT (Spearman’s ρ 0.17, p = 0.006). Amount of 
alcohol and maximum LVWT were not associated (Spearman’s ρ 0.09, p = 0.15).
Temporary periprocedural AV block was present in 78 patients (29%). This resulted in 
permanent pacemaker implantation in 14 patients (10%) of the low dose group and 9 patients 
(7%) of the high dose group (p = 0.5). Within the first 30 days of follow-up 4 patients died, of 
table 1 – Baseline characteristics of 267 alcohol septal ablation patients.
n =
Low alcohol group
(≤ 2.0 mL)
High alcohol group
(> 2.0 mL)
143 124 P
Age, median ± IQR, years 63 ± 24 58 ± 22 0.005
Female 63 (44) 50 (40) 0.5
NYHA III/IV 108 (76) 105 (85) 0.05
Maximum LVWT, median ± IQR, mm 20 ± 5 20 ± 6 0.1
LVOT gradient, median ± IQR, mmHg 90 ± 86 100 ± 42 0.8
Systolic dysfunction (EF < 50%) 3 (2) 11 (9) 0.03
Coronary artery disease 34 (24) 23 (19) 0.3
Atrial fibrillation 37 (26) 24 (19) 0.2
Medication
β-receptor antagonist 92 (64) 87 (70) 0.3
Calcium-channel blocker 54 (38) 41 (33) 0.4
Risk factors
Sudden cardiac death survivor 4 (3) 3 (2) 1.0
≥ 2 conventional risk factors for SCD 13 (9) 14 (11) 0.4
Procedure
Volume of alcohol injected, median ± IQR, mL 2 ± 0 3 ± 1.5 < 0.001
Mean volume of alcohol injected, mL 1,8 3,7
Ostium area, median ± IQR, mm² 1.8 ± 1.4 2.3 ± 1.4 < 0.001
Data represented as n (percentage) unless stated otherwise. EF: ejection fraction, IQR: interquartile 
range, LVOT: left ventricular outflow tract, LVWT: left ventricular wall thickness, NYHA: New York 
Heart Association, SCD: sudden cardiac death.
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which 3 received a high amount of alcohol (p = 0.3). The causes of death were peri-procedural 
VF in 2 patients, tamponade one day post-procedure in 1 patient, and ventricular tachycardia 
with deterioration to VF two days post-procedure in 1 patient. AAE occurred in 10 patients, 
of which 6 received a high amount of alcohol (p = 0.3) (table 3). Besides the above, these 
comprised of peri-procedural VF with successful defibrillation in 3 patients, and VF dur-
figure 1 – The learning-curve effect. Showing systematic reduction of the mean amount of alcohol 
injected during the procedure over time.
figure 2 – LVOT gradient reduction. Pre-procedure LVOT gradient (grey circles) and post-proce-
dure LVOT gradient (red squares) over time.
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ing the first week post-procedure with successful resuscitation in 4 patients. The latter all 
received an ICD for secondary prevention.
Long-term outcomes
Of the 267 patients, follow-up was completed in 263 patients (99%) with a median follow-up 
duration of 6.3 ± 3.7 years. The 4 patients lost to follow-up had moved abroad and could not 
be reached. During follow-up there was a total of 38 deaths in the entire cohort (table 2): 
13 (34%) were HCM-related, 22 (58%) patients died of certified non-cardiac causes, and no 
cause of death could be identified in 3 (8%). Kaplan-Meier estimates of survival are shown in 
table 2 – Long-term outcomes after alcohol septal ablation in 263 patients.
n =
Low alcohol group
(≤ 2.0 mL)
High alcohol group
(> 2.0 mL)
142 121 P
Years of follow-up, median ± IQR 4.9 ± 6.1 7.6 ± 4.1 < 0.001
Residual LVOT gradient > 3 months post-
procedure, median ± IQR, mmHg
11 ± 18 6 ± 20 < 0.001
Reduction in LVOT gradient > 3 months post-
procedure, median ± IQR, %
86 ± 25 95 ± 21 < 0.001
NYHA class III/IV > 3 months post-procedure 8 (6) 15 (12) 0.08
Redo septal reduction therapy 8 (6) 18 (15) 0.01
Mortality
Total mortality 17 (12) 21 (17) 0.2
HCM-related death 5 (4) 8 (7) 0.2
Non-cardiac 11 (8) 11 (9) 0.7
Unknown 1 (1) 2 (2) 0.5
5-year survival, % 94 91 0.5
10-year survival, % 89 85 0.8
Adverse arrhythmic events (> 30 days post-procedure)
Total adverse events 7 (5) 9 (7) 0.4
Sudden cardiac death 2 (1) 3 (2) 0.5
Resuscitated cardiac arrest 2 (1) 1 (1) 1.0
Appropriate ICD shocks 2 (1) 4 (3) 1.0
Annual events, %/year 0.91 0.99 0.4
Data are represented as n (percentage), unless stated otherwise. HCM: hypertrophic cardiomyopathy, 
ICD: internal cardioverter defibrillator, IQR: interquartile range, LVOT: left ventricular outflow tract, 
NYHA: New York Heart Association.
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figure 3. All-cause mortality was similar in patients who received ≤ 2.0 mL and patients who 
received > 2.0 mL intracoronary alcohol during ASA (p = 0.2). The same applied for HCM-
related mortality (p = 0.2). The 5- and 10-year survival for patients receiving a low amount 
of alcohol was 94% and 89%, respectively. Which was similar to the 91% and 85% for patients 
receiving a high amount of alcohol (p = 0.5 and p = 0.8, respectively). The only independent 
predictor of all-cause mortality was age (HR 1.1 95% CI 1.0-1.1, p < 0.001). A persisting high 
post-procedural LVOT gradient (≥ 50 mmHg) showed a trend towards increased mortality (p 
= 0.06) (table 4).
AAE during long-term follow-up were also similar in the two groups: 7 events (5%) oc-
curred in the low dose group and 9 events (7%) in the high dose group (p = 0.4). This translates 
in an annual event rate of 0.91% after ASA with < 2.0 mL alcohol and 0.99% after ASA with > 
2.0 mL alcohol. Five patients died of SCD, 3 patients were resuscitated from cardiac arrest, 
and 6 patients received an appropriate ICD shock (table 2). Multivariable analysis identified 
the following independent predictors of AAE: maximum CK-MB > 240 U/L (HR 3.3 95% CI 
1.5-7.2, p = 0.003), and SCD survivor (HR 5.9 95% CI 1.7-20.3, p = 0.004) (table 4).
table 3 – Periprocedural (< 30 days) outcomes after alcohol septal ablation in 267 patients.
n =
Low alcohol group
(≤ 2.0 mL)
High alcohol group
(> 2.0 mL)
143 124 P
Maximal CK-MB levels, median ± IQR, U/L 152 ± 91 213 ± 137 < 0.001
Atrioventricular block 46 (32) 32 (26) 0.2
Pacemaker implantation 14 (10) 9 (7) 0.5
Periprocedural mortality
Total mortality 1 (1) 3 (2) 0.3
Sudden cardiac death 1 (1) 2 (2) 0.5
Cardiac tamponade - 1 (1) -
Periprocedural adverse arrhythmic events
Total adverse events 4 (3) 6 (5) 0.3
Sudden cardiac death 1 (1) 2 (2) 0.5
Sustained ventricular tachycardia 2 (1) - -
Resuscitated cardiac arrest 1 (1) 4 (3) 0.2
Data are represented as n (percentage) unless stated otherwise. IQR: interquartile range.
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dIsCussION
The most important finding of this study was that long-term mortality and AAE rates after 
ASA were not increased if a higher dose of alcohol was used. Also, periprocedural AAE and 
mortality, AV-blocks and pacemaker implantations were similar in both high dose alcohol and 
low dose alcohol groups.
AsA and alcohol dosage
ASA was introduced in 1995 as an alternative to surgical myectomy (7). Initially, relatively 
high doses of alcohol were used (3-6 mL). Over time clinical experience combined with better 
strategies to identify the target septal branches (e.g. the use of intramyocardial ultrasound 
table 4 – Predictors of all-cause mortality and adverse arrhythmic events - Analysis of clinical vari-
ables associated with all-cause mortality and adverse arrhythmic events in 263 patients after ASA.
Univariable Multivariable
HR CI 95% P HR CI 95% P
Mortality (n = 38)
Age 1.06 1.03-1.09 < 0.001 1.07 1.04-1.10 < 0.001
Female 2.2 1.12-4.13 0.02 1.2 0.56-2.64 0.6
High dose alcohol (> 2.0 mL) 1.0 0.53-1.93 1.0
Post-procedure NYHA III/IV 1.7 0.64-4.38 0.3
Post-procedure LVOT gradient > 50 
mmHg
2.8 1.09-7.35 0.03 2.6 0.97-6.78 0.06
Coronary artery disease 2.2 1.15-4.30 0.02 1.6 0.78-3.30 0.2
Adverse arrhythmic events (n = 26)
Age 0.99 0.97-1.02 0.6
Female 0.8 0.40-1.93 0.7
High alcohol dose (> 2.0 mL) 1.3 0.63-2.99 0.4
CK-MB > 240 U/L 4.5 2.02-10.1 < 0.001 3.3 1.51-7.16 0.003
Ostium area > 2 mm² 1.9 0.90-4.10 0.09 1.7 0.77-3.79 0.2
Atrial fibrillation 1.2 0.51-2.90 0.7
Coronary artery disease 0.8 0.33-2.35 0.8
Sudden cardiac death survivor 6.8 2.02-22.9 0.002 5.9 1.74-20.3 0.004
≥ 2 conventional risk factors for SCD 3.8 1.66-8.83 0.002 2.2 0.66-7.05 0.2
Backwards multivariable Cox regression analysis was used. CI: confidence interval, HR: hazards ratio, 
LVOT: left ventricular outflow tract, NYHA: New York Heart Association, SCD: sudden cardiac death.
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contrast agents) led to the use of lower doses of alcohol during ASA (8-10). The subsequent 
“learning curve” of the centers participating in this study is shown in figure 1.
The first study to investigate the correlation between amount of intracoronary alcohol 
and outcome of ASA was conducted by Kuhn et al (12). This retrospective study comprises 
two series: 329 patients treated in a dose finding strategy with decreasing amounts of alcohol 
until 2001, and 315 patients of the “low alcohol dose era” treated until 2005. Patients treated 
with high amounts of alcohol (> 2.0 mL) had a higher mortality rate than those treated with 
less alcohol. The mean follow-up of this cohort was no more than 2.1 years though. Also, the 
patients treated with a high dose of alcohol were by definition the first patients to undergo 
ASA at this center.
Veselka et al (13) conducted a prospective study with 76 patients who were randomized 
into two equal groups, and subsequently treated with ≤ 2.0 mL and > 2.0 mL intracoronary 
alcohol. They found no differences in post-procedural complications between both groups 
and after a median follow up of 7 years all-cause mortality was equal. Though these findings 
are in line with this study, the small size of the study doesn’t allow for a reliable survival 
analysis and the study may not be powered enough to detect this difference.
In the study by ten Cate et al (11), which included a subset of the patients included in this 
study, ASA was associated with an increased risk for SCD. The study was criticized for the 
use of high amounts of alcohol (3.5 ± 1.5 mL) in its ASA patients. In their analysis no effect 
figure 3 – Survival after Alcohol septal ablation. Kaplan Meier graphs showing 10-year survival in 
263 patients after alcohol septal ablation.
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of alcohol dosage on their primary endpoint (composite of cardiac death and aborted SCD 
including appropriate ICD firing) was observed however.
AsA and infarct size
We found that higher CK-MB levels after ASA predicted AAE during follow-up. Although 
no direct effect of alcohol dosage on AAE was observed, a higher amount of intracoronary 
alcohol was associated with higher CK-MB levels. This is in line with previous studies (18-
20). In addition to amount of alcohol, caliber of the target septal perforator(s) and LVWT 
also showed a positive correlation with CK-MB levels. The infarct size and concomitant risk 
of AAE may therefore be the resultant of a combination of these variables. Since the separate 
correlations are mild to moderate at best however, the infarct size for an individual patient 
can still be hard to predict. On the contrary, finding high CK-MB levels post-procedure could 
warrant extended monitoring or preventive ICD implantation, especially in the presence of 
other risk factors for SCD.
A low dose of intracoronary alcohol in ASA can be as effective as a high dose. Veselka et 
al (14) showed that the use of a very low dose of alcohol (mean 1.0 ± 0.1 mL) is as effective in 
reducing the LVOT gradient as using a mean dose of 2.5 ± 0.8 mL. Boekstegers et al (15) came 
to the same conclusion after treating 50 patients with a mean amount of 1.9 ± 0.7 mL intra-
coronary alcohol. These findings are in line with our study. Despite a slightly lower gradient at 
follow-up in the high dose group, this did not lead to a difference in NYHA class at follow-up, 
nor to a lower rate of re-do procedures. In fact, re-interventions were even more common in 
the high dose group compared with the low dose group (15% vs. 6%). Furthermore, we found 
no association between amount of alcohol and LVWT. In other words, thicker intraventricular 
septa did not per definition require more intracoronary alcohol. Consequently, the fact that 
more alcohol leads to higher CK-MB levels may indicate that a high amount of alcohol leads 
to infarction of unnecessary septal tissue.
This circumstantial evidence suggests that the smallest effective infarct size should be 
pursued. This may be achieved by using a low dose of alcohol, more distally in the target 
septal perforator(s).
study limitations
This study has several limitations. Data collection was limited to variables that were routinely 
collected. The study was performed in 2 referral centers for the care of HCM, and selection 
and referral bias can be present. It was not possible to correct for individual or local altera-
tions of percutaneous technique. However, all procedures were performed by experienced 
interventional cardiologists, plus this implies that our findings are more generalizable than 
those of single-center investigations. Furthermore, like in the study by Kuhn et al (12) most 
of the patients treated with a high dose of alcohol underwent ASA in the early days of our 
experience (figure 1). The cause of death could not be determined in 3 of the 38 deaths (8%) 
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that occurred. In addition there was a large group (10%) in which no dose of alcohol could be 
retrieved, however events in this group were low (1 case of SCD). Finally, the cut-off value 
of 2.0 mL of alcohol was arbitrarily chosen because this was the median alcohol dose in this 
ASA cohort and previous studies have used this cutoff value, facilitating comparison to these 
studies. Choosing a cut-off value of 3.0 mL however, didn’t result in a significant difference in 
long-term mortality and AAE either.
CONCLusION
Alcohol dosage appears not to have a long-term effect on mortality and AAE. A larger infarct 
size created by ASA increases the risk of AAE, and extended monitoring of these patients is 
advised.
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ABstrACt
Objectives
The aim of this study is to compare outcomes of alcohol septal ablation (ASA) in young and 
elderly patients with obstructive hypertrophic cardiomyopathy (HCM).
Background:
The ACCF/AHA guidelines reserve ASA for elderly patients and patients with serious 
comorbidities. Information on long-term age-specific outcomes after ASA is scarce.
methods:
This cohort study included 217 HCM patients (54±12 years) who underwent ASA because 
of symptomatic left ventricular outflow tract (LVOT) obstruction. Patients were divided in 
a young (≤55 years) and elderly (>55 years) group, and matched by age in a 1:1 fashion to 
non-obstructive HCM patients.
results:
Atrioventricular block following ASA was more common in elderly patients (43% vs. 21%, 
P=0.001), resulting in pacemaker implantation in 13% and 5%, respectively (P=0.06). Residual 
LVOT-gradient, post-procedural NYHA class, and necessity for additional septal reduction 
therapy was comparable between age groups. During a follow-up of 7.6 ± 4.6 years, 54 patients 
died. Five- and 10-year survival following ASA was 95% and 90% in patients ≤55 years, and 
93% and 82% in patients >55 years, comparable to their control groups. The annual adverse 
arrhythmic event (AAE) rate following ASA was 0.7%/year in young patients, and 1.4%/year 
in elderly patients, comparable to their control groups.
Conclusion:
ASA is similarly effective for reduction of symptoms in young and elderly patients, however 
younger patients have a lower risk of procedure-related atrioventricular conduction distur-
bances. The long-term mortality rate and risk of AAE following ASA are low, both in young 
and elderly patients, and comparable to age-matched non-obstructive HCM patients.
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INtrOduCtION
If patients with obstructive hypertrophic cardiomyopathy (HCM) remain severely symptom-
atic despite optimal medical therapy, septal reduction therapy should be considered. This 
can be done, either by surgical myectomy or alcohol septal ablation (ASA).(1,2) ASA was 
introduced as a percutaneous alternative to surgical myectomy, and has shown to be effective 
in reducing left ventricular outflow tract (LVOT) obstruction and associated symptoms in 
the 20 years since.(3-5) Concerns about ASA remain however, especially about the pos-
sible arrhythmogenic effect of the ablation scar in patients already at an increased risk of 
life-threatening arrhythmias.(6) The American College of Cardiology Foundation/American 
Heart Association guidelines on HCM state that ASA should be reserved for elderly patients 
and patients with serious comorbidities.(1)
Little is known about the differences in outcome of the procedure between young and 
elderly patients. The aim of this study is to compare complication rates, symptom relief and 
long-term outcomes of ASA in young and elderly patients.
metHOds
study design and patient population
A multicenter observational cohort design was used. The study population consisted of 217 
consecutive HCM patients who underwent ASA in the St. Antonius Hospital Nieuwegein, 
Nieuwegein, the Netherlands (n = 147), or the Thoraxcenter, Erasmus Medical Center, 
Rotterdam, the Netherlands (n = 70). All patients met the criteria for invasive treatment: 
(i) ventricular septal thickness ≥15 mm, (ii) (provocable) LVOT gradient ≥50 mmHg, and 
(iii) persistent New York Heart Association (NYHA) class III/IV dyspnea or Canadian Car-
diovascular Society class III/IV angina despite optimal medical therapy.(1,2) The choice of 
ASA instead of surgical myectomy was based on patient profile (age, comorbidities, etc.) and 
patient preference. ASA was performed as described previously.(7,8)
All patients gave informed consent prior to the procedure. Local institutional review 
board approval was obtained. Patients were divided in a ≤ 55 years group and a group >55 
years of age. A 55-year cut-off was chosen because this was the median age of the study 
population (range 18-80 years). For the long-term outcomes two control groups were selected 
from a cohort of 349 non-obstructive HCM patients, also used as control group in a previous 
analysis.(9) These patients, from the St. Antonius Hospital Nieuwegein, Erasmus Medical 
Center Rotterdam, and University Hospital Leuven (Belgium), all had a LVOT gradient of 
<30 mmHg after provocation. They were matched by age in a 1:1 fashion to patients who 
underwent ASA.
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Follow-up and endpoints
Follow-up started at the time of ASA or, for the non-obstructive patients, at first outpatient 
clinic contact after January 1st, 1990. At baseline all patients were evaluated for the following 
characteristics: age, sex, NYHA class, maximum left ventricular wall thickness (LVWT), 
maximum (provocable) LVOT gradient, left ventricular function, coronary artery disease, 
atrial fibrillation, and conventional risk factors for sudden cardiac death (SCD).(1)
The primary endpoints of this study were all-cause mortality and adverse arrhythmic 
events (AAE) during long-term follow-up (i.e., after 30-days post-procedure). AAE consisted 
of: SCD, resuscitated cardiac arrests due to ventricular fibrillation or tachycardia, and appro-
priate implantable cardioverter-defibrillator (ICD) shock. Secondary endpoints were HCM-
related death (death due to heart failure, stroke or SCD), peri-procedural (<30 days) AAE 
and mortality, new right bundle branch block, (temporary) atrioventricular block, permanent 
pacemaker implantation, ICD implantation, reduction in LVWT, LVOT gradient and NYHA 
class >3 months post-procedure, and re-intervention (ASA or myectomy).
Mortality and adverse events were retrieved from hospital patient records at the center 
where follow-up occurred, from civil service population registers, and from information pro-
vided by patients themselves and/or their general practitioners. All ICD shocks were evalu-
ated by an experienced electrophysiologist, unaware and independent of the study purpose 
and endpoints. If no events occurred during follow-up, the administrative censoring date was 
set at November 1st, 2012.
statistical Analysis
SPSS version 20 (IBM, Armonk, NY, USA) and Microsoft Excel 2010 (Microsoft Corpora-
tion, Redmond, WA, USA) were used for all statistical analyses. Categorical variables were 
summarized as percentages. Normally distributed continuous data are expressed as mean ± 
standard deviation and non-normally distributed data are expressed as median ± interquartile 
range. To compare continuous variables Student t test or Mann-Whitney U-test were used, 
and to compare categorical variables the χ2-test was used. Kaplan-Meier graphs were used to 
show survival rates. In all analyses, a P value of <0.05 was considered significant.
resuLts
Clinical characteristics
The baseline characteristics of the 217 patients who underwent ASA and their age matched 
control groups are shown in table 1. The mean age of the patients ≤55 years was 43 ± 8 years, 
and the mean age of the patients >55 years was 64 ± 6 years. There were more non-obstructive 
patients with systolic dysfunction, as compared to patients who underwent ASA. A higher al-
cohol dose was used for ASA in patients ≤55 years, compared to patients >55 years (P = 0.013).
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Procedural outcomes
Procedural outcomes of the patients who underwent ASA are shown in table 2. Atrioven-
tricular block following ASA was more common in patients >55 years compared to patients 
≤55 years (43% vs. 21%, P = 0.001), resulting in permanent pacemaker implantation in 13% 
and 5%, respectively (P = 0.06). Other peri-procedural complications, including AAE and 
mortality, were similar in both groups. Residual LVWT, LVOT gradient and NYHA class >3 
months post-procedure were comparable in both age groups, as was necessity for additional 
septal reduction therapy.
Long-term outcomes
During a mean follow-up of 7.6 ± 4.6 years there was a total of 20 deaths in the ASA cohorts, 
and 34 deaths in the control groups. Follow-up was complete in 98% of patients. The 5- and 
10-year survival following ASA of patients ≤55 years was 94.9% (95% CI, 90.4%-100.0%) and 
90.2% (95% CI, 82.2%-98.1%), respectively, compared to 98.0% (95% CI, 95.4%-100.0%) and 
88.1% (95% CI, 80.1%-96.1%) in the control group (P = 0.87, figure 1). The 5- and 10-year 
survival following ASA of patients >55 years was 93.2% (95% CI, 88.0%-98.5%) and 81.9% (95% 
CI, 71.8%-91.9%), respectively, compared to 91.7% (95% CI, 86.1%-97.3%) and 82,7% (95% CI, 
table 1 – Baseline characteristics of 107 patients ≤55 years and 110 patients > 5 years
n=
< 55 years > 55 years P
ASA controls ASA controls
107 107 P 110 110 P
Age, years 43 ± 8 43 ± 8 0.99 64 ± 6 64 ± 6 0.98 <0.001
Female 21 (20) 30 (28) 0.20 54 (49) 39 (36) 0.056 <0.001
NYHA III/IV 90 (84) 9 (8) <0.001 84 (76) 18 (16) <0.001 0.21
Maximum LVWT, mm 20 ± 6 18 ± 5 <0.001 19 ± 4 18 ± 5 0.17 0.001
Maximum LVOT gradient, 
mmHg
65 ± 56 6 ± 5 <0.001 60 ± 63 7 ± 5 <0.001 0.68
Systolic dysfunction (EF < 50%) 2 (2) 15 (14) 0.002 10 (9) 25 (23) 0.010 0.042
Coronary artery disease 8 (8) 12 (11) 0.48 37 (34) 18 (16) 0.005 <0.001
Atrial fibrillation 20 (19) 29 (27) 0.19 26 (24) 47 (43) 0.004 0.47
Sudden cardiac death survivor 4 (4) 8 (8) 0.38 2 (2) 11 (10) 0.022 0.44
≥ 2 conventional risk factors for 
SCD
16 (15) 16 (15) 1.0 9 (8) 22 (20) 0.020 0.18
Amount of alcohol, mL 3.0 ± 1.0 - - 2.0 ± 1.0 - - 0.013
Values are mean ± SD, n (percentage), or median (interquartile range) for skewed distributions. ASA 
= alcohol septal ablation; EF = ejection fraction; LVOT = left ventricular outflow tract; LVWT = left 
ventricular wall thickness; NYHA = New York Heart Association; SCD = sudden cardiac death.
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72.9%-92.6%) in the control group (P = 0.51, figure 2). The annual AAE rate following ASA 
in patients ≤55 years was 0.7% per year, compared to 1% per year in the control group (P = 
0.6). The annual AAE rate following ASA in patients >55 years was 1.4% per year, compared 
to 0.5% per year in the control group (P = 0.07).
dIsCussION
The most important result of this 7.6-year follow-up study is that long-term survival following 
ASA in young and elderly patients is comparable to survival in age matched non-obstructive 
HCM patients, and the same holds true for AAE rates. Furthermore, ASA is similarly effec-
tive for reduction of symptoms in young and elderly patients, although younger patients have 
a lower risk of procedure related atrioventricular conduction disturbances.
table 2 – Procedural outcomes after alcohol septal ablation in 107 patients ≤55 years and 110 patients 
>55 years.
n =
ASA ≤ 55 years ASA > 55 years
107 110 P
Peri-procedural(<30 days) complications
New right bundle branch block 42 (39) 39 (36) 0.66
(temporary) atrioventricular block 22 (21) 47 (43) 0.001
Permanent pacemaker implantation 5 (5) 14 (13) 0.063
ICD implantation 15 (14) 11 (10) 0.48
Adverse arrhythmic events 8 (8) 8 (7) 1.0
Mortality 2 (2) 0 (0) 0.24
Procedure efficacy
Residual LVWT > 3 months post-procedure, mm 14 ± 5 14 ± 4 0.45
Residual LVOT gradient > 3 months post-procedure, 
mmHg
12 ± 27 10 ± 27 0.99
Reduction in LVOT gradient > 3 months post-
procedure, %
78 ± 60 76 ± 60 0.68
NYHA class III/IV > 3 months post-procedure 5 (5) 9 (9) 0.43
Redo septal reduction therapy 14 (13) 13 (12) 0.94
Values are n (percentage), or median (interquartile range). ASA = alcohol septal ablation; ICD = internal 
cardioverter defibrillator; LVOT = left ventricular outflow tract; LVWT = left ventricular wall thick-
ness; NYHA = New York Heart Association.
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Previous age specific AsA studies
Currently, information on the long-term age-specific outcomes after ASA in patients with ob-
structive HCM is scarce. Two previous studies(10,11) have evaluated age specific outcomes 
of ASA patients during a follow-up period of respectively 1 and 5.1 years. Leonardi et al(10) 
compared the outcomes of 360 HCM patients undergoing ASA of 3 age categories (<45, 45-
64, and >65 years). Likewise, they found that the reduction in LVOT gradient and NYHA 
class following ASA was similar independent of age, and that elderly patients more often 
required pacemaker implantation after the procedure. There were no control groups however, 
and not surprisingly the mortality rate after a follow-up of 1 year was highest in patients >65 
years. Veselka et al(11) assessed the 5.1-year outcomes following ASA in 75 patients aged 42 ± 
7 years, which is comparable to the mean age of our young patients. They found a survival free 
of all-cause mortality at 5- and 10 years of 94% each, in line with our findings. No comparisons 
with elderly patients were made however.
Current guidelines
The American College of Cardiology Foundation/American Heart Association guidelines 
on HCM of 2011 state that ASA should be reserved for elderly patients and patients with 
serious comorbidities, and gives a class III recommendation (level of evidence C) to ASA for 
younger patients if myectomy is a viable option.(1) The procedural mortality rate is reported 
to be <1% for myectomy versus up to 4% for ASA.(1,12-14) Larger, more recent ASA studies 
have shown rates of 0.3%-0.6%, however.(15,16) Also, a recent meta-analysis comparing ASA 
to myectomy showed similarly low peri-procedural and long-term mortality rates.(17) Fur-
thermore, subsequent to the publication of the 2011 guidelines, the post-ASA prognosis was 
figure 1 – Kaplan-Meier graph of all-cause survival in patients ≤ 55 years who underwent ASA vs. 
age-matched non-obstructive HCM patients
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demonstrated to be comparable with the sex- and age-matched population,(15,16,18) and with 
matched post-myectomy patients.(18) Notably, these and other studies(15,16,19) showed that 
age was the only independent predictor of mortality following ASA. Implying that survival in 
patients after ASA is not determined by ASA, but HCM itself.
One of the main concerns about ASA in younger patients is the potential arrhythmogenic 
effect of the ablation scar in patients already at an increased risk of life-threatening arrhyth-
mias.(6) Recent studies have shown however, that the long-term risk of SCD after ASA is low 
and comparable to patients who undergo myectomy.(9,17,18) This study showed an annual 
AAE rate following ASA of 0.7% per year in the young patients, which was similar to age-
matched non-obstructive HCM patients, and half the rate of elderly patients.
Another conceivable reason to choose myectomy instead of ASA in younger patients is 
the >2 times higher risk of atrioventricular block requiring pacemaker implantation following 
ASA.(17,20) This higher need for pacemaker implantation may at least partly be explained by 
the higher age of the patients undergoing ASA: the ASA patients from both meta-analyses 
were on average 9 years older than the myectomy patients. The present and previous studies 
have shown that atrioventricular conduction disturbances following ASA are mainly seen 
in elderly patients,(10,21) with a need for pacemaker implantation in only 5% of the young 
patients. This, despite the use of a higher amount of alcohol in the young patients. Large 
outcome studies following myectomy in HCM patients of similar age categories (mean age 
37-47 years) showed incidences of atrioventricular block requiring pacemaker implantation 
of 1-6%.(12,13,22,23)
Since the improvement in functional status following ASA in young and elderly patients 
is similarly good as well, we propose that the indication for ASA can be broadened to younger 
patients. In other words, younger age alone should not be a reason not to consider ASA. For 
figure 2 – Kaplan-Meier graph of all-cause survival in patients >55 years who underwent ASA vs. 
age-matched non-obstructive HCM patients.
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children and adolescents however, little to no results are available following ASA, while there 
is substantial experience with myectomy.(24) We therefore recommend against ASA in this 
age group, until studies have proven the safety and efficacy of the procedure in these very 
young patients.
Patient selection and specialized care
In line with the 2011 American College of Cardiology(1) and the 2014 European Society of 
Cardiology(2) guidelines, we recommend that all patients considered for septal reduction 
therapy are assessed by a multidisciplinary heart team (consisting of at least one cardiothoracic 
surgeon, an interventional cardiologist, and a cardiologist specialized in the care of patients 
with HCM) to determine the optimal therapy, by taking into account not only age, but also 
factors like mitral valve anatomy, coronary anatomy, septal thickness, and comorbidities. 
When both procedures are possible, shared decision making between the informed patient 
and treating physician should also be part of the equation. Furthermore, septal reduction 
therapy should be performed by experienced operators and confined to centers with substan-
tial and specific expertise in HCM care.
table 3 – Long-term outcomes after alcohol septal ablation in 107 patients ≤55 years compared to their 
age matched control group.
n =
ASA ≤ 55 years control ≤ 55 years
107 107 P
Years of follow-up 7.2 ± 3.4 9.2 ± 5.6
Mortality (>30 days post-procedure)
Total mortality 5 (5) 15 (14) 0.036
HCM-related death 3 (3) 11 (10) 0.055
Non-cardiac 2 (2) 4 (4) 0.68
5-year survival, % 93 97 0.87
10-year survival, % 90 75 0.87
Adverse arrhythmic events (>30 days post-procedure)
Total adverse events 5 (5) 9 (8) 0.41
Sudden cardiac death 2 (2) 4 (4) 0.68
Resuscitated cardiac arrest 1 (1) 2 (2) 1.0
Appropriate ICD shocks 2 (2) 3 (3) 1.0
Annual events, %/year 0.7 1.0 0.58
Values are median (interquartile range), or n (percentage), unless stated otherwise. ASA = alcohol sep-
tal ablation; HCM: hypertrophic cardiomyopathy, ICD: internal cardioverter defibrillator.
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study limitations
There were significant differences in baseline characteristics between the young and elderly 
patients who underwent ASA. Besides the to be expected differences in prevelance of systolic 
dysfunction and coronary artery disease, we noted a use of higher amounts of alcohol in the 
≤55 years population. The same also held true in a recent study comparing the use of low 
(≤2.0 mL) versus high (>2 mL) doses of alcohol for ASA.(25) In this study of same patient 
population as the present study, patients from the high dose group were significantly younger 
than those from the low dose group. Although the two groups did not differ in maximal 
LVWT or LVOT gradient, the patient from the high dose group did have a larger caliber of 
the target septal perforator(s), which might explain the difference. This study has several 
other limitations. The study was performed in tertiary referral centers for the care of HCM, 
and the patient population might not represent the general HCM population. This referral 
and selection bias could have influenced the results. Data collection was limited to variables 
that were routinely collected. It was not possible to correct for individual or local alterations 
of percutaneous technique. However, all procedures were performed by experienced inter-
ventional cardiologists, plus this implies that our findings are more generalizable than those 
of single-center investigations.
table 4 – Long-term outcomes after alcohol septal ablation in 107 patients >55 years compared to their 
control group.
n =
ASA > 55 years control > 55 years
110 110 P
Years of follow-up 6.5 ± 3.8 7.5 ± 4.8
Mortality(>30 days post-procedure)
Total mortality 15 (14) 19 (17) 0.58
HCM-related death 4 (4) 10 (9) 0.17
Non-cardiac 11 (10) 8 (7) 0.63
5-year survival, % 92 90 0.51
10-year survival, % 79 80 0.51
Adverse arrhythmic events (>30 days post-procedure)
Total adverse events 10 (9) 4 (4) 0.17
Sudden cardiac death 3 (3) 0 (0) 0.25
Resuscitated cardiac arrest 2 (2) 1(1) 1.0
Appropriate ICD shocks 5 (5) 3 (3) 0.72
Annual events, %/year 1.4 0.5 0.070
Values are median (interquartile range), or n (percentage), unless stated otherwise. ASA = alcohol sep-
tal ablation; HCM: hypertrophic cardiomyopathy, ICD: internal cardioverter defibrillator.
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CONCLusION
ASA is similarly effective for reduction of symptoms in young and elderly patients, however 
younger patients have a lower risk of procedure related atrioventricular conduction distur-
bances. The long-term mortality rate and risk of AAE following ASA is low, both in young and 
elderly patients, and comparable to age matched non-obstructive HCM patients. We propose 
that the indication for ASA can be broadened to younger patients.
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Patient selection for alcohol septal ablation: does age matter?
Eleid MF, Nishimura RA
JACC Cardiovasc Interv. 2016 Mar 14;9(5):470-1
Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.
— Mark Twain [1]
Septal reduction therapy plays an important role in the treatment of patients with hypertro-
phic cardiomyopathy (HCM) and symptoms due to a dynamic left ventricular outflow tract 
obstruction refractory to medical therapy. Surgical resection of septal hypertrophy has been 
an established treatment for over 5 decades, with excellent symptomatic and hemodynamic 
improvement and a mortality rate of 0.4% among the most experienced centers [2]. Although 
percutaneous transcatheter alcohol septal ablation (ASA) was first introduced 20 years ago 
[3], data regarding the long-term outcome of patients receiving this treatment have become 
available only in recent years [4,5]. The 2011 American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) guideline for the diagnosis and treatment of hy-
pertrophic cardiomyopathy had previously recommended ASA as an alternative to myectomy 
in the presence of advanced age or other comorbidities (Class IIa) or due to patient preference 
(Class IIb) [6]. These recommendations were made on the basis of: 1) the lack of long-term 
follow-up with concern regarding long-term arrhythmic potential related to iatrogenic infarc-
tion; and 2) lesser efficacy in terms of symptom relief, particularly in the younger patient.
The study by Liebregts et al. [7] in this issue of JACC: Cardiovascular Interventions is a 
valuable contribution to the accumulating knowledge regarding long-term outcome of patients 
undergoing ASA. In their retrospective observational study at 2 tertiary referral centers, the 
outcomes of young (<55 years) and older (>55 years) patients undergoing ASA (n = 217) were 
compared with nonobstructive HCM patients managed medically. Five- and 10-year survival 
following ASA in young (95% and 90%, respectively) and older (93% and 82%, respectively) 
groups were quite favorable and were similar to an age-matched control group of patients 
with nonobstructive HCM. Furthermore, short-term procedural efficacy was similar between 
young and older patients (>90% of patients having New York Heart Association (NYHA) 
functional class I or II symptoms after 3 months of follow-up), as was the rate of additional 
septal reduction therapy (13% and 12%, respectively). The mean maximal left ventricular sep-
tal wall thickness was similar in young and older patients (20 ± 6 and 19 ± 4 mm, respectively). 
As expected, the rate of atrioventricular block requiring permanent pacemaker implantation 
appeared to be higher in older (13%) compared with younger patients (5%).
This study provides some reassurance regarding longer-term survival and procedural 
efficacy in young patients undergoing ASA, challenging the recommendation that ASA be 
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reserved for older patients [6]. However, despite the low event rate observed in the present 
study (5 arrhythmic events and 3 cardiac deaths), it is difficult to ignore prior warnings of 
increased ventricular arrhythmogenicity following ASA [8-10], compared with a signal for 
reduced rates of ventricular arrhythmia following myectomy [11], when considering treat-
ment options for a young individual with many decades of a good quality of life ahead of 
them. On the basis of results to date, it is probable that ASA does not increase the overall risk 
of malignant arrhythmias, but myectomy may decrease this risk [12,13]. The ACCF/AHA 
guidelines also hinge on the concept that septal myectomy is a more effective procedure, 
with a higher percentage of patients having complete relief of symptoms as well as a lower 
rate of repeat procedures compared with ASA, particularly for younger patients <65 years 
of age [14]. The study by Liebregts et al. [7] did not include a surgical myectomy group for 
comparison, and thus, conclusions regarding the efficacy of ASA relative to myectomy in 
this population cannot be drawn from this investigation. Although the outcome measures of 
NYHA functional class at 3 months were promising, what patients really desire is long-term 
durability of symptom relief to allow return to a normal lifestyle, which was not addressed.
At HCM centers of excellence where both myectomy and ASA are offered, patient se-
lection for septal reduction therapy is highly nuanced and patient-centered, with a shared 
decision-making approach. Older patients and those with multiple comorbidities may be at 
higher risk for complications from septal myectomy, making a less-invasive option potentially 
more attractive for these patients [6]. Multiple other factors must be taken into consideration, 
including the degree of septal hypertrophy, the location and size of septal perforators relative 
to septal hypertrophy, concomitant mitral valve pathology including aberrant papillary muscle 
insertion, as well as baseline conduction system disease and patient preference, which all may 
affect the risk–benefit ratio of ASA. Accordingly, age may only be 1 factor in the integration 
of all clinical data to arrive at a patient-centered recommendation for therapy. Local institu-
tional expertise is another critical factor weighing on the choice of septal reduction therapy. 
At a HCM center of excellence with experience in septal myectomy, the weight of evidence 
continues to favor this option for a young patient being considered for septal reduction 
therapy, due to very low operative mortality, superior efficacy and lesser need for subsequent 
procedures. However, growing evidence supports that ASA is not fraught with the high risk 
that had been suspected and that long-term survival after ASA may be comparable to that 
of myectomy, potentially opening this treatment modality to a younger population as well as 
to centers that do not have the surgical expertise. It must be remembered that, as with any 
interventional technique, outcomes are highly dependent upon the knowledge and experience 
of the operators, and the excellent results in this study may not necessarily be extrapolated to 
all other centers.
Future studies comparing the long-term clinical outcomes of ASA directly with surgi-
cal myectomy in patients across a broad age spectrum at institutions with expertise in both 
techniques may help answer the question of whether ASA should be considered in a younger 
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population. Additionally, even longer-term data will be required to determine the lasting 
impact of the iatrogenic septal infarction of ASA on lifetime arrhythmogenic risk in a younger 
population. Until that time, the question of how much age really matters in patient selection 
for ASA will remain.
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Chapter 8
microsphere embolisation as an alternative 
for alcohol in percutaneous transluminal 
septal myocardial ablation
Vriesendorp PA, Van Mieghem NM, Vletter WB, Ten Cate FJ, 
de Jong PL, Schinkel AF, Michels M.
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ABstrACt
Background
Percutaneous transluminal septal myocardium ablation using microsphere embolization is a 
new interventional technique to treat patients with hypertrophic obstructive cardiomyopathy
methods and results
In two patients, considered at high risk for myectomy, targeted septal perforators were oc-
cluded with microsphere embolization instead of alcohol ablation to reduce left ventricular 
outflow gradient. In both cases the left ventricular outflow tract gradient immediately was 
reduced. No adverse events occurred.
Conclusion
This is the first clinical experience with Embozene® Microspheres in the Netherlands as an 
alternative for alcohol septal ablation. In both cases it resulted in immediate improvement in 
hemodynamics, without any adverse events.
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INtrOduCtION
Dynamic obstruction of the left ventricular outflow tract (LVOT) is an important component 
of the pathophysiology of hypertrophic cardiomyopathy (HCM) and is described in almost 
70% of HCM-patients.[1] Therapy in severely symptomatic patients aims at reducing the 
extent of the LVOT obstruction, either medically using negative inotropic drugs or invasively 
by either myectomy or percutaneous transluminal septal myocardium ablation (PTSMA) 
using alcohol.[2, 3] PTSMA precludes general anesthesia, sternotomy and cardiopulmonary 
bypass and thus results in overall shorter in-hospital stay as compared to surgical myectomy. 
Conversely, PTSMA may be associated with a higher permanent pacemaker implantation 
rate for total atrioventricular block. [4] Furthermore there is ongoing debate on the long-term 
impact of the resultant myocardial scar with arrhythmogenic potential.[5] In the current 
guidelines PTSMA is an alternative intervention for selected patients who are no optimal 
surgical candidates.[2, 3]
Alcohol has been traditionally used for PTSMA. Its inherent cardiotoxicity and the risk 
of procedural alcohol spilling into the left anterior descending artery (LAD) have spurred 
interest in reliable and potentially safer embolic alternatives. There is a vast experience with 
microspheres as an embolic agent to control bleeding or occlude the blood supply of certain 
tumours or arteriovenous malformations. Microspheres allow for an easy, safe and targeted 
delivery.[6, 7] Recently, Embozene® Microspheres have been demonstrated by Latsios et al. 
[8] as a potential alternative for alcohol in PTSMA. The aim of this report is to demonstrate 
the safety and efficacy of PTSMA using Embozene® Microspheres.
mAterIAL ANd metHOds
microspheres
Embozene® Microspheres are specially designed spherical embolic agents, developed by 
CeloNova Biosciences Inc. (San Antonio, TX, USA). The microspheres are hydrogel cores 
with an anorganic polymer surface (Polyzene®-F), which is biocompatible and not absorbable. 
There are several different sizes, which range from 40µm to 900µm in diameter, and each 
size has a different colour. For PTSMA the use of the 75µm-microspheres is recommended. 
A total of 0.6 mL Microspheres solution is diluted with 6 mL of contrast agent for optimal 
deliverability and visualization.
Patients
Two HCM patients (age 64 and 77 years) with severe LVOT obstruction (>90 mmHg at rest) 
were selected for PTSMA because of invalidating symptoms (NYHA functional class IV) 
despite optimal medical therapy. Based on multiple co-morbidities both patients were refused 
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for surgery by multidisciplinary heart-team consensus and thus considered for PTSMA. Both 
patients provided written informed consent for the procedure.
Intervention
The invasive PTSMA procedure evolves under transthoracic echocardiographic monitoring 
and conscious sedation. The right and left femoral artery and right femoral vein are cannu-
lated using standard Seldinger technique. A temporary pacemaker lead is placed in the apex 
of the right ventricle. Full anticoagulation is obtained with heparine aiming for an activated 
clotting time between 250 and 300 seconds. A 6F double lumen Langston™ pigtail catheter 
is advanced into the left ventricle allowing for simultaneous pressure recordings in the left 
ventricle and the ascending aorta. The LVOT gradient is measured invasively and simul-
taneously with continuous wave Doppler throughout the procedure. The Brockenbrough-
Braunwald-Morrow sign is assessed at baseline by artificially provoking ventricular ectopy 
(figure 1). The left main coronary artery is selectively engaged with a 6F Judkins left guid-
ing catheter. After visual assessment of the septal perforator branches of the left anterior 
descending artery the first or second septal perforator is wired with a 0.014” hydrophilic 
coronary guidewire introduced into a 1.50 X 15mm over-the-wire (OTW) Balloon (Trek™, 
Abbott Vascular). The OTW balloon is advanced into the septal perforator and inflated up 
to 6 atmospheres. After removal of the coronary guidewire, 2mL of echo contrast (Sonovue, 
Bracco Diagnostics, Milan, Italy) is selectively injected into the septal perforator through the 
inner lumen of the OTW balloon to allow for echocardiographic identification of the basal 
left ventricular septum as appropriate anatomical target for the microspheres (figure 2). 
Subsequently, with the balloon still inflated 0.6 ml of Embozene Microspheres are injected. 
Filling of the septal perforator with eventual stasis of the injected solution is confirmed by 
fluoroscopy and continuous invasive hemodynamic monitoring demonstrates progressive 
reduction in LVOT gradient. The OTW balloon is deflated and removed. figure 3 illustrates 
a favorable reduction in LVOT gradient from 65 mmHg to 5 mmHg and abolition of the 1st 
septal perforator.
resuLts
safety
Both procedures evolved uneventful. No allergic reactions were reported after the use of mi-
crospheres. Transient per-procedural atrioventricular conduction disturbances were noted in 
1 patient. The temporary pacemaker wire could be safely removed after 24 hours. No patient 
required a permanent pacemaker implantation.
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figure 1 – Baseline coronary angiography (A) of the targeted septal artery (black arrow) and left 
ventricular outflow tract gradient measured with continuous wave Doppler (B) and invasively (C) direct 
before the procedure.
figure 2 – Balloon inflation (A) in targeted septal artery (red arrow) and contrast agent downstream of 
the balloon (red circle). Opacification of the targeted septal area on 2D echocardiography (B).
figure 3 – Post-procedural situation with angiography (A) showing that targeted septal artery is no 
longer visible (black arrow) and decrease in left ventricular outflow tract gradient measured with con-
tinuous wave Doppler (B) and invasively (C) directly after the procedure.
Chapter 8
134
efficacy
Continuous recording of LVOT gradient revealed an almost instant reduction of the LVOT 
pressure gradient (-50 mmHg and -60 mmHg) in both patients. Focal septal wall infarction 
was obtained as demonstrated by peak CK-MB levels (20 resp. 227 µg/L) and echocardio-
graphic confirmation of hypokinesis and thinning of the basal septal wall.
dIsCussION
Alcohol injection in the septal artery is the most commonly used technique of PTSMA in 
patients with hypertrophic obstructive cardiomyopathy (HOCM). However due to the direct 
toxicity of the alcohol on the myocardial tissue and the risk of leakage in the LAD with subse-
quent anterior wall infarction this procedure is not without risks. Coil embolization has been 
proposed as an alternative for alcohol. Coils,
like microspheres, may provide the opportunity to create a more controlled infarction. 
However drawbacks of this technique are persistence or reoccurrence of LVOT obstruction 
during long-term follow-up and the risk of periprocedural migration of coils to the LAD with 
subsequent complications such as myocardial infarction and rarely a ventricular septal defect.
[9, 10]
For the first time in the Netherlands, we used Embozene® Microspheres as an alternative 
for alcohol to perform PTSMA in 2 patients and confirm its feasibility corroborating the find-
ings by the Siegburg group, where in one patient the LVOT obstruction was reduced from 70 
to 10 mmHg without any complications.[8] The immediate improvement in hemodynamics 
and decrease of LVOT gradient is most likely caused by the focal infarction and subsequent 
akinesia of the septal wall. Long-term results need further research, but it is expected that due 
to thinning of the myocardium the LVOT gradient will further decrease.
Microsphere embolization in these two patients was safe and effective in inducing focal 
basal septal wall infarction. Its higher viscosity makes it safe to inject and reduces the risk of 
spilling into the LAD. Also the absence of intrinsic cardiotoxic effects (as seen with alcohol) 
may preclude untoward acute myocardial damage and create a more controlled infarction.
CONCLusION
This is the first clinical experience with Embozene® Microspheres in the Netherlands as an 
alternative for the use of alcohol in PTSMA in severely symptomatic patients with HOCM. 
In both cases it resulted in immediate improvement in hemodynamics, without any adverse 
events.
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ABstrACt
Background
The recently released 2014 ESC guidelines of hypertrophic cardiomyopathy (HCM) use a 
new clinical risk prediction model for sudden cardiac death, based on the HCM Risk-SCD 
study. Our study is the first external and independent validation of this new risk prediction 
model.
methods and results
The study population consisted of a consecutive cohort of 706 HCM patients without prior 
SCD event, from 2 tertiary referral centers. The primary endpoint was a composite of SCD 
and appropriate ICD therapy, identical to the HCM Risk-SCD endpoint. The 5-year SCD 
risk was calculated using the HCM Risk-SCD formula. ROC curves and C-statistics were 
calculated for the 2014 ESC guidelines, and risk stratification methods of the 2003 ACC/ESC 
guidelines and 2011 ACCF/AHA guidelines.
During follow-up of 7.7 ±5.3 years, SCD occurred in 42 (5.9%) of 706 patients (age 49 ±16 
years, 34% female). The C-statistic of the new model was 0.69 (95% CI 0.57-0.82, p = 0.008), 
which performed significantly better than the conventional risk factor models based on the 
2003 guidelines (C-statistic of 0.55 95% CI 0.47-0.63, p = 0.3), and 2011 guidelines (C-statistic 
of 0.60, 95% CI 0.50-0.70, p = 0.07).
Conclusion
The HCM Risk-SCD model improves the risk stratification of HCM patients for primary 
prevention of SCD, and calculating an individual risk estimate contributes to the clinical deci-
sion making process. Improved risk stratification is important for the decision making before 
ICD implantation for the primary prevention of SCD.
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INtrOduCtION
Sudden cardiac death (SCD) is a relatively rare but devastating clinical event in hypertrophic 
cardiomyopathy (HCM) with an incidence of 0,5-1%/year in patients with HCM.1 High risk 
patients can be protected from SCD by implantable cardioverter-defibrillators (ICD), but this 
protection comes at a price of inappropriate shocks and device related complications.2
Originally, in the 2003 ACC/ESC guidelines and 2011 ACCF/AHA guidelines, the 
identification of high-risk patients was based on five clinical characteristics: a family history 
of SCD in first-degree relatives < 40 years of age, maximal left ventricular wall thickness 
(LVWT) of >30 mm, unexplainable syncope, non-sustained ventricular tachycardia (nsVT) 
and abnormal blood pressure response during exercise.3, 4 Although it was clear that the risk 
of SCD increases with increasing number of risk factors, O’Mahony et al.5 demonstrated 
that both 2003 and 2011 guidelines distinguish high and low risk patients with only limited 
power. Recently the HCM Outcomes Investigators presented a novel clinical risk prediction 
model for SCD (HCM Risk-SCD), based on a cohort of 3675 patients from six centers.6 This 
model provides an individualized 5-year risk, based on most of the aforementioned risk fac-
tors, combined with left ventricular outflow tract (LVOT) gradient, left atrial (LA) diameter, 
and age at evaluation. This new model was more accurate in predicting SCD compared with 
the conventional risk factors, and the recently released 2014 ESC guidelines incorporated the 
HCM Risk-SCD model to classify patients as low risk (5-year risk of SCD <4%), intermediate 
risk (5-year risk of SCD 4-6%) or high risk (5-year risk of SCD >6%). ICD implantation was 
respectively a IIB or IIA recommendation in the latter groups.
This improvement of identification of high risk patients is a promising development in the 
prevention of SCD in HCM, but the final model needs external validation for generalizability. 
The aim of this study is to perform an external and independent validation of the novel clini-
cal risk prediction model, and to compare it with the 2003 and 2011 guidelines.
metHOds
study design and population
An international two-center, observational cohort design was used. The study conforms to the 
principles of the Helsinki Declaration and local institutional review board approval was obtained.
The study population consisted of 747 adult (≥16 years of age) consecutively evaluated 
patients with HCM at the University Hospital Leuven, Leuven, Belgium and the Thorax-
center, Erasmus Medical Center, Rotterdam, the Netherlands. The same inclusion and 
exclusion criteria as described in the HCM Risk-SCD study were used, and 41 patients with 
a history of SCD prior to or as first contact were excluded.6 Each patient had an established 
diagnosis of HCM, based on unexplained left ventricular hypertrophy of ≥15 mm, assessed 
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by echocardiography.3, 4 Patients with HCM linked to Noonan’s syndrome, Fabry’s disease, 
mitochondrial disease or congenital heart defects were excluded. All patients with a history of 
cardiac arrest or sustained ventricular tachycardia were also excluded.
Outcomes and follow-up
The primary endpoint of SCD was equivalent to the endpoint used in the HCM Risk-SCD 
study. It was a composite endpoint and consists of (1) instantaneous and unexpected death 
within 1 hour of a witnessed collapse in patients who were previously in a stable clinical 
condition, or nocturnal death with no antecedent history of worsening symptoms; (2) suc-
cessful resuscitation after cardiac arrest; and (3) appropriate ICD interventions for VF or 
fast VT (>200 bpm), in line with previous studies.6, 7 Mortality and adverse events were 
retrieved from hospital patient records at the center where follow-up occurred, from civil 
service population registers, and from information provided by patients themselves or their 
general practitioners. For primary prevention, a cut-off rate for ventricular tachycardia (VT) 
detection of 175–180 b.p.m. with a series of antitachycardia pacing (ATP) bursts followed by 
shocks was programmed. Detection for ventricular fibrillation (VF) was usually set at 220 
b.p.m. with direct shock application. All ICD interventions were evaluated by an experienced 
electrophysiologist at each center. Follow-up extended from first evaluation up to an endpoint 
or the administrative censoring date, set at November 1st, 2012. If patients were lost to follow-
up, the patient would be censored at last known contact date.
risk factors and profiles
Risk factors for SCD were evaluated at baseline and based on the conventional risk factors and 
the variables described in the HCM Risk-SCD study. The following risk factors were identi-
fied: (1) age at evaluation; (2) a family history of SCD in ≥ 1 first-degree relatives < 40 years 
of age or in a first degree relative with confirmed HCM at any age; (3) maximal LVWT; (3) 
history of unexplainable syncope, (4) documented nsVT ≥ 3 beats at a rate of ≥ 120 bpm; (5) 
maximal LVOTO gradient (either resting or provocable gradient); (6) LA diameter measured 
in parasternal long axis; and (7) abnormal blood pressure response during exercise was also 
identified (as a conventional risk factor). The 5-year risk of SCD for individual patients were 
calculated using the HCM Risk-SCD formula: PˆSCD at 5 years = 1 – 0.998exp(Prognostic Index), where 
Prognostic Index = 0.15939858*maximal LVWT (mm) – 0.00294271*maximal LVWT² 
(mm²) + 0.0259082*LA diameter (mm) + 0.00446131*maximal LVOT gradient (mmHg) + 
0.4583082*Family history of SCD+0.82639195*nsVT + 0.71650361*unexplained syncope-
0.01799934*age at evaluation (years); (The ESC calculator is available at http://www.
doc2do.com/hcm/webHCM.html). Additionally, risk profiles based on 2003 ACC/ESC 
guideline and 2011 ACCF/AHA guideline were calculated. In the 2003 guideline, each risk 
factor was of equal weight and the profile was calculated as the sum of all risk factors present 
in the patient. The approach for the 2011 guideline was similar, except that documented nsVT 
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and abnormal blood pressure response during exercise only were considered if at least one of 
the other risk factors was present.
statistical Analysis
SPSS version 21 (IBM, Armonk, NY, USA), R version 3.1.1 (The R Foundation, Vienna, 
Austria) and Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) were used 
for all statistical analyses. Categorical variables were summarized as percentages. Normally 
distributed continuous data are expressed as mean ± standard deviation and non-normally 
distributed data are expressed as median (interquartile range). To compare continuous vari-
ables between groups Student t test or Mann-Whitney U-test were used, and to compare 
categorical variables the χ2-test was used. The performance of the novel risk model, and the 
models based on conventional risk factors, was determined by the C-statistic, which indicates 
how well a model discriminates here between high and low risk for SCD in HCM patients. 
A C-statistic of 0.5 indicates no predictive value, and 1.0 indicates perfect performance. A 
receiver operating characteristic (ROC) curve was constructed to visualize the model per-
formances, by plotting the sensitivity against 1-specificity. The C-statistic was based on a 
Cox regression model, using R’s survival and survivalROC packages. Kaplan-meier estimates 
were calculated, and compared using the log-rank test. Univariable cox regression analysis 
was performed to identify predictors of outcome. All tests were 2-sided and a p-value <0.05 
was considered statistically significant. To deal with missing data, we used a similar approach 
outlined in the HCM Risk-SCD study: missing data was identified and imputed using mul-
tiple imputation. A total of 25 imputed data sets were generated and pooled. Patients with 50% 
missing predictors were excluded from model development.
resuLts
Clinical characteristics
The final study population consisted of 706 HCM patients (age 49 ± 16, 66% male) and table 1 
lists the baseline characteristics of these patients. A baseline LVOT gradient ≥ 30 mmHg was 
present in 375 patients (53%). During follow-up 109 patients (15%) underwent septal ablation 
and 139 patients (20%) underwent surgical myectomy. Atrial fibrillation was documented in 
170 patients (24%) during follow-up. A total of 524 patients (74%) were treated with at least 
a β-receptor antagonist or verapamil. An ICD was implanted for primary prevention in 117 
patients (17%). Risk stratification was not complete in all patients: in 107 patients (15%) the 
exercise testing was lacking, in 116 patients (16%) the Holter-monitoring, in 52 patients (7.3%) 
there was LVOT gradient, and in 52 patients LA diameter was missing. No patients were 
excluded because of missing data. Predictors of missingness were: age at first contact, gender, 
and NYHA class, and date of exit of the study.
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sudden cardiac death
Follow-up was 7.7 ±5.3 years (range 22.7), with a total of 5438 patient-years. During follow-up 
42 patients (5.9%) reached the SCD endpoint. Of these, 4 (10%) had successful cardiac resus-
citation, 16 (38%) had appropriate ICD shocks and 22 (52%) died suddenly. Patients with SCD 
were younger (44 vs 50 years), had increased LVWT (23 vs 20 mm) and left atrial diameter 
(49 vs 45 mm). Twenty patients (28%) reached the SCD endpoint in the first 5 years after 
initial risk stratification. Univariable Cox-regression analysis identified only left ventricular 
wall thickness as a predictor for SCD (table 2).
HCm risk-sCd score and the 2003 and 2011 guidelines
In the patients reaching the SCD endpoint, mean calculated 5-year SCD risk was 4.9% (IQR 
3.8%) and these patients had a median of 1 (IQR 2) established risk factor. In patients without 
SCD calculated 5-year risk was 2.8% (IQR 3.0%; p = 0.002), with a median of 0 (IQR 1) estab-
lished risk factors (p=0.03).
table 1 – Clinical characteristics of 706 HCM patients
n=
All Patients with SCD Patients without SCD
706 42 664
Female 242 (34) 10 (24) 232 (35)
Age, y 49 ± 16 44 ± 17 50 ± 16
NYHA III/IV 232 (33) 19 (41) 213 (32)
Atrial fibrillation 170 (24) 15 (36) 155 (23)
Left ventricular wall thickness, mm 20 ± 5 23 ± 5 20 ± 5
Left atrial diameter, mm 45 ± 8 49 ± 9 45 ± 7
Maximal LVOT gradient, mmHg 48 ± 44 48 ± 43 48 ± 44
Surgical myectomy 139 (20) 6 (14) 133 (20)
Septal ablation 109 (15) 10 (24) 99 (15)
Family history of SCD 141 (20) 14 (33) 127 (19)
Syncope 72 (10) 7 (17) 65 (10)
Left ventricular wall thickness ≥30mm 46 (7) 8 (19) 38 (6)
Non-sustained ventricular tachycardia 157 (22) 16 (38) 141 (21)
Abnormal blood pressure during exercise 89 (13) 5 (12) 84 (13)
0 Risk factors 345 (49) 12 (29) 333 (50)
1 Risk factor 245 (35) 17 (40) 228 (34)
≥ 2 Risk factors 116 (16) 13 (31) 103 (16)
Data are represented as n (percentage) unless stated otherwise. LVOT: left ventricular outflow tract;
SCD: sudden cardiac death.
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The C-statistic for the HCM Risk-SCD model was 0.69 (95% CI 0.57-0.82, p=0.008). The 
C-statistic was also calculated for the 2003 guidelines: 0.55 (95% CI 0.47-0.63, p=0.3); and for 
the 2011 guidelines: 0.60 (95% CI 0.50-0.70, p=0.07). The ROC curves are shown in figure 1. 
We also examined whether using the HCM Risk-SCD score results in correct reclassification 
of high-risk patients. Net reclassification index (NRI) was 0.27 (95% CI -0.02 – 0.57, p=0.07) 
table 2 – Univariable Cox regression model of predictors for SCD in 706 HCM patients.
HR CI 95% p
Age, y 0.98 0.96-1.01 0.2
Male 3.0 0.87-10.1 0.08
Left ventricular wall thickness, mm 1.09 1.02-1.17 0.009
Left atrial diameter, mm 1.05 0.99-1.10 0.09
Maximal LVOT gradient, mmHg 1.01 1.00-1.02 0.1
Family history of SCD 1.7 0.66-4.45 0.3
Syncope 1.6 0.47-5.51 0.4
Left ventricular wall thickness ≥30mm 4.6 1.68-12.7 0.003
Non-sustained ventricular tachycardia 1.2 0.46-3.21 0.7
Abnormal blood pressure during exercise 0.7 0.17-3.13 0.7
CI: confidence interval; HCM: Hypertrophic cardiomyopathy; HR: hazard ratio; LVOT: left ventricular 
outflow tract; SCD: sudden cardiac death.
figure 1 – Time-dependent receiver operating characteristic curves for the risk prediction models of 
the 2014 ESC guidelines (AUC=0.69), 2003 ACC/ESC guidelines (AUC=0.55), and 2011 ACCF/AHA 
guidelines (AUC=0.60), and the reference line (AUC=0.5).
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compared with 2003 guidelines and NRI was 0.16 (95% CI -0.17 – 0.45, p=0.2) compared with 
2011 guidelines. A complete overview is shown in table 3.
risk groups and clinical implications
The predicted and observed risk per group are illustrated in figure 2, SCD risk was over-
estimated, especially in the high risk group. Optimal sensitivity and specificity of the HCM 
Risk-SCD model in the original study was determined at ≥4% per 5-year, with a sensitivity and 
specificity of 71% and 70%. In this study a calculated 5-year SCD risk of 4% showed similar 
sensitivity (70%) and specificity (67%, figure 1), and was a significant predictor for SCD (HR 
4.2 95% CI 1.6-11.0, p=0.003). In contrast, the presence of ≥1 (HR 2.2 95% CI 0.9-5.3, p=0.08; 
2011 guidelines) or ≥2 (HR 1.7 95% CI 0.6-4.6, p=0.3; 2003 guidelines) risk factors were not 
predictive of SCD. Kaplan-Meier estimates for risk of SCD are shown in figure 3.
table 3 – Reclassification of predicted risk among cases (patients with SCD-event) and controls.
Predicted risk 
classified downward 
in new model
Predicted risk not 
changed in new 
model
Predicted risk 
classified upward 
in new model
Total
2014 vs. 2003 guidelines model
Cases (SCD-patients), n (%) 0 (0) † 11 (55) 9 (45)* 20
Controls, n (%) 12 (2)* 540 (79) 134 (20) † 686
2014 vs. 2011 guidelines model
Cases (SCD-patients), n (%) 2 (10) † 12 (60) 6 (30)* 20
Controls, n (%) 75 (11)* 513 (75) 98 (14) † 686
* indicates correct reclassifications in the new model. † indicates incorrect reclassifications in the new 
model. SCD = sudden cardiac death †
figure 2 – Predicted and observed risk of SCD in the different risk groups.
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figure 3 – Kaplan Meier estimates of SCD risk in 706 HCM patients, based on the 2003 ACC/ESC 
guidelines, 2011 ACCF/AHA guidelines, and HCM Risk-SCD model (SCD risk ≥4%/5-year).
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To prevent 1 case of SCD in 5 years, 17 ICD implantations are necessary when using the 
≥4% cut-off. The 2003 guideline model requires 22 ICD implantations to prevent 1 SCD and 
the 2011 guideline model requires 20 ICD implantations (table 4).
dIsCussION
This study is the first independent and external validation of the novel clinical risk prediction 
model (HCM Risk-SCD) used in the 2014 ESC guidelines.1, 6 The most important finding of 
this study is that in an independent setting, the HCM Risk-SCD score discriminates better 
between patients with high or low SCD risk, than the risk stratification models proposed by 
older clinical guidelines.
Identification of high risk patients
The 2003 and 2011 guidelines3, 4 are based on the five aforementioned established risk factors 
to determine whether or not patients with HCM are at increased risk of SCD. O’Mahony 
et al. demonstrated in 2013 that both models are limited to discern high from low risk 
patients5. The HCM Risk-SCD model was developed to improve the risk stratification of 
HCM patients. Instead of an algorithm based on the sum of the established risk factors, as 
those guidelines do, this model calculates individual 5-year SCD risk estimates. Our results 
show that, in an independent setting, the ability to predict SCD by using the HCM Risk-SCD 
model (C-statistic = 0.69) is improved when compared with current guidelines (C-statistic = 
0.55-0.60).
The biggest changes in the HCM Risk-SCD model, compared with the risk stratifica-
tion models proposed by the older guidelines are the following: (1) abnormal blood pressure 
response during exercise is no longer included in the risk stratification; (2) increasing age 
is a protective factor; (3) LVWT is no longer regarded as dichotomous, but as a continuous 
variable; and (4) LA diameter and LVOT gradient are added as continuous risk factors. All 
table 4 – ICD implantations and 5-year risk of SCD based on the HCM Risk-SCD model, and 2003 
and 2011 risk prediction models
n = 706
Patients with SCD Patients without SCD
ICD No ICD ICD No ICD
2003 guidelines (≥2 established risk factors) 5 (25) 15 (75) 111 (16) 575 (84)
2011 guidelines (≥1 established risk factor) 10 (50) 10 (50) 210 (31) 476 (69)
HCM Risk-SCD score ≥4% 14 (70) 6 (30) 229 (33) 457 (67)
Data are represented as number (percentage). HCM: hypertrophic cardiomyopathy; ICD: implantable 
cardioverter defibrillator; SCD: sudden cardiac death.
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clinical variables are easily obtained, especially since abnormal blood pressure response dur-
ing exercise is no longer a risk factor. Although there was a univariable association between 
blood pressure response and SCD8, it remained unclear if it was only of clinical importance in 
patients ≤40 years old7, or how the finding was related to the increase in dynamic LVOT gradi-
ent. In the 2011 guidelines the usefulness of ICD implantation in the presence of an abnormal 
blood pressure response as only risk factor was deemed uncertain (Class IIb, level of evidence 
C)4, and it was excluded as potential risk factor in the HCM Risk-SCD model because it was 
not associated with SCD in any multivariable survival analyses7, 9, 10. Age is considered to be 
protective of SCD in this model. A number of studies have demonstrated that a younger age 
is associated with an increased risk of SCD11-13, and a recent study showed a very low SCD risk 
in patients >60 years of age14.
Cardiac remodeling and sCd
Another advantage of the new model is that the effects of cardiac remodeling on SCD are 
now considered. HCM is not a static disease and Olivotto et al. identified 4 clinical stages of 
HCM and demonstrated that disease progression is associated with an increase of SCD risk: 
from 0.5%-1%/year in patients with classic phenotype to 10%/year in patients with overt dys-
function15. This increase of risk is not considered in the conventional risk prediction models. 
The new HCM Risk-SCD model is partially based on factors of disease progression including 
maximal LVWT, LA diameter and LVOT gradient. These factors are, as mentioned above, 
included in the model as continuous variables, and changes herein are reflected in the SCD 
risk score.
ICd implantation for primary prevention of sCd
Patients that are considered at high risk for SCD should be considered for ICD implantation, 
after taking into account the potential complications of long-term ICD implantation2. The 
improved discriminatory power of the HCM Risk-SCD model might imply that more patients 
at increased risk (both intermediate and high risk) of SCD (a 5-year risk of 4-6% and ≥6%) 
are correctly identified and become eligible for ICD implantation, but also that unnecessary 
and potential harmful ICD implantations in patients without increased risk of SCD can be 
avoided. In our population, for every 17 ICD’s implanted in patients with a 5-year risk of ≥ 4%, 
1 patient could be saved from SCD at 5 years. This is similar with the 16 ICD implantations 
needed to prevent 1 SCD in the HCM Risk-SCD study, and lower than current risk stratifica-
tion models. It is important to note that the calculated risk score is not a replacement of 
clinical judgment, but should be used as the authors state: “to complement clinical reasoning 
by providing objective individualized prognostic information.”6 This is in line with the 2011 
guidelines that state: “The decision for placement of primary prevention ICD in HCM often 
involves a large measure of individual clinical judgment, particularly when evidence for risk 
is ambiguous. The potential for SCD needs to be discussed with each fully informed HCM 
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patient and family member in the context of their concerns and anxieties and should be bal-
anced against the risks and benefits of proposed prophylactic ICD strategy.”4
model limitations and future developments
Further development of the model will determine the role of other clinical variables. SCD 
in HCM is assumed to originate from the myocardial disarray and scar tissue7, 16, which is, 
for example, more present in patients with increased LVWT. Several studies have shown 
that the presence of extensive fibrosis, demonstrated by delayed gadolinium enhancement on 
cardiac magnetic resonance imaging, might increase the risk of SCD17-20, but a recent meta-
analysis did not show any relationship with SCD21. There is a relationship however between 
extensive delayed enhancement and progression to heart failure22. The additional value of 
delayed enhancement in the prediction of SCD could be assessed in a future version of the 
risk prediction model.
A similar approach can be used for genetics: it is not evident whether genetic information 
is predictive of outcome. Genotype was not predictive of appropriate ICD interventions23, 
but patients with double or triple mutations are at increased risk of end-stage progression 
and ventricular arrhythmias24. Current DNA sequencing is expensive and time-consuming; 
especially if analysis has to be continued after the first mutation has been found. With next-
generation sequencing it will be possible to screen for a larger number of genes, and it will 
possibly lead to identification of more patients carrying mutations. It might become easier to 
identify patients with multiple mutations and include this information in the individual risk 
stratification. In addition, specific electrocardiographical features, such as paced electrogram 
fractionation analysis, may provide further improvement of the risk model.25 Finally, it is 
unclear how septal reduction therapy (both surgical myectomy and septal ablation) influences 
the individual SCD risk, and whether or not it is suffice to calculate the new 5-year risk by us-
ing the post-procedural LVOT gradient and LVWT. Several studies demonstrated that SCD 
rates after myectomy are low, but the SCD risk after septal ablation is more controversial.26-29
study limitations
This study has several limitations. The comparison between different risk models is limited 
due to the small numbers of SCD events. Both participating centers are tertiary referral 
centers for the diagnostic and therapeutic care of HCM, and due to this selection and referral 
bias, the patient population might not represent the general HCM population. As rhythm 
documentation of the event was not available for all SCD cases, it was not possible to ascer-
tain that all deaths were arrhythmic in nature. Also a more conservative setting would have 
influenced the occurrence of ICD interventions. Risk stratification was not complete in all 
patients: in 107 patients (15%) the exercise testing was lacking, and in 116 patients (16%) the 
Holter-monitoring. The same approach to missing data was used as in the HCM Risk-SCD 
study.6
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CONCLusION
The HCM Risk-SCD model improves the risk stratification of HCM patients, and calculat-
ing an individual risk estimate contributes to the clinical decision making process. Improved 
risk stratification is important for the decision making before ICD implantation for primary 
prevention of SCD.
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Prophylactic implantable defibrillators for hypertrophic cardiomyopathy: 
disarray in the era of precision medicine
Grace A
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):763-6
Discussions with individuals and families affected by hypertrophic cardiomyopathy (HCM) 
concerning prophylactic implantable defibrillators (ICDs) will on occasion offer some new chal-
lenges. In a bold attempt to provide categorical answers, the European Society of Cardiology 
have incorporated a mathematical approach to risk prediction into their 2014 guidelines [1] that 
includes some risk factors (RFs) that are not broadly agreed and without any prior independent 
testing.[2] Furthermore, 2 groups have now examined how the guidance would have performed 
in their patients and arrived at essentially polar opposite conclusions on utility.[3,4]
HCM is common with a broad clinical expression and overall an annual sudden cardiac 
death (SCD) risk that is <1%.[5,6] It is the exemplar monogenic cardiac disorder and study of 
the underlying genetics has enhanced understanding of disease pathophysiology opening up 
candidate therapeutic approaches.[7] More complete follow-up along with multidisciplinary 
considerations of the range of treatment options has allowed better timing of surgical/non-
surgical interventions.[1,6] Such progress has had a significant impact on improving patient 
outcomes, but there is the critical issue that we remain only modestly capable of identifying 
accurately the small subset that will benefit from an ICD.[1,3,4,8]
Why risk prediction remains so difficult has been extensively considered.[1,5] Despite 
large patient cohorts, it is the phenotypic diversity of HCM, the low SCD event rates, the 
long recruitment periods, evolving assessment methods and corresponding incomplete data 
that have all confounded clear answers. The only option for the provision of protection is the 
ICD and prospective, randomized comparisons have not been possible.[9] Accordingly, guid-
ance has relied on cumulative clinical observation.[5,6,8] What is agreed is that individual 
RFs that have been associated with risk have low positive predictive power, in the range of 
10% to 20%,5 and even with aggregate RF assessment sensitivity and specificity in regard to 
the prediction of SCD remains poor.[5] Family history is undoubtedly relevant, but epigenetic 
and other acquired influences have substantially greater impact on risk so that genetic studies 
have few roles in SCD risk assessment in the propositus.[1]
Possible RFs have been the subject of long-standing dispute on both their definition 
and relative importance.[1,4,10] These include syncope,[10] ventricular wall thickness, 
exercise-associated blood pressure responses, nonsustained ventricular tachycardia, and left 
ventricular outflow tract (LVOT) obstruction.11 One point that is striking is that neither the 
nature nor the number of RFs predicts ICD discharge.[9,12] Furthermore, factors previously 
not considered risk markers, eg, fractional shortening, have been associated with appropri-
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ate shocks thereby again questioning individual RF validity.[12] Simply stacking up RFs has 
low predictive power strongly supported by an observational, retrospective, cohort study of 
1606 patients in whom 5 RFs were assessed in their capacity to predict risk.[13] Although risk 
was seen to increase with multiple RFs, the C-statistic obtained from the receiver operating 
characteristic curve (in the range 0.61 to 0.64 at 5 years) indicated limited capacity to resolve 
risk.[13] These data essentially recapitulate prior evidence provided from a prospective evalu-
ation of the same RFs.14 The results taken together provide substantial support for the view 
that softer but nonetheless effective contributions such as physician experience are crucial to 
making the right decisions.[1,4,5]
The HCM Risk-SCD algorithm has been presented with an aim “to develop and validate 
a new SCD prediction model that provides individualized risk estimates”[2] and is the basis 
of the European Society of Cardiology 2014 risk guidance.[1]The algorithm is based on a 
Cox proportional hazards model internally validated with boot strapping. The data populating 
the model was obtained from a retrospective, multicenter, longitudinal cohort study involv-
ing 3675 consecutively presenting patients. The model was developed across 5 sites (2082 
patients) with validation at a further participating center (1593 patients). Seven continuous or 
binary RFs (age, maximal LV wall thickness, left atrial [LA] size, max. LVOT gradient, family 
history of SCD, nonsustained ventricular tachycardia, and unexplained syncope) derived 
from the literature and each independently associated with SCD in at least one multivariable 
survival analysis were then assessed in respect of the occurrence of SCD or appropriate ICD 
shocks. These events occurred in [almost equal to]5% of patients over a median follow-up of 
5.7 years. Patients were then banded into one of 3 groups based on 5-year risks of SCD. If the 
5-year risk was calculated at <4%, an ICD would not be recommended; if in the range 4% to 6%, 
it would be contingent; and if >6%, an ICD would be recommended. The C-statistic reported 
using this modified approach was 0.70. RFs can now be inputted into an online calculator and 
a recommendation obtained as to whether to recommend or seek out ICD implantation.[1]
The predictor variables included in the HCM Risk-SCD algorithm that have probably at-
tracted most comment are LA enlargement and LVOT obstruction. At first pass, LA enlarge-
ment is not the most intuitively obvious potential predictor of the risk of SCD. The incorpo-
ration in the algorithm has been justified by a single observation in which LA enlargement 
conferred a relative risk of 1.03 (confidence interval, 1.00–1.06; P<0.04).[10] LA enlargement 
has been used, rather than the presence of atrial fibrillation, as we are told: “LA enlargement 
predisposes to atrial fibrillation and contained less missing data.”[2] A further problem is that 
the association between atrial fibrillation and SCD in HCM has never been robust and in a 
recent study of 3673 patients, although atrial fibrillation enhanced overall risk, there was no 
significant influence on the risk of SCD.[15] The problems raised by the inclusion of LVOT 
obstruction mainly relate to frequency of occurrence, variability, and modest impact.[4]
The performance of the HCM Risk-SCD algorithm has now been assessed in an obser-
vational cohort design conducted in twin tertiary referral centers.[3] A total of 706 HCM 
157
Validation of the new SCD risk prediction model for HCM
9
patients who had been under consideration for a prophylactic ICD have been included, and 
the end points of SCD-equivalent event (SCD, appropriate ICD discharge) was observed in 
5.9% of patients at follow-up. Interestingly, basal LVOT gradient was >30 mm in 53% patients, 
and >30% of patients underwent interventions that could have had a significant impact on key 
inputs into the algorithm (LVOT gradient, LA size). Of course, we already know that relief 
of LVOT obstruction with myectomy is associated with subsequent low rates of SCD.[16] 
The research provides similar results to those in the first description of HCM Risk-SCD 2 
with an improved C-statistic (0.69) when compared with derivations based on the 2003 [17] 
(C-statistic, 0.55) and 2011 [5] guidance (C-statistic, 0.60). Using this approach still required 
the implantation of 17 ICDs to save one life at the end of 5 years.
To directly test the algorithm, a US group has also retrospectively examined the clini-
cal prediction capabilities of HCM Risk-SCD in 1629 consecutive patients followed up for 
a median of 6.4 years of whom 460 received ICDs.[4] Forty-six patients went on to receive 
appropriate ICD interventions, but 27 (59%) of this group had low HCM Risk-SCD scores 
that would have precluded an ICD recommendation. In addition, only 16 of the total of 81 
(20%) who had an SCD-equivalent event had a high HCM Risk-SCD score along with a 
definite ICD recommendation. This group also tested the algorithm in a series of simula-
tions providing examples of patients with large single RFs (who would not receive an ICD 
according to HCM Risk-SCD) and situations such as a combination of relative youth, LVOT 
obstruction, and increased LA size (who would not currently receive an ICD but in whom 
with uncritical application of HCM Risk-SCD would now get an ICD). The main conclusion 
was that application of HCM Risk-SCD might reduce the number of inappropriate ICDs but 
was thoroughly insensitive to the accurate identification of high-risk patients.[4]
In view of these various continuing issues, it is likely that most of us will (for now) steer 
clear of an algorithmic approach that might obscure useful raw data.[1,2] Some patients will 
undoubtedly access the HCM Risk-SCD algorithm, input their own data, and raise possibly 
challenging questions that will need to be addressed. To minimize such occurrences, a single, 
inclusive community effort in guideline formulation based on international cooperation 
should again be our aim.[17] Most experienced physicians will continue to take a careful his-
tory probing difficult aspects (family history, syncope), review all the data in multidisciplinary 
discussion, and reach a measured conclusion to take back to the well-informed patient. 
Patients without manifest RFs will be reassured in the knowledge that their risk is low and 
not too far away from the general population mean.[5] The question of risk will be revisited 
at future visits in the light of their further test results and accumulating research findings.[5] 
In those in whom an ICD is thought likely to provide net benefit, the simplest device possible 
for that patient should be used to minimize adverse risks.[12]This may be a single ventricular 
lead, single-coil transvenous unit but consideration should be made of the subcutaneous ICD, 
especially in young patients who will be especially prone to the issues emerging from both 
acute and progressive lead failure.[9,12,18,19]
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The variable performance of the HCM risk-SCD algorithm again highlights the need for 
new methods to identify those at risk of ventricular fibrillation.[20] It is universally agreed 
that the source of risk is myocardial, and that the presence of myofibrillar disarray is a key 
determinant yet no current assessment method addresses this aspect directly.[5,6,14] The 
use of late gadolinium enhancement as a possible means of risk stratification is of great inter-
est, but it is unlikely to be sensitive to the presence of disarray.21 Gadolinium is taken up 
into expanded extracellular spaces and detects large areas of scar tissue during washout but 
smaller patches of collagen, interstitial fibrosis, and disarray may not be detected.[21,22]Late 
gadolinium enhancement is, however, relevant to HCM-related heart failure outcomes,[22] 
and although the relationship to SCD outcomes is not yet secure and probably again mod-
est, it associates with potential surrogates of SCD (hypertrophy, nonsustained ventricular 
tachycardia).22,23 The American College of Cardiology/American Heart Association guide-
lines support a potential role of late gadolinium enhancement in decision making 5 although 
whether the absence of late gadolinium enhancement predict those at low risk remains a 
point of much discussion.[8,23,24] The National Institutes of Health–funded HCMR (Novel 
Predictors of Outcome in HCM) study plans to recruit 2750 subjects with 5-year follow-up to 
address the question of the best use of advanced imaging in risk stratification and is due for 
completion in 2018.[25]
Developments of cardiac MRI technology, eg, T1 mapping,[26] will no doubt usefully 
input into phenotypic categorization. It would, however, appear that the architectural pattern 
not the density of fibrosis had the most impact on the electrophysiology of human cardiomyo-
pathic hearts when studied ex vivo.[27,28] So while diffuse, short-strand fibrosis had marginal 
effects on conduction delay, patchy fibrosis with long fibrotic strands substantially delayed 
conduction [27] and such patterns are more likely to facilitate wavebreak and fibrillation.[29] 
The direction of wavefront activation is also of relevance to the occurrence of nonuniform 
anisotropic conduction with effects being the most prominent with activation perpendicular 
to fiber direction.[27] Clearly, some elements of this complex structural/functional milieu are 
going to be more amenable to noninvasive imaging than others.
Invasive electrophysiological assessment of patients with HCM is not usually recom-
mended having fallen out of favor after disappointing, contentious responses to conventional 
ventricular stimulation.[1,5] Nonetheless, evidence of regional voltage variation, increased la-
tency, and delayed conduction has been consistently observed.30,31 In addition, the feasibility 
of invasive assessment of electrograms with the aim of addressing the functional significance 
of myofibrillar disarray without arrhythmia induction has been reported.[14] The capacity of 
such approaches to enhance risk prediction was strongly supported in a prospective study of 
179 patients followed up over 4 years. This investigation demonstrated that the electrophysi-
ological approach predicted outcome with a high PPV (C-statistic, 0.88) although further 
validation is required.[14]
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The ICD provides an effective means of protecting HCM patients from SCD but we 
must precisely target high-risk subcategories of the disease to gain most benefit.[32] To make 
further significant progress, we require a focus on deep phenotyping (imaging/electrophysi-
ology) directed to the heart muscle to address the prognostic consequences of myofibrillar 
disarray. In the interim, as Spiegelhalter has pointed out, we should be cautious in the use of 
large data sets as “precision will delude us if selection bias and overinterpretation of associa-
tions as causation are not properly taken into account.” [33]
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Impact of adverse left ventricular remodeling on 
the risk of sudden cardiac death in patients with 
hypertrophic cardiomyopathy
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ABstrACt
Background:
Adverse left ventricular (LV) remodeling predicts heart failure symptoms and overt LV 
dysfunction in patients with hypertrophic cardiomyopathy (HCM), but its influence on the 
occurrence of SCD is unknown.
Hypothesis:
The aim of this study is to investigate the effect of adverse LV remodeling on sudden cardiac 
death (SCD) risk in patients with HCM.
methods:
This study included 41 patients with HCM who experienced SCD; each case was matched 
with 3 controls based on age, gender, and time of first contact. In this population of 164 pa-
tients, predictors of SCD were identified using univariable and multivariable logistic regres-
sion and expressed as odds ratio (OR) with 95% confidence interval.
results:
Baseline characteristics, such as NYHA class, systolic and diastolic left ventricular function, 
left ventricular wall thickness, left atrial size, atrial fibrillation and established risk factors 
for SCD, were similar in cases and controls. Independent predictors of SCD during follow-
up (median follow-up: 7.7 ± 6.5 years) were : increase in NYHA class (OR 8.7 [2.5-30.5], 
p=0.001), decrease of fractional shortening (per % decrease, OR 1.09 [1.03-1.14], p=0.001), 
and decrease of diastolic function (OR 3.5 [1.2-10.2], p=0.02).
Conclusion:
This study shows that SCD risk in HCM increases when adverse remodeling occurs. Since 
cases and controls were similar at baseline, these findings emphasize the importance of 
vigilant follow-up of HCM patients and could aid clinical decision-making concerning ICD 
implantation, especially in patients with moderate risk for SCD.
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INtrOduCtION
Sudden cardiac death (SCD) is the most devastating expression of hypertrophic cardiomy-
opathy (HCM). The annualized rate of SCD in HCM patients is presumed to be ± 1% per 
year.[1,2] Implantable cardioverter defibrillators (ICDs) have proven to be an effective way 
of preventing SCD in HCM patients, both in primary as in secondary prevention.[3-5] For 
secondary prevention there is universal agreement that ICDs should be implanted. The SCD 
risk in primary prevention is assessed by risk stratification based on the work of Elliott et al in 
2000 [1,6] and updated to its current form in the 2011 ACCF/AHA guidelines.[7]
HCM is not a static disease and the guidelines recommend to repeat the risk stratification 
every 12-24 months. Recently Olivotto et al. [8] identified 4 clinical stages of HCM: non-
hypertrophic HCM, classic phenotype, adverse remodeling and overt dysfunction. Adverse 
remodeling is characterized by the presence of unfavorable structural and functional changes 
and patients with adverse remodeling are presumed to be at increased risk of heart failure 
and overt dysfunction.[8-11] Characteristics of adverse remodeling as described by Olivotto 
et al. are the following: a decrease in systolic and diastolic left ventricular function (LVF)
[11], left atrial (LA) and left ventricular (LV) dilatation[9,12], an increase in symptoms and 
functional limitations[9], the occurrence of atrial fibrillation (AF)[13], reduction or loss of 
LVOT obstruction[10,14] and thinning of LV walls[10]. The SCD risk increases from 0.5-1%/
year for patients with the classic phenotype to 10%/year for patients with overt dysfunction, 
but the SCD risk of patients with adverse remodeling is unknown.[8] We performed therefore 
a case-control study to investigate the relation between adverse LV remodeling and the risk 
of SCD in HCM patients.
metHOds
study design and patient population
This study included 41 patients with HCM who died because of SCD and 123 age and gender-
matched control patients with HCM attending the adult outpatient clinic at the Thoraxcenter, 
Erasmus Medical Center, Rotterdam, the Netherlands between January 1st, 1995 and Decem-
ber 31st, 2011. Each patient had an established diagnosis of HCM, based on unexplained left 
ventricular hypertrophy of ≥ 15 mm.[15] Patients with HCM linked to Noonan’s syndrome, 
Fabry’s disease, mitochondrial disease or congenital heart defects were excluded. Patients 
younger than 16 years were excluded. The study protocol conforms to the ethical guidelines 
of the 1975 Declaration of Helsinki and was approved by the institutional review board.
Cases were defined as HCM patients with SCD and controls as HCM patients without 
SCD. Patients with a prior SCD event before the study period or first contact were excluded. 
Cases were identified at the time of SCD and chart review was done retrospectively. SCD 
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is defined as death occurring < 1 hour from the onset of symptoms in patients who had 
previously experienced a relatively stable or uneventful clinical course. In this study SCD 
also included successfully resuscitated cardiac arrest or appropriate ICD intervention for 
ventricular fibrillation (VF) or fast (≥ 200 bpm) ventricular tachycardia (VT). Each case was 
matched with 3 controls based on the following parameters: age (± 1 years) and gender, and 
year of first contact (± 3 years).
Assessment of Adverse remodeling
The following clinical characteristics and signs of adverse remodeling were examined at 
baseline and at last documented contact before SCD or end of follow-up: New York Heart 
Association (NYHA) functional class, maximal left ventricular wall thickness (LVWT), end 
systolic diameter (ESD), end diastolic diameter (EDD), LA size, LVOT gradient during 
rest and/or exercise, systolic LVF, diastolic LVF, the occurrence of AF (either persistent or 
paroxysmal), medical therapy and a history of septal reduction therapy (SRT), either alcohol 
septal ablation or myectomy.
Systolic LVF was evaluated by visual assessment of ejection fraction (EF) and scored as 
normal (EF > 55%), mildly reduced (EF 45-55%), moderate (EF 30-45%) and poor LVF (EF 
< 30%).[16] Additionally fractional shortening (FS) was calculated. Decrease of systolic LVF 
was defined as the decrease of >1 classification during follow-up (e.g. from normal to mildly 
reduced). Diastolic LVF was described as normal, abnormal relaxation (stage I), pseudo-
normalization (stage II) and restrictive filling (stage III) and was based on the latest guidelines.
[17,18] Decrease of diastolic LVF was defined as the decrease of ≥ 1 stage (e.g. from normal to 
abnormal relaxation).
Patient follow-up
Mortality was provided from civil service population registers and information provided by 
general practitioners and at the center where follow-up occurred. Clinical characteristics were 
retrieved from hospital patient records provided by the center where follow-up occurred.
Echocardiographic evaluation was independently performed by cardiologists with 
extensive experience in reading echocardiograms, who were blinded to clinical data. The 
administrative censoring date for follow-up in the control group was November 1st, 2012.
statistical Analysis
SPSS version 20 (IBM, Armonk, NY, USA) and Microsoft Excel 2010 (Microsoft Corpora-
tion, Redmond, WA, USA) were used for all statistical analyses. Categorical variables were 
summarized as percentages. Normally distributed continuous data are expressed as mean ± 
standard deviation and non-normally distributed data was expressed as median ± interquartile 
range. For comparing variables, means and medians χ2-test, Student t test or Mann-Whitney 
U-test were used, for categorical and continuous data respectively. To identify clinical predic-
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tors of SCD univariable and multivariable logistic regression analysis were used. Clinical vari-
ables - from last contact prior SCD or censoring date - were selected for backward stepwise 
multivariable analysis if univariable p-value was < 0.1 and were expressed as odds ratio (OR) 
with 95% confidence interval (CI). The final number of variables was restricted according to 
the number of end-points to avoid overfitting the multivariable model. A p-value <0.05 was 
considered statistically significant.
resuLts
Baseline characteristics
A total of 41 cases of SCD were identified. Seventeen patients died, 11 were successfully 
resuscitated after cardiac arrest and 13 patients had appropriate ICD intervention for either 
VF or fast VT (> 200 bpm). Three controls per case were identified based on age, gender, 
and year of first contact, and thus the total study population consisted of 41 cases and 123 
controls (table 1). The majority of cases and controls were male (112 (66%) patients) with 
an average age of 46 ± 15 years (range 16-73) at baseline. No significant differences were 
described at baseline between cases and controls in NYHA class, diastolic LVF, EDD, ESCD, 
fractional shortening, LVOT gradient, maximal LVWT, and LA size. More cases had systolic 
impairment at baseline (9 (21%) patients and 9 (7%) patients, p=0.03). Both groups had similar 
numbers of patients with a family history for SCD, unexplained syncope and LVWT ≥ 30mm, 
figure 1 – Distribution of risk factors – Showing the distribution of the number of established risk 
factors for sudden cardiac death in 41 cases and 123 controls.
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and distribution of major risk factors was comparable (figure 1). The medication used to 
alleviate symptoms was not significantly different in both groups.
Follow-up
The median follow-up was 7.7 ± 6.5 years, 6.6 ± 8.0 years for cases and 7.9 ± 5.8 years for 
controls (p=0.01). Compared to the controls the cases showed increase of NYHA class, 
table 1 – Baseline characteristics of 41 cases (SCD) and 123 controls (no SCD)
n =
SCD No SCD p
41 123
Age, y 45.6 ± 15 45.6 ± 15 1.0
Male 27 (66) 81 (66) 1.0
NYHA III/IV 18 (44) 41 (33) 0.2
Maximum LVWT, mm 22 ± 5 21 ± 5 0.4
Left atrial size, mm 48 ± 10 45 ± 8 0.07
LVOT gradient, mmHg 54 ± 48 51 ± 44 0.9
Left ventricular function
End diastolic diameter, mm 45 ± 6 42 ± 6 0.07
Fractional shortening, % 45 ± 9 42 ± 9 0.2
Reduced ejection fraction (<55%) 9 (17) 9 (7) 0.02
Diastolic dysfunction 21 (51) 70 (57) 0.7
Risk factors for SD
SCD in family history 9 (22) 21 (17) 0.5
nsVT on Holter-monitoring 9 (22) 19 (15) 0.3
Abnormal exercise BP response 5 (12) 7 (6) 0.6
Syncope 12 (30) 23 (19) 0.08
LVWT ≥ 30 mm 8 (20) 10 (8) 0.2
≥ 2 risk factors 11 (27) 17 (14) 0.06
Medication:
Betablocker 14 (34) 60 (49) 0.1
Calcium channel blocker 11 (27) 35 (28) 0.8
Amiodarone 4 (10) 4 (3) 0.09
Data are presented as number (percentage) unless stated otherwise. BP: blood pressure; LVOT: left 
ventricular outflow tract; LVWT: left ventricular wall thickness; nsVT: non-sustained ventricular tachy-
cardia; NYHA: New York Heart Association; SCD: sudden cardiac death
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table 2 – Clinical characteristics at last evaluation of 41 cases (SCD) and 123 controls (no SCD)
n =
SCD No SCD p
41 123
Age, y 51.9 ± 16 53.8 ± 15 0.4
duration of follow-up, y 6.6 ± 8.0 7.9 ± 5.8 0.01
NYHA III/IV 14 (34) 7 (6) < 0.001
Maximum LVWT, mm 20 ± 5 19 ± 4 0.09
Left atrial size, mm 52 ± 12 47 ±8 0.01
Atrial fibrillation 15 (37) 16 (13) 0.001
LVOT gradient, mmHg 29 ± 35 27 ± 30 0.8
Left ventricular function:
End-diastolic diameter, mm 50 ± 10 45 ± 7 0.002
Fractional shortening, % 32 ± 10 42 ± 10 < 0.001
Reduced ejection fraction (< 55%) 18 19 < 0.001
Diastolic dysfunction 35 78 < 0.02
Septal reduction:
Alcohol septal ablation 10 (24) 21 (17) 0.3
Myectomy 9 (22) 20 (16) 0.4
Data are presented as number (percentage) unless stated otherwise. LVOT: left ventricular outflow 
tract; LVWT: left ventricular wall thickness; NYHA: New York Heart Association; SCD: sudden car-
diac death
table 3 – Characteristics of adverse remodeling between 41 cases (SCD) and 123 controls (no SCD)
n =
SCD No SCD p
41 123
Increase of NYHA class, n (%) 13 (32) 9 (7) < 0.001
Decrease of LVWT, mm 1 ± 5 2 ± 4 0.6
Increase of left atrial size, mm 4 ± 7 1 ± 5 0.04
Increase of end-diastolic diameter, mm 6 ± 9 2 ± 5 0.04
Decrease of fractional shortening, % 10 ± 11 0 ± 10 < 0.001
Decrease of systolic LV function, n (%) 17 (41) 13 (11) < 0.001
Decrease of diastolic LV function, n (%) 19 (46) 29 (24) 0.004
Atrial fibrillation, n (%) 15 (37) 16 (13) 0.001
LV: left ventricular; LVWT: left ventricular wall thickness; NYHA: New York Heart Association; SCD: 
sudden cardiac death
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decreased systolic and diastolic LVF, increased EDD, increased left atrial size, decrease of 
fractional shortening and a higher incidence of AF. Septal reduction therapy was performed 
in 19 (46%) cases and in 41 (33%) controls (p=0.3). (table 2 and 3). LVOT gradient reduc-
tion in this group was from 93 ±36mmHg at baseline to 28 ±33 mmHg at last follow-up, and 
procedure was successful in 45 patients (76%). During follow-up, an ICD was implanted in 27 
patients, in 19 (46%) cases and 8 (7%) controls (p < 0.001).
Predictors of sCd
table 4 summarizes the results of univariable and multivariable analysis. Characteristics 
of adverse remodeling such as decrease in systolic and diastolic function, advancement of 
NYHA class, left atrial and ventricular dilation and decrease of fractional shortening were all 
significant predictors in univariable analysis. In multivariable analysis independent predictors 
for SCD were: fractional shortening (per % decrease, OR 1.09 [1.03-1.14], p=0.001), decrease 
of diastolic function (OR 3.5 [1.2-10.1], p =0.02), and increase of NYHA functional class (OR 
8.7 [2.5-30.5], p=0.001).
Table 4. Analysis of clinical variables associated with sudden cardiac death in 164 HCM patients (41 
cases and 123 controls)
Predictor
Univariate Multivariate
OR CI 95% p OR CI 95% p
Indicators of adverse LV remodeling:
 Increase of NYHA Class 5.8 2.2-14.9 < 0.001 8.7 2.5-30.5 0.001
 Decrease of systolic left ventricular function 6.0 2.6-14.0 < 0.001
 Decrease of diastolic left ventricular function 3.0 1.3-6.4 0.005 3.5 1.2-10.1 0.02
 Decrease of LVWT (per mm) 1.0 0.9-1.1 0.5
 Increase of end-diastolic diameter (per mm) 1.09 1.02-1.15 0.008 1.01 0.93-1.09 0.8
 Decrease of fractional shortening (per %) 1.09 1.04-1.15 < 0.001 1.08 1.03-1.14 0.003
 Increase of left atrial diameter (per mm) 1.07 1.01-1.14 0.02
 Atrial fibrillation 3.9 1.7-8.8 0.001 2.3 0.5-10.7 0.3
Additional predictors:
 Alcohol septal ablation 1.6 0.7-3.7 0.3
 Surgical myectomy 1.4 0.6-3.5 0.4
 ≥2 risk factors 2.3 1.0-5.4 0.06
CI: confidence interval; HCM: hypertrophic cardiomyopathy; LA: left atrial; LVOT: left ventricular 
outflow tract; LVWT: left ventricular wall thickness; NYHA: New York Heart Association; OR: odds 
ratio
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dIsCussION
The findings of this study suggest that the presence of signs of adverse LV remodeling in HCM 
patients increases the risk for SCD. Additionally, deterioration of the NYHA functional class 
and decrease of systolic and diastolic LV function are predictors of SCD in HCM patients.
A decrease of systolic function (in this study identified by LV dilatation, a decrease in 
fractional shortening and visual assessment of the EF) is more prevalent in the cases than in 
the controls. The increased risk of SCD in HCM patients with a low EF is already established, 
not only in general heart disease but also in HCM [9-11,19]. Our findings suggest that not 
only a low EF but the decrease of systolic function (EF < 55%) on its own increases the risk of 
SCD. The same statement can be made for diastolic dysfunction. Not only is a severe diastolic 
dysfunction a strong independent predictor for SCD, [20] but deterioration of diastolic LV 
function indicates an increased risk of SCD.
Current risk stratification for SCD is based on 5 major risk factors identified in the last two 
decades. This includes a detailed family history of SCD, a personal history of unexplained 
syncope, the assessment of maximal LVWT, Holter monitoring and blood pressure response 
to exercise. HCM patients are at increased risk in case of a family history of SCD in first-
degree relatives, an LVWT of ≥ 30 mm and a personal history of syncope. In these patients 
ICD implantation is considered reasonable (Class IIa, level of evidence: C). Other indications 
are the presence of non-sustained ventricular tachycardia on Holter-monitoring or abnormal 
blood pressure response during exercise-testing, especially in presence of other potential risk 
modifiers for SCD, such as the presence of left ventricular outflow tract (LVOT) obstruction ≥ 
30 mmHg, left ventricular apical aneurysms or delayed enhancement on magnetic resonance 
imaging [7,21]. The presence of delayed enhancement correlates with ECG changes[22], 
and has an trend toward significance for the risk of SCD [23]. Although SCD does occur in 
patients with no risk factors, there is consensus not to implant an ICD in these patients.
Risk stratification in patients with only 1 risk factor remains a gray area, in which the pres-
ence of the aforementioned potential arbitrators may lead to implantation of an ICD. This 
is a relevant clinical challenge as in our population 72 (40%) patients had only 1 major risk 
factor (figure 1). The presence of signs of adverse LV remodeling could aid clinical decision 
making in these patients. If signs of adverse LV remodeling are present, it could be considered 
an additional argument towards implanting an ICD. In patients with no classic risk factors, the 
presence of signs of adverse remodeling could trigger repeating the risk stratification.
Both guidelines [1,7] advise to repeat the risk stratification every 12-24 months. However, 
this is an arbitrary time-interval, and with the results of our study it should be advised to 
repeat the risk stratification when the aforementioned signs of adverse LV remodeling are 
identified. Additionally, as our results imply that adverse LV remodeling is also a potential 
arbitrator, it should be evaluated at every repeated risk stratification.
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Furthermore, it is important to note that at baseline both cases and controls were similar 
and no independent predictors for SCD could be identified. It was only during follow-up that 
differences between both groups were identified. This underscores the importance of vigilant 
follow-up of HCM patients, not only repeating the SCD risk stratification and evaluating 
systolic and diastolic LVF and symptoms to determine if adverse LV remodeling is present.
Limitations
This study has several limitations. This study was performed in a referral center for patients 
with HCM, therefore selection bias may have influenced the study results. The findings in 
this study will not be helpful in the first assessment of the patient, as baseline characteristics 
should be known, and the patient should be followed over time. This made data collection 
limited to variables that were routinely collected and novel developments during follow-up 
period were difficult to include. For this reason, advanced echocardiographic imaging such 
as strain rate imaging and cardiac magnetic resonance information was insufficient to use in 
this study. Rhythm documentation of the event was not available for all SCD cases. Consider-
ing appropriate ICD shocks as SCD endpoint could overestimate the SCD rate. A greater 
proportion of patients in the SCD group had septal ablation (24% vs. 17%) or myectomy (22% 
vs. 16%) than those without SCD. Although the incidence of septal reduction therapy was 
not statistically significant between the groups, the confounding effect of septal reduction 
therapy cannot be excluded, because the study may not be powered sufficiently to adjust for 
this variable in the multivariable model.
CONCLusION
Adverse LV remodeling is not only a predictor for heart-failure and overt dysfunction in HCM 
patients, but these patients are also at increased risk for SCD. This can only be identified 
during vigilant follow-up of HCM patients as initial screening might not show any signs of 
adverse remodeling. During follow-up not only should current risk stratification be repeated, 
but signs of adverse remodeling should be evaluated. It also implies that SCD occurs not only 
in the young and asymptomatic but especially when the disease progresses.
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Outcome and complications after implantable 
cardioverter defibrillator therapy in hypertrophic 
cardiomyopathy: systematic review and meta-analysis.
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ABstrACt
Background
Previous observational studies demonstrated that hypertrophic cardiomyopathy (HCM) 
patients at risk for sudden cardiac death (SCD) may benefit from implantable cardioverter 
defibrillator (ICD) therapy. A complete overview of outcome and complications after ICD 
therapy is currently not available. This study pools data from published studies on outcome 
and complications after ICD therapy in patients with HCM.
methods and results
A PubMed database search returned 27 studies on 16 cohorts reporting outcome and/or 
complications after ICD therapy in HCM patients. In case of >1 publications on a particular 
cohort, the publication with the largest number of patients was included in the meta-analysis. 
ICD interventions, complications, and mortality rates were extracted, pooled and analyzed. 
There were 2190 patients (mean age 42 y, 38% women), most of whom (83%) received an 
ICD for primary prevention of SCD. Risk factors for SCD were left ventricular wall thickness 
≥30 mm (20%), family history of SCD (43%), non-sustained ventricular tachycardia (46%), 
syncope (41%), and abnormal blood pressure response (25%). During 3.7 year follow-up, an-
nualized cardiac mortality rate was 0.6%, non-cardiac mortality rate 0.4%, and appropriate 
ICD intervention rate 3.3 %. Annualized inappropriate ICD intervention rate was 4.8% and 
annualized ICD related complication rate was 3.4%.
Conclusion
This meta-analysis demonstrates a low cardiac and non-cardiac mortality rate after ICD 
therapy in patients with HCM. Appropriate ICD intervention occurred at a rate of 3.3%/year, 
thereby most probably preventing SCD. Inappropriate ICD intervention and complications 
are not uncommon.
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INtrOduCtION
Patients with hypertrophic cardiomyopathy (HCM) are at increased risk for sudden cardiac 
death (SCD), mostly caused by ventricular arrhythmias. SCD may occur as the initial presen-
tation of HCM, often in asymptomatic or mildly symptomatic patients (1). In fact, HCM is 
the most frequent cause of SCD in young people, including trained athletes (2,3). Implantable 
cardioverter defibrillator (ICD) therapy may effectively terminate potentially life threatening 
ventricular arrhythmias, thereby preventing SCD and prolonging life. Still, ICD therapy is 
not without risk, because inappropriate interventions and device related complications may 
occur.
Previous observational studies have reported on the use of ICD therapy for primary 
and secondary prevention of SCD in HCM (4-30). A complete overview of outcome and 
complications after ICD therapy in HCM patients at risk for SCD is currently not available. 
The goal of this analysis was to pool the individual studies in an effort to examine the precise 
rate of cardiac and non-cardiac mortality, appropriate and inappropriate interventions, and 
complications. This knowledge may aid clinical decision making and counselling in HCM 
patients at increased risk for SCD considered for ICD therapy.
metHOds
study design
This systematic review and meta-analysis included all available original studies reporting 
clinical outcome and/or complications in HCM patients who underwent ICD implantation. 
Studies that did not provide data on outcome or complications and review manuscripts were 
excluded. Studies focussing on SCD in HCM patients without ICD were excluded.
Literature search
The online MEDLINE database was searched for literature in March 2012 using PubMed 
(National Center for Biotechnology Information, U.S. National Library of Medicine, Bethes-
da, Maryland). The search strategy was: “hypertrophic cardiomyopathy” and “defibrillator”. 
No time restriction for publication dates was used. All titles and abstracts of the articles were 
evaluated. After exclusion based on the title and abstract, full articles were evaluated, and 
articles meeting the inclusion criteria were identified. In addition, a manual search of the 
reference lists of the identified studies was performed, and references were evaluated using 
the same inclusion and exclusion criteria.
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data extraction
Selected studies were reviewed and relevant patient characteristics, known risk factors for 
SCD, and follow-up duration were registered. Extracted outcome parameters were: cardiac 
mortality, non-cardiac mortality, heart transplant, appropriate ICD intervention, inappropri-
ate ICD intervention, and complication including lead malfunction, infection, lead displace-
ment, psychological complication and total complications. The outcome parameter total 
complications included all reported ICD related complications, except inappropriate ICD 
intervention, this parameter was registered separately. No time restriction for complications 
was used; both early and late complications were included in the analysis. Studies with over-
lapping data were identified, and in cases of apparent serial reporting of a particular patient 
cohort, only the publication with the largest number of patients was included in the meta-
analysis. However, all serial publications on a particular cohort were registered and tabulated.
statistical Analysis
Statistical analysis was performed using Microsoft Excel 2010 (Microsoft Corporation, 
Redmond, Washington) and SPSS version 15.0 (SPSS Inc., Chicago, Illinois). Continuous 
variables were reported as mean. Categorical variables were summarized as percentages. The 
total number of risk factors for SCD was divided by the total number of patients to assess the 
average number of risk factors per patient. Heterogeneity among the studies was assessed 
using the Q test and I² index. Random effects model was used to calculate summary estimates 
of the outcome data. From the pooled data, summary estimates of patient characteristics and 
risk factors for SCD were calculated. Meta-analysis of the outcome data was performed and 
weighted event rates and weighted annualized event rates were calculated. Forest plots were 
constructed using the method of Neyeloff et al. (31).
resuLts
search results
The literature search yielded 469 articles (figure 1). After review, exclusion, and cross-refer-
encing, a total of 27 observational studies were included in the systematic review (table 1). 
Overall, 16 different patient cohorts were identified in these 27 studies (4-30). Because of 
apparent serial reporting of patient cohorts, and to avoid duplicate entering of data, only 1 
study per patient cohort was included in the meta-analysis. Hence, the summary estimate 
of clinical data and outcome is based on 16 studies (4,7,9,12-14,16,18-20,24-28,30). Thirteen 
(81%) studies reported on a population of HCM patients with an ICD for primary or second-
ary prevention of SCD, 1 (8%) study focused on HCM patients with an ICD for primary 
prevention of SCD, 2 (13%) studies reported on hypertrophic obstructive cardiomyopathy 
(HOCM) patients who underwent alcohol septal ablation (ASA), and had received an ICD.
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Patient Characteristics
There were 2190 patients (mean age 42 y, 38% women), most of whom (83%) received an 
ICD for primary prevention of SCD. Risk factors for SCD were left ventricular wall thickness 
≥30 mm (20%), family history of SCD (43%), non-sustained ventricular tachycardia (46%), 
syncope (41%), and abnormal blood pressure response (25%). Patients had on average 1.8 risk 
factors for SCD. HOCM was present in 27% of the patients.
ICd Interventions and Outcome
During 3.7 year follow-up, 311 of 2190 (14%) of the patients had an appropriate ICD interven-
tion (table 2). Annualized appropriate ICD intervention rate was 3.3% (figure 2). Data on 
inappropriate ICD intervention was available in 13 studies. Inappropriate ICD intervention 
occurred in 388 of 1966 (20%) of the patients. Annualized inappropriate ICD intervention 
rate was 4.8% (figure 3). Mortality data was reported in 13 studies: there were 53 (3%) cardiac 
deaths and 49 (2%) non-cardiac deaths. Annualized cardiac mortality rate was 0.6%, and an-
nualized non-cardiac mortality rate was 0.4%. Five studies reported follow-up data on heart 
transplantation, this occurred in 28 of 1214 patients (2%), and annualized heart transplanta-
tion rate was 0.5%.
Complications
Information on ICD related complications was available in 9 of 16 studies including a total of 
1691 patients (table 2). Of them, 260 (15%) had any form of ICD related complication. The 
most frequently observed complication was lead malfunction in 118 (7%). Other complications 
figure 1 – Flow chart of the literature searches and study selection. The initial search yielded 469 
eligible studies, 141 review articles were excluded. The remaining 328 studies were evaluated, and on 
basis of title and abstract, 286 articles were considered unrelated and were excluded. The remaining 42 
articles were evaluated and after cross-referencing, a total of 27 articles were included in the systematic 
review and meta-analysis. A total of 15 articles were excluded, because of the following reasons: not all 
patients had HCM (n = 2), not all patients had an ICD (n = 4), no follow-up data (n = 1), study on socio-
economical aspects (n = 2), editorial or case-report (n = 6).
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were infection in 59 (3%) and lead displacement in 28 (3%). Only 1 study provided information 
on psychological complications, these occurred in 5 of 132 (4%) patients.
dIsCussION
This meta-analysis demonstrates a low cardiac and non-cardiac mortality rate after ICD 
therapy in patients with HCM. In HCM patients with on average 1.8 risk factors for SCD, 
figure 3 – Forest plot of annualized inappropriate ICD intervention rate (%/year).
figure 2 – Forest plot of annualized appropriate ICD intervention rate (%/year).
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appropriate ICD intervention occurred at a rate of 3.3%/year, thereby most probably prevent-
ing SCD. These findings emphasize the importance of ICD therapy in HCM patients at risk 
for SCD.
Current ACCF/AHA guidelines (32) recommend comprehensive SCD risk stratification 
at initial evaluation and on a periodic basis (every 12 to 24 months) for patients with HCM. 
A personal history for ventricular fibrillation, sustained VT or SCD is recommended and 
established risk factors for SCD should be evaluated. ICD placement is recommended (class 
I recommendation) for patients with HCM and prior documented cardiac arrest, ventricular 
fibrillation, or hemodynamically significant VT. A comparable decision strategy for ICD im-
plantation for secondary prevention of SCD was applied in the studies included in the present 
analysis. In the pooled analysis, 17% of the HCM patients received an ICD for secondary 
prevention of SCD.
For primary prevention of SCD in HCM patients, the guideline state that it is reasonable 
to recommend (class IIa recommendation) an ICD for patients with HCM with SCD presum-
ably related to HCM in ≥1 first-degree relatives, or a maximum LV wall thickness ≥30 mm, or 
≥1 recent unexplained syncopal episodes (32). An ICD can be useful in select patients with 
NSVT in the presence of other SCD risk factors or modifiers, or with an abnormal blood 
pressure response to exercise in the presence of other SCD risk factors or modifiers. It is 
reasonable to recommend an ICD for high-risk children with HCM, based on unexplained 
syncope, massive LV hypertrophy, or family history of SCD, after taking into account the 
relatively high complication rate of long-term ICD implantation.
In the present analysis, the majority of the studies did not provide clear information on 
the clinical decision strategy for ICD implantation for primary prevention of SCD. Complete 
information on all 5 established risk factors for SCD in HCM patients was available in only 7 
of 16 (44%) cohorts. Primary prevention of SCD in HCM patients depends on the presence 
of SCD risk factors and modifiers; therefore complete information on all established risk fac-
tors is highly relevant. All reported cohorts were collected before publication of the current 
practice guideline on HCM, and it is not certain that the results from the pooled analysis 
also apply to HCM patients that currently receive an ICD. Nevertheless, the present analy-
sis demonstrates that HCM patients with an ICD had on average 1.8 risk factors for SCD. 
Consequently the population in the pooled analysis was at high-risk for SCD, and is probably 
comparable to the population that should be considered for ICD implantation according to 
the current guideline (32).
The pooled analysis demonstrates that inappropriate ICD intervention and complications 
are not uncommon (4.8%/year and 3.4%/year respectively). Previous studies suggested that 
HCM patients are more vulnerable to ICD related complications and inappropriate ICD 
therapy because of young age at implant and increased prevalence of atrial fibrillation (24). 
Reports from large ICD registries including predominantly patients with ischemic heart 
disease demonstrate an early complication rate varying from 3.3% to 11% during the hospital 
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admission for ICD implantation (33, 34). Long-term follow-up data on ICD-related complica-
tions in general practice are not available, hampering comparison of the inappropriate ICD 
intervention and ICD-related complication rates observed in HCM patients. Most HCM 
patients who underwent ICD implantation were young (mean age 42 y), and therefore the 
risk of ICD related complications should be carefully considered and discussed with the 
patient during the decision making process before implantation. This is particularly relevant 
because of the long periods that young patients will live with the implanted device and leads. 
Only 1 study (6) reported the occurrence of ICD related psychological complications. The 
psychological and behavioural aspects of ICD therapy in HCM patients should receive more 
attention because many HCM patients considered for ICD therapy are otherwise healthy and 
often asymptomatic young individuals.
Limitations
This systematic review and meta-analysis has inherent limitations. The data were extracted 
from observational studies. A potential risk of pooling data from different studies is to mix 
patients with different clinical characteristics and SCD risk profile. The decision strategy 
for ICD implantation was not specified in most studies. The currently available studies have 
reported on outcome and complications after ICD therapy in populations with predominantly 
adult HCM patients, except the study of Pablo Kaski (6). More information is desired con-
cerning ICD therapy in children and adolescents with HCM. Data on cycle length of the 
arrhythmia and type of arrhythmia were not available in the majority of the studies. Finally, 
the first report was from 1998, and over the years significant progress in ICD devices and 
leads has been made, and experience with implantation and follow-up has increased.
Future studies
ICD therapy has proven benefits in HCM patients at increased risk for SCD. Future studies 
on ICD therapy for prevention of SCD in HCM patients are needed to refine risk stratification 
for SCD, and to define the role of other risk markers including cardiac magnetic resonance 
imaging. There are indications that HCM patients with extensive delayed enhancement on 
contrast-enhanced cardiac magnetic resonance imaging are at increased risk of ventricular 
arrhythmias. Efforts to further reduce inappropriate ICD intervention and complication rates 
may have substantial clinical and financial benefits. Authors of future reports on ICD therapy 
in HCM patients are encouraged to provide complete information on clinical characteristics 
of the study population, established clinical risk factors for SCD, decision strategy for ICD 
implantation, and device related complications and outcome (including at least appropriate 
and inappropriate ICD intervention, and cardiac and non-cardiac mortality).
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CONCLusIONs
This meta-analysis demonstrates a low cardiac and non-cardiac mortality rate after ICD 
therapy in patients with HCM. Appropriate ICD intervention occurred at a rate of 3.3%/year, 
thereby most probably preventing SCD. Inappropriate ICD intervention and complications 
are not uncommon (4.8%/year and 3.4%/year respectively). The benefits and risks of ICD 
therapy in HCM patients should be carefully weighted.
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ABstrACt
Background
Sudden cardiac death (SCD) is the most devastating complication of hypertrophic cardiomy-
opathy (HCM) but this can be prevented by an implantable cardioverter-defibrillator (ICD). 
The aim of this study is to evaluate HCM patients with ICDs for primary or secondary 
prevention of SCD.
methods
The study population consisted of all HCM patients with an ICD in 2 tertiary referral clinics. 
Endpoints during follow-up were total and cardiac mortality, appropriate and inappropriate 
ICD intervention, and device related complications. Cox-regression analysis was performed 
to identify predictors of outcome.
results
ICDs were implanted in 134 HCM patients (mean age 44 ± 17 years, 34% women, 4.2 ± 4.8 
years follow-up). Annualized cardiac mortality rate was 3.4%/year and associated with NYHA 
class III/IV (HR 5.2 [2.0-14, p=0.002]) and cardiac resynchronization therapy (HR 6.3 [2.1-
20, p=0.02]). Appropriate ICD interventions occurred in 38 patients (6.8%/year) and was 
associated with implantation for secondary prevention of SCD (HR 4.0 [1.8-9.1], p=0.001) 
and male gender (HR 3.3 [1.2-9.0], p=0.02). Inappropriate ICD intervention occurred in 21 
patients (3.7%/year) and in 20 patients device related complications were documented (3.6%/
year).
Conclusion
ICDs successfully abort life-threatening arrhythmias in HCM patients at increased risk of 
SCD with an annualized intervention rate of 6.8%/year. End-stage heart failure is the main 
cause of mortality in these patients. The annualized rate of inappropriate ICD intervention 
was 3.7%/year, whereas device related complications occurred 3.6%/year.
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INtrOduCtION
Hypertrophic cardiomyopathy (HCM) is the most prevalent (1:500 individuals) inheritable 
myocardial disease and the most common cause of sudden cardiac death (SCD) in young 
people and trained athletes.1-3 The use of an implantable cardioverter-defibrillator (ICD) may 
prevent SCD and prolong life in HCM patients by terminating life-threatening arrhythmias.4-6 
With an incidence of SCD in HCM patients of 0.7-1.0% per year, careful selection of patients 
considered for ICD therapy is needed.7-9 Moreover, ICD therapy has its drawbacks, as patients 
are subject to inappropriate interventions and device-related complications.10
Previous observational studies have confirmed that ICD therapy effectively prevents SCD 
in HCM patients.6,11-16 However most of these previous studies did not provide a complete 
overview of total mortality, cardiac mortality, appropriate ICD interventions, inappropriate 
ICD interventions, and complications. Additionally, complete information on established risk 
factors17 for SCD was not available in 44% of the studies in a recent meta-analysis.18
The goals of the current study are therefore: (1) to provide a complete overview of out-
come and complications after ICD therapy in HCM patients at increased risk of SCD based 
on the established risk factors and (2) to identify predictors of outcome and complications in 
these patients.
metHOds
study design and patient population
The study population consisted of 152 consecutive HCM patients who received an ICD 
between April 1994 and December 31st, 2011 at the Thoraxcenter, Erasmus MC, Rotterdam, 
The Netherlands or the University Hospitals Leuven, Leuven, Belgium. All patients gave 
written informed consent for ICD implantation and the study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki. The study was approved by the institutional 
review board. Each patient had an established diagnosis of HCM, based on unexplained left 
ventricular hypertrophy of ≥ 15 mm.9 Patients with HCM linked to Noonan’s syndrome, 
Fabry’s disease, mitochondrial disease or congenital heart defects were excluded.
ICDs were implanted for primary prevention of SCD, based on the presence of estab-
lished major risk factors for SCD (non-sustained ventricular tachycardia (VT) on Holter-
monitoring, unexplained syncope, abnormal blood pressure response during exercise testing, 
left ventricular wall thickness (LVWT) ≥ 30 mm or a family history of ≥ 1 HCM-related SCD 
in close relatives), or for secondary prevention of SCD in patients with a history of ventricular 
fibrillation (VF) or sustained ventricular tachycardia (VT).19,20 ICDs were also implanted in 
HCM patients who developed complete AV-block after alcohol septal ablation (ASA).
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The following clinical characteristics and other less well-established risk factors for SCD 
were examined: gender, age at implantation, New York Heart Association (NYHA) functional 
class, indication for cardiac resynchronization therapy (CRT), atrial fibrillation (AF), left 
ventricular outflow tract (LVOT) obstruction, history of myectomy or ASA, the presence of 
delayed gadolinium enhancement on MRI, genotype, coronary artery disease (CAD), induc-
ible VF during electrophysiological testing, and anti-arrhythmic medication used by patients. 
If genetic testing was applied, the following genes were screened for mutations: cardiac 
myosin binding protein C (MYBPC3), β-cardiac myosin heavy chain (MYH7), myosin regulatory 
light chain (MYL2), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), α-actin, and 
α-tropomyosin.
No extramural funding was used to support this work and the authors are solely respon-
sible for the design and conduct of this study, all study analyses and drafting and editing of 
the paper.
devices
Patients received single or dual-chamber ICDs, or biventricular ICDs if CRT was indicated21, 
with transvenous lead systems. All devices were capable of antitachycardia and antibrady-
cardia pacing, and can deliver shock therapy. The rate cutoff for detection of VF or VT and 
activation of antitachycardia pacing (ATP) was set at the discretion of the treating electro-
physiologist.
endpoints
Endpoints were total and cardiac mortality, appropriate ICD intervention, appropriate ICD 
shocks, inappropriate ICD shocks, and ICD related complications. Cardiac mortality was 
defined as SCD, death from stroke, death from end-stage heart failure, and heart transplanta-
tion. Patients undergoing heart-transplantation were censored at the time of the procedure. 
Mortality, ICD interventions, and complications were retrieved from hospital patient records, 
from civil service population registers, and from information provided by general practitioners 
or other centers where follow-up had occurred. All ICD interventions were evaluated by an 
experienced electrophysiologist. Appropriate ICD intervention was defined as an intervention 
(either shock or ATP) triggered by an arrhythmia that was ventricular in origin. Appropriate 
ICD shock was defined as an ICD shock triggered by a sustained ventricular arrhythmia. 
Inappropriate ICD shock was defined as ICD shocks triggered by non-sustained ventricular 
arrhythmias, supraventricular arrhythmias, sinus tachycardia, oversensing or device malfunc-
tion (e.g. lead fracture leading to inappropriate shocks). If revision or hospital readmission 
related to the device was required, it was identified as a major complication. Follow-up started 
at the time of ICD implantation. The administrative censoring date was set at July 1st, 2012.
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statistical Analysis
SPSS version 20 (IBM, Armonk, NY, USA) and Microsoft Excel 2010 (Microsoft Corpora-
tion, Redmond, WA, USA) were used for all statistical analyses. Categorical variables were 
summarized as percentages. Normally distributed continuous data are expressed as mean ± 
standard deviation and non-normally distributed data was expressed as median ± interquartile 
range (IQR). For comparing variables either χ2-test or Mann Whitney U-test were used, for 
categorical and continuous data respectively. Estimated survival and actuarial event-free rates 
from ICD intervention were calculated according to the Kaplan-Meier method and were com-
pared using the log-rank test. Patients who underwent heart transplantation were censored 
alive on the day of transplantation. Cox regression analysis was used to determine predictors 
of outcome. Variables were selected for multivariable analysis if univariable p-value was < 
0.10 and were expressed as hazard ratio (HR) with 95% confidence interval. The final number 
of variables was restricted according to the number of endpoint events to avoid overfitting the 
multivariable model. A p-value <0.05 was considered statistically significant.
resuLts
Baseline characteristics
In total 152 HCM patients with an ICD were identified. Fifteen patients were excluded be-
cause they were lost to follow-up when they moved abroad and access to full medical records 
was not possible. Three patients with a subcutaneous ICD were also excluded for further 
analysis, although there were no events in these patients. In the final group of 134 patients, 
93 patients (69%) received an ICD for primary prevention and 41 patients (31%) for secondary 
prevention. Patients who received an ICD for primary prevention (age 49 ± 16 years) tended 
to be older at implantation than patients who received an ICD for secondary prevention (age 
44 ± 19 years, p = 0.08). The majority of patients was male (66%) and LVOT obstruction was 
present in 62 patients (46%). The clinical characteristics of these patients are summarized in 
table 1.
Total follow-up time was 602 patient-years with a median follow-up of 4.2 ± 4.8 years 
and follow-up was completed in all included patients. Genetic analysis was performed in 85 
patients and mutations were identified in 63 patients (47%); of these, 86% had mutations in the 
MYBPC3 and MYH7 genes. CRT was deemed necessary in 7 patients (5%, 4 males) according 
to the guidelines. These patients were in NYHA class III or IV at the time of implantation, EF 
≤ 35% and there was a wide QRS-complex (≥ 120 ms). In two of these patients an initial dual 
chamber ICD was upgraded to a CRT device.
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table 1 – Baseline characteristics of 137 patients with hypertrophic cardiomyopathy and implantable 
defibrillators
Patients
All patients Primaryprevention
Secondary
prevention
134 93 41
Age at implant, y 47 ±17 49 ±16 44 ±19
Male gender 89 (66) 63 (68) 26
NYHA class III/IV 32 (24) 28 (30) 4 (10) *
Indication for CRT 7 (5) 6 (6) 1 (2)
Atrial fibrillation 43 (32) 33 (35) 10 (24)
Coronary artery disease 16 (12) 9 (10) 7 (17)
LVOT obstruction (> 30 mmHg) 62 (46) 45 (48) 17 (41)
Surgical myectomy 28 (21) 21 (23) 7 (17)
Alcohol septal ablation 23 (17) 18 (19) 5 (12)
Confirmed genetic mutation:
- MyBPC3 43 (32) 28 (30) 15 (37)
- MyH7 11 (8) 9 (10) 2 (5)
- Other 6 (4) 5 (5) 1 (2)
Anti-arrhythmic medication:
- β-blocker 91 (68) 68 (73) 23 (56)
- Amiodarone 23 (17) 16 (17) 7 (17)
- Calcium channel blocker 20 (15) 15 (16) 5 (12)
Risk factors:
- Non-sustained ventricular tachycardia 58 (43) 55 (59) 3 (7) †
- Unexplained syncope 34 (25) 26 (28) 8 (20)
- Abnormal BP response at exercise 25 (19) 19 (20) 6 (15)
- Maximum LVWT ≥ 30 mm 10 (7) 9 (10) 1 (2)
- Family history of SCD 36 (27) 30 (32) 6 (15) *
- Total risk factors 1.2 ± 0.9 1.5 ± 0.9 0.6 ± 0.7 †
Data are presented as number (percentage) unless stated otherwise. *: p-value < 0.05; †: p-value < 
0.001; BP: blood pressure; CRT: cardiac resynchronization therapy; LVOT: Left ventricular outflow 
tract; LVWT: left ventricular wall thickness; MyBPC3: Myosin bindin protein C-gene; MyH7: Myosin 
heavy chain-gene; NYHA: New York Heart Association; SCD: sudden cardiac death
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risk profile for sCd
The distribution of risk factors among 93 patients who received an ICD for primary preven-
tion is shown in figure 1; Non-sustained ventricular tachycardia (59%) was most frequently 
identified. On average patients had 1.5 ± 0.9 major risk factors for SCD; 29 patients (31%) had 
1 risk factor and 50 patients (54%) had ≥ 2 risk factors. Fourteen patients (15%) received an 
ICD after ASA complicated by total AV-block. In the patients with 1 major risk factor the deci-
sion to implant an ICD was based on potential modifiers such as late gadolinium enhancement 
on MRI or the presence of inducible VF during electrophysiological testing (only performed 
in the years 2000-2005).
figure 1 – The distribution of major risk factors for SCD in patients who received an ICD for primary 
prevention of SCD.
Cardiac mortality
During the median follow-up of 4.2 ± 4.8 years 14 patients (10.4%) died and in 11 patients (8.2%) 
the cause of death was cardiac and 3 patients (2.2%) died of non-cardiac causes. End-stage 
heart failure was the main cause for cardiac mortality leading to death in 9 patients (6.6%). 
The two other patients died as a consequence of having had VF, despite restoration of cardiac 
rhythm by ICD intervention. One patient with end-stage disease had no return of cardiac out-
put, in the other the arrhythmia caused a severe motor vehicle accident because of syncope 
and ultimately leading to death. Also 8 patients (6.0%) underwent heart-transplantation. The 
annualized rate for the combined cardiac mortality endpoint was 3.4%/year. Multivariable 
analysis demonstrated that NYHA functional class III or IV (figure 2a) and the indication 
for CRT were independent predictors of mortality. (table 2)
Appropriate ICd interventions
Appropriate ICD interventions occurred in 38 patients (6.8%/year). The median time to first 
appropriate ICD intervention was 3.2 ± 4.5 years. Appropriate ICD shocks occurred in 29 
Chapter 12
198
patients. Of these patients, 18 (62%) received more than one appropriate ICD shock. In 15 pa-
tients (52%), the arrhythmia leading to the shock was VF. Multivariable analysis demonstrated 
that male gender and implantation of the ICD for secondary prevention were independent 
predictors of appropriate ICD intervention. (table 3) The Kaplan-Meier curves demon-
strating the event-free survival in patients who received an ICD for primary or secondary 
prevention of SCD are shown in figure 2b. Twenty (22%) patients who received an ICD 
for primary prevention of SCD had an appropriate ICD intervention (5.1%/year), 13 patients 
(14%) received an appropriate ICD shock (3.3%/year).
Inappropriate ICd shocks
Inappropriate ICD shocks occurred in 21 patients (3.7%/year) and was caused by AF in 50% of 
the cases. The median time to first inappropriate shock was 3.3 ± 4.2 years after implantation. 
Fifteen (71%) of these patients had >1 inappropriate ICD shock. Patients with pre-existent AF 
(figure 2c) were at increased risk for inappropriate ICD shock as were patients after surgical 
myectomy with or without mitral valve repair. (table 4)
A B
C
figure 2 – Kaplan-Meier event-free survival for (A) the endpoint of cardiac mortality in patients with 
NYHA class I/II and II/IV at implantation, (B) the endpoint of appropriate ICD intervention in patients 
who received an ICD for primary or secondary prevention of SCD, and (C) the endpoint of inappropri-
ate ICD intervention comparing patients with and without atrial fibrillation (AF).
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In 89 patients (65%) the ICD was programmed in a dual-zone configuration with a median 
cycle length set for the VF-zone of 290ms (IQR 280-300) and 350ms (336-360) for VT-zone. 
Device settings, such as longer cycle length for VF-zone (HR 0.82, p=0.655) or VT-zone (HR 
0.83, p=0.726), did not influence the frequency of inappropriate ICD shock. The amount of 
inappropriate ICD shocks was similar in patients with an atrial lead and patients without (14% 
vs. 17%, p = 0.7).
ICd related complications
ICD related complications are shown in figure 3 and were diverse: pocket-infection, lead 
failure or dislocation, pneumothorax, and minor pocket related problems: pocket hematoma, 
severe wound pain requiring prolonged hospital stay, allergic reactions to device material, and 
migration of the device. Revision was necessary in 15 patients (11%), mostly because of lead 
dislocation/fracture or pocket related problems. During follow-up complications occurred 
table 2 – Analysis of clinical variables associated with cardiac mortality (19 events in 134 patients with 
hypertrophic cardiomyopathy)
Predictor
Univariable Multivariable
HR CI 95% p HR CI 95% p
Age at implantation, y 1.00 0.98-1.04 0.7
Female 2.5 1.0 -6.3 0.06 2.3 0.9-5.8 0.09
NYHA III/IV 5.2 2.0-13.7 0.001 4.9 1.8-13.2 0.002
CRT-D 6.3 2.1-19.7 0.001 4.1 1.3-13.4 0.02
Atrial fibrillation 1.8 0.7-4.5 0.2
Coronary artery disease 1.9 0.6-5.8 0.3
LVOTO ≥ 30 mmHg 0.8 0.3-2.3 0.8
Surgical myectomy 2.8 1.1-7.5 0.04 1.6 0.6-4.3 0.4
Alcohol septal ablation 0.03 0.0-3.1 0.1
Sudden death survivor 0.6 0.2-1.8 0.4
≥2 risk factors 2.4 0.9-6.1 0.08
Genetic mutations:
- MYBPC3 1.7 0.6-4.9 0.3
- MYH7 3.4 0.9-13.5 0.08
- MYL2 6.0 0.7-50.1 0.1
Backwards multivariable Cox regression analysis was used. CI: confidence interval; CRT-D: cardiac 
resynchronization therapy – defibrillator; HR: hazard ratio; LVOTO: left ventricular outflow tract ob-
struction, MYBPC3: cardiac myosin binding protein; MYH7: myosin heavy chain; MYL2: myosin light 
chain; NYHA: New York Heart Association
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table 3 – Analysis of clinical variables associated with appropriate ICD interventions (38 events in 134 
patients with hypertrophic cardiomyopathy)
Predictor
Univariable Multivariable
HR CI 95% p HR CI 95% p
Age at implantation, y 0.99 0.97-1.01 0.3
Male 2.8 1.2-6.5 0.01 3.3 1.2-9.0 0.02
NYHA III/IV 0.6 0.2-1.6 0.3
Atrial fibrillation 1.1 0.6-2.2 0.8
Coronary artery disease 4.1 0.9-18.6 0.06 1.9 0.4-8.7 0.4
LVOTO ≥ 30 mmHg 1.6 0.8-3.0 0.2
Surgical myectomy 0.9 0.4-2.1 0.9
Alcohol septal ablation 0.6 0.3-1.5 0.3
Sudden death survivor 2.5 1.3-4.8 0.005 4.0 1.8-9.1 0.001
≥2 risk factors 0.9 0.5-1.8 0.8
Genetic mutations:
- MYBPC3 1.7 0.9-3.4 0.1
- MYH7 1.0 0.2-4.1 0.9
- MYL2 3.3 0.4-25.3 0.3
- TNNI3 1.9 0.2-14.3 0.5
Backwards multivariable Cox regression analysis was used. CI: confidence interval; HR: hazard ratio; 
LVOTO: left ventricular outflow tract obstruction, MYBPC3: cardiac myosin binding protein; MYH7: 
β-cardiac myosin heavy chain; MYL2: myosin regulatory light chain; NYHA: New York Heart Associa-
tion; TNNI3: cardiac troponin I
figure 3 – Distribution of adverse events in 134 HCM patients with an ICD.
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in 20 patients (3.5%/year) with lead failure in one third of the cases. None of the patients 
died because of device-related complications or required admission to an intensive care unit. 
Combining inappropriate ICD therapy and device-related complications, adverse ICD events 
occurred in 36 patients (6.4%/year). There was no difference in devices implanted before or 
after 2007 (HR 0.6, p=0.2).
dIsCussION
The findings in this study demonstrate that in a consecutive group of HCM patients consid-
ered at increased risk of SCD, appropriate ICD interventions happened frequently (6.8%/
year) and ICD interventions were effective at restoring sinus rhythm and cardiac output. 
With a median time to first shock of 3.2 years (3.4 years in primary prevention patients and 
table 4 – Analysis of clinical variables associated with inappropriate ICD interventions (21 events in 
134 patients with hypertrophic cardiomyopathy)
Predictor
Univariable Multivariable
HR CI 95% p HR CI 95% p
Age at implantation, y 1.00 0.97-1.03 0.9
Male 0.8 0.3-1.9 0.6
NYHA III/IV 0.8 0.3-2.4 0.7
Atrial fibrillation 5.4 2.2-13.4 < 0.001 5.4 2.2-13.4 < 0.001
Coronary artery disease 2.5 0.3-19.8 0.4
Surgical myectomy 2.8 1.2-6.9 0.02 3.1 1.2-7.6 0.02
Alcohol septal ablation 0.4 0.09-1.6 0.2
Sudden death survivor 0.9 0.3-2.3 0.8
≥2 risk factors 0.6 0.2-1.5 0.3
Device-related:
Single lead (VVI) 1.2 0.5-2.8 0.7
Atrial lead (DDD) 0.8 0.3-2.0 0.7
CRT-D 1.0 0.1-7.2 1.0
Implantation before 2007 2.2 0.9-5.6 0.09 2.4 0.9-6.0 0.07
VF-zone only 1.2 0.5-2.9 0.7
VF-zone cycle length > 290 ms 0.8 0.3-1.9 0.6
Backwards multivariable Cox regression analysis was used. CI: confidence interval; CRT-D: cardiac 
resynchronization therapy – defibrillator; HR: hazard ratio; LVOTO: left ventricular outflow tract ob-
struction; NYHA: New York Heart Association; VF: ventricular fibrillation
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3.2 years in secondary prevention patients) this was remarkably longer than the time to first 
shock in ischemic cardiomyopathy: in the MADIT-trial 60% of the patients received the first 
appropriate ICD therapy in the first two years.22 With SCD being prevented, the main cause 
of mortality in these patients was severe heart failure. Patients who received an ICD for sec-
ondary prevention of SCD more frequently had appropriate ICD interventions. This confirms 
that a history of VF or sustained VT is a strong predictor of having subsequent episodes as 
compared with primary prevention patients.
A recent meta-analysis18 pooled the results of 16 studies reporting the outcome and 
complications of ICD therapy in a total of 2190 HCM patients (mean age 42 y, 38% women). 
Schinkel et al. found that the majority of patients (83%) received an ICD for primary preven-
tion. During an average follow-up of 3.7 years, annualized cardiac mortality rate was 0.7%, 
non-cardiac mortality rate 0.7%, and appropriate ICD intervention rate 3.9 %. The relatively 
high appropriate ICD intervention rate found in our study may be caused by the fact that a 
larger proportion of our study population had an ICD for secondary prevention of SCD (31%). 
Also, the duration of our follow-up was somewhat longer and most arrhythmic events seem to 
occur several years after implantation.
The drawbacks of ICD therapy – inappropriate ICD shocks (3.7%/year) and device-related 
complications (3.5%/year) – were not uncommon. The rate of annualized inappropriate ICD 
shocks and ICD-related complications were similar between the findings of Schinkel et al.18 
and our study. These annual rates are substantial, and especially in young HCM patients the 
probability of complications cumulates considerably during lifetime. We found that patients 
with pre-existent AF were at increased risk for inappropriate ICD shocks, which has previ-
ously been reported both for HCM and non-HCM patients.23,24 The presence of an atrial lead 
did not reduce the frequency of inappropriate ICD shocks in these patients significantly. Thus 
to prevent inappropriate ICD shocks, strict rate or rhythm control in HCM patients with 
AF is necessary, and so is good device programming.25 In drug-refractory AF radiofrequency 
ablation can be attempted but it is in these patients still in a preliminary stage: its success-rate 
are mediocre and redo procedures are often necessary.26
The effectiveness of ICDs in HCM patients with an increased risk for SCD and the high 
appropriate ICD intervention rate show the importance of ICD therapy in these patients. 
In both centers the decision to implant an ICD was based on the latest recommendations 
or – after they were established – European guidelines.19 Implantation for primary prevention 
was advised if ≥ 2 major risk factors were present or in the presence of 1 major risk factor and 
other individual SCD risk modifiers. In 29 patients (31%) the presence of 1 major risk factor 
and other less well-established risk factors was sufficient to implant an ICD. In this group 
the appropriate ICD intervention rate was 4.0%/year. Patients who received an ICD after 
ASA, even with no other risk factors present, showed comparable appropriate ICD interven-
tion rates as other patients (respectively 14% and 13%). This suggests that ASA might be a 
potential risk factor on its own.27 Recent findings link the amount (but not the presence) of 
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late gadolinium enhancement with an increased risk for SCD.28 In our population there were 
insufficient MRI-data available to evaluate this.
We also found that genotype was not predictive of mortality or appropriate ICD interven-
tions. Patients with double or triple mutations are at increased risk of end-stage progression 
and ventricular arrhythmias.29 Current DNA sequencing is expensive and time-consuming, 
especially if analysis has to be continued after the first mutation has been found. With next-
generation sequencing it will be possible to screen for a larger number of genes and it will 
possibly lead to identification of more patients carrying mutations and it might become easier 
to identify patients with multiple mutations and include this information in the individual risk 
stratification.
Limitations
This is a retrospective study and data collection is restricted to those variables that were 
routinely collected. For this reason, information from magnetic resonance imaging and 
echocardiographic information (e.g. ejection fractions) were not included. In 15 patients 
follow-up could not have been completed and were excluded from the analyses. This could 
have influenced the current results, especially concerning appropriate and inappropriate ICD 
interventions. Finally, this study covers a 17-year period in which there has been a considerable 
evolution in devices and expertise in implantation, which could have affected the outcome. 
But there was no difference in ICD-related complications or inappropriate interventions in 
ICDs implanted before or after 2007.
CONCLusION
ICDs successfully abort life-threatening arrhythmias in HCM patients at increased risk of 
SCD with an annualized intervention rate of 6.8%/year. End-stage heart failure is the main 
cause of mortality in these patients. The annualized rate of inappropriate ICD intervention 
was 3.7%/year, whereas device related complications occurred in 3.6%/year.
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ABstrACt
Pathogenic gene mutations are found in about 50 % of hypertrophic cardiomyopathy (HC) 
patients. Previous studies have shown an association between sarcomere mutations and 
medium-term outcome. The association with long-term outcome has not been described. 
The aim of this cohort study was to assess the long-term outcomes of genotype positive (G+) 
and genotype negative (G-) HC patients. The study population consisted of 626 HC patients 
(512 probands, and 114 relatives) who underwent phenotyping and genetic testing between 
1985 and 2014. End points were: all-cause mortality, cardiovascular (CV) mortality, heart 
failure (HF) related mortality and sudden cardiac death/aborted sudden cardiac death (SCD/
aborted SCD). Kaplan Meier and multivariate cox regression analyses were performed. A 
pathogenic mutation was detected in 327 (52%) patients. G+ probands were younger than 
G- probands (46±15 vs 55±15 years, p<0.001), had more non sustained ventricular tachycar-
dia (34% vs 13%; p<0.001), more often a history of syncope (14% vs 7%; p=0.016), and more 
extreme hypertrophy (maximal wall thickness ≥ 30 mm 7% vs 1%; p<0.001). G- probands were 
more symptomatic (NYHA ≥ II 73% vs 53%, p<0.001) and had higher left ventricular outflow 
tract gradients (42±39 vs 29±33 mmHg, p=0.001). During 12±9 years follow-up, G+ status 
was an independent risk factor for all-cause mortality (HR 1.90; 95% CI 1.14 –3.15; p=0.014), 
CV mortality (HR 2.82; 95% CI 1.49–5.36; p=0.002), HF related mortality (HR 6.33; 95% 
CI 1.79–22.41; p=0.004), and SCD/aborted SCD (HR 2.88; 95% CI 1.23–6.71; p=0.015). In 
conclusion, during long-term follow-up, G+ HC patients are at increased risk of all-cause 
death, CV death, HF related death, and SCD/aborted SCD.
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INtrOduCtION
Hypertrophic cardiomyopathy (HC) is the most common inherited myocardial disease, with 
an estimated prevalence of 1 in 500.[1] Although the majority of patients with HC have a 
good prognosis, a small minority may experience life-threatening complications, such as 
heart failure (HF), sudden cardiac death (SCD) and atrial fibrillation, leading to stroke.[2] 
The difficulty in determining the prognosis of HC patients lies in the genetic and clinical 
heterogeneity. More than 1500 pathogenic mutations in at least 11 genes encoding thick and 
thin myofilament protein components of the sarcomere have been identified.[1] A pathogenic 
mutation is found in about 50% of HC patients.[3] Current guidelines advise to genotype HC 
patients in order to facilitate family screening.[4] The prognostic significance of genetic test 
results in patients with HC is still under debate. Previous studies have shown an association 
between sarcomere mutations and clinical outcome.[5-8] The follow-up duration in these 
studies varied from 1[5] to 6.6[7] years. Information on the value of genetic testing for the 
prediction of the long-term outcome in patients with HC is currently not available. Therefore, 
the aim of this study was to investigate the association between G+ status and long-term clini-
cal outcome.
metHOds
This prospective cohort study included 626 HC patients (probands: n=512, 82%; relatives: 
n=114, 18%), who attended the cardio-genetic outpatient clinic between May 1985 and August 
2014. Probands were defined as patients with HC who presented with signs or symptoms of 
HC. Relatives were defined as patients with HC who were identified via family screening. 
Each patient had an established diagnosis of HC based on maximal wall thickness (MWT) ≥ 
15 mm unexplained by loading conditions, or ≥ 13 mm for relatives of HC patients. Patients 
with HC linked to other causes were excluded. The study conforms to the principles of the 
Declaration of Helsinki. All patients gave informed consent, and review board approval was 
obtained.
All patients underwent genetic counselling. Before the year 2012, DNA analysis consisted 
of direct sequencing of all coding intro-exon boundaries of the following genes: myosin bind-
ing protein C (MYBPC3), myosin heavy chain 7 (MYH7), regulatory myosin light chain 2 
(MYL2), regulatory myosin light chain 3 (MYL3), troponin T (TNNT2), troponin I (TNNI3), 
cysteine and glycine-rich protein 3 (CSRP3), titin-cap/telethonin (TCAP), α-tropomyosin 1 
(TPM1), cardiac muscle alpha actin (ACTC1), cardiac troponin C (TNNC1), and teneurin 
C-terminal associated peptides (TCAP). From 2012, next-generation-sequencing was used, 
covering the following genes: ABCC9, ACTC1, ACTN2, ANKRD1, BAG3, CALR3, CAV3, 
CRYAB, CSRP3, CTNNA3, DES, DSC2, DSG2, DSP, EMD, FHL1, GLA, JPH2, JUP, 
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LAMA4, LAMP2, LDB3, LMNA, MIB1, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYOZ2, 
MYPN, NEXN, PKP2, PLN, PRDM16, PRKAG2, RBM20, SCN5A, TAZ, TCAP, TMEM43, 
TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR and VCL. Variants were classified into classes: 
(I) benign; (II) likely benign; (III) variant of unknown clinical significance; (IV) likely patho-
genic; or (V) pathogenic, adapted from the classification proposed by Plon et al.9 Patients 
were considered G+ when the mutation was classified as class IV or V.
Follow-up data were obtained in November 2014, and was complete for 99 % of patients. 
Mortality was retrieved from the civil register. An electrophysiologist evaluated ICD inter-
ventions. The study end points were: all-cause mortality, CV mortality, HF related mortality, 
and SCD/aborted SCD. Cardiac transplantation was considered HF related mortality. CV 
mortality consisted of HF related death, SCD/aborted SCD, postoperative death after a 
cardiac intervention and stroke related death. SCD/aborted SCD was defined as: (1) instanta-
neous and unexpected death in patients who were previously in a stable clinical condition, or 
nocturnal death with no history of worsening symptoms; (2) resuscitation after cardiac arrest; 
or (3) ICD intervention for ventricular fibrillation or for fast ventricular tachycardia (>200 
beats/min). Syncope was defined according to the guidelines.[4]
Statistical analyses were performed using SPSS 21 (IBM, Armonk, New York) and 
Microsoft Access 2010 (version 14.0.7143.5000). Unpaired t-test or the chi-square test 
were used to compare variables. P values < 0.05 were considered significant. Multivariate 
analysis was performed with a model in which each variable with p < 0.05 (based on univari-
ate analysis) was entered, with a maximum of 1 variable per 10 events. Survival curves were 
constructed according to the Kaplan Meier method, and compared using the log rank test. 
Due to a high prevalence of three MYBPC3 founder mutations (c.2373dupG, c.2827C>T 
and c.2864_2865delCT)[10], we adjusted for the founder effect by including only the first 
enrolled proband with a founder mutation. Founder mutations were defined according to 
Alders et al.[11] All reported annual mortality rates are in 50-year survivors.
resuLts
The baseline characteristics are presented in table 1. A pathogenic mutation was detected in 
234 (46%) probands, and in 93 (82%) relatives. G+ probands were younger than G- probands 
(46±15 vs 55±15 years, p<0.001), had more atrial fibrillation (26% vs 15%; p<0.001), and a 
higher MWT (20±5 mm vs 18±4 mm; p<0.001). The following risk factors for SCD were 
more common in G+ probands: family history of SCD, non-sustained ventricular tachycardia, 
syncope, and MWT ≥ 30 mm. G- probands were more symptomatic (NYHA ≥ II 73% vs 
53%, p=<0.001) and had higher LVOT gradients (42±39 vs 29±33 mmHg, p=0.001). Relatives 
presented to clinic primarily through familial evaluation (n=66, 58%) and through positive 
genetic screening (n=48, 42%). Compared to probands, relatives were younger (46±15 vs 
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51±15 y, p=0.003), had fewer AF (11% vs 20%, p=0.034), were less symptomatic (NYHA ≥ II 
18% vs 64%, p<0.001), had a lower MWT (17±4 vs 19±5 mm, p<0.001), smaller left atria (41±7 
vs 45±8, p<0.001), and had lower LVOT peak gradients (11±15 vs 36±37, p<0.001). Relatives 
more often had a family history of SCD (28% vs 12%, p<0.001). There were no significant 
differences between G+ and G- relatives (table 1).
The distribution of the affected genes is presented in figure 1. Next-generation sequenc-
ing was performed in 161 (26%) patients. Most patients had MYBPC3 mutations (n=240; 73%), 
followed by MYH7 mutations (n=47; 14%) and thin filament mutations (n=19; 6%). figure 2 
table 1 – Baseline characteristics of probands and relatives with hypertrophic cardiomyopathy.
Variable
Entire
cohort
(n=626)
Probands (n=512) Relatives (n=114)
Genotype
+ (n=234)
Genotype
- (n=278) p-value
Genotype
+ (n=93)
Genotype
- (n=21) p-value
Male 404 (65%) 159 (68%) 171 (62%) 0.130 61 (66%) 13 (62%) 0.749
Age (years) 51±15 46±15 55±15 <0.001 45±15 51±13 0.092
AF (by history) 115 (18%) 61 (26%) 41 (15%) 0.001 1 (12%) 2 (10%) 0.764
NYHA II or higher 216 (55%) 81 (53%) 121 (73%) <0.001 11 (16%) 3 (25%) 0.473
Maximal wall 
thickness 18±5 20±5 18±4 <0.001 17±4 17±4 0.806
Left atrial size 44±8 45±8 45±7 0.996 43±8 41±7 0.340
LV end diastolic 
diameter 46±6 45±6 46±7 0.438 46±5 47±7 0.541
Apical morphology 31 (5%) 4 (2%) 22 (8%) 0.001 3 (3%) 2 (10%) 0.203
LVOT peak gradient 32±16 29±33 42±39 0.001 10±14 16±20 0.325
LVOT PG > 30 
mmHg 178 (28%) 67 (29%) 106 (38%) 0.024 3 (3%) 2 (10%) 0.203
LV systolic 
dysfunction 70 (12%) 31 (15%) 31 (12%) 0.430 7 (8%) 1 (5%) 0.632
Family history of 
SCD 61 (12%) 46 (20%) 15 (6%) <0.001 26 (30%) 5 (25%) 0.706
nsVT on Holter 
monitoring 111 (22%) 67 (34%) 26 (13%) <0.001 14 (18%) 4 (22%) 0.675
Abnormal exercise 
BPR 79 (16%) 28 (14%) 41 (20%) 0.141 8 (10%) 2 (12%) 0.790
Syncope 52 (10%) 32 (14%) 20 (7%) 0.016 4 (4%) 1 (5%) 0.926
MWT ≥ 30 mm 18 (4%) 16 (7%) 2 (1%) <0.001 0 0 -
All values are mean ± SD or number (%) AF = atrial fibrillation, BPR = blood pressure response, LV = left 
ventricle, LVOT = left ventricular outflow tract, MWT = maximal wall thickness, NYHA = New York 
Heart Association functional class, nsVT = non sustained ventricular tachycardia, PG = peak gradient, 
SCD = sudden cardiac death.
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figure 1 – The distribution of pathogenic gene mutations in 512 probands (A; top) and 114 relatives (B; 
bottom). G- = genotype-negative HC patients. Thick = patients with thick filament associated gene muta-
tions: myosin binding protein C (MYBPC3), myosin heavy chain (MYH7), regulatory myosin light chain 
2 (MYL2) and regulatory myosin light chain 3 (MYL3). Thin = patients with thin filament associated gene 
mutations: troponin I, troponin T and α-tropomyosin 1. Rare = patients with rare mutations: calreticulin 
3, cysteine and glycine-rich protein 3, and myopalladin. Multiple = patients with multiple mutations.
figure 2 – The distribution of founder and non-founder mutations in the myosin binding protein C 
(MYBPC3) gene. MYBPC3 founder mutations include: c.2373dupG (purple); n=78 (33%), c.2827C>T 
(green); n=42 (18%) and c.2864_2865delCT (red); n=33 (14%). Non-founder MYBPC3 mutations 
(black): n=86 (36%).
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demonstrates the distribution of the MYBPC3 founder mutations. MYBPC3 founder muta-
tions were present in 101 (47%) G+ probands and 53 (57%) G+ relatives. A detailed overview of 
the individual pathogenic mutations is presented in supplementary table 1. Three patients 
(1%) had multiple mutations: one compound heterozygous MYBPC3 mutation in trans and 
two double heterozygous (MYBPC3/MYL2 and MYH7/MIB1) mutations. Most mutations 
were truncating mutations (n=184; 56%) followed by missense (n=101; 31%) and splice site 
mutations (n=34; 10%). supplementary table 2 illustrates the varying types of mutations 
in the patients who died from HF and SCD/aborted SCD. The gene most commonly affected 
figure 3 – Kaplan-Meier analysis comparing (A; top) all-cause mortality in G+ probands and G- pro-
bands and (B; bottom) cardiovascular mortality in G+ probands and G- probands. * = age at presentation 
(red for G+ and black for G-). G+ = genotype-positive. G- = genotype-negative. Cardiovascular mortality 
is defined as death related to heart failure or stroke, sudden cardiac death or postoperative death after a 
cardiac intervention.
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in SCD/aborted SCD was MYBPC3 (founder: n=10, non-founder: n=6), followed by MYH7 
(n=2), and a double mutation carrier. SCD/aborted SCD did not occur among TNNT2 muta-
tion carriers (n=10; mean age 61±9).
Mortality and interventions during follow-up are presented in table 2. During the mean 
follow-up period of 12±9 years, G+ probands had a greater probability of all end points: all-
cause mortality, HF related mortality, CV mortality, and SCD/aborted SCD (figures 3 and 
4). Annual rates for G+ vs G- patients were as follows: (1) all-cause mortality: 2.4% vs 1.0%, 
log rank p<0.001; (2) HF related mortality: 0.9% vs 0.2%, log rank p<0.001; (3) CV mortality: 
figure 4 – Kaplan-Meier analysis comparing (A; top) heart failure related mortality in G+ probands 
and G- probands and (B; bottom) sudden cardiac death/aborted sudden cardiac death in G+ probands 
and G- probands. * = age at presentation (red for G+ and black for G-). G+ = genotype-positive. G- = 
genotype-negative.
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1.8% vs 0.4%, log rank p<0.001; and (4) SCD/aborted SCD: 1.1% vs 0.15%, log rank p=0.002. 
After adjustment for the founder effect, all of these differences remained significant. ICDs for 
primary prevention were implanted more often in G+ probands (16% vs 9%; p=0.019). There 
was no significant difference in the number of septal reduction therapies (both ASA and 
surgical myectomy) between G+ and G- probands (31% vs 33%; p=0.710). All-cause mortality 
for relatives was comparable to probands (10% vs 14%, p=0.247), with an annual all-cause 
mortality rate of 1.3%. Compared to probands, cardiovascular death trended lower in relatives 
(4% vs 9%, p=0.084). There were no significant differences between G+ and G- relatives. Mul-
tivariate cox regression analyses of G+ status in probands for the end points are presented in 
table 3. G+ status was an independent predictor of all-cause mortality (HR 1.90, p=0.014), 
CV mortality (HR 2.82, p=0.002) and HF related mortality (HR 6.33, p=0.004). G+ status 
was also a predictor of SCD/aborted SCD, after adjusting for established risk factors for SCD 
as described in the guidelines from 2003[12] and 2011[13].
table 3 – Cox regression analysis of genotype-positive status for the clinical endpoints of 512 probands
End point Predictor HR (95% CI) P-value
All-cause mortality Genotype-positive status 1.90 (1.14-3.15) 0.014
Atrial fibrillation 2.15 (1.30-3.56) 0.003
Systolic left ventricular dysfunction 1.92 (1.07-3.47) 0.030
Extreme hypertrophy (MWT ≥ 30 mm) 6.22 (2.33-16.60) <0.001
Cardiovascular mortality Genotype-positive status 2.82 (1.49-5.36) 0.002
Atrial fibrillation 3.31 (1.81-6.06) <0.001
Systolic left ventricular dysfunction 2.33 (1.18-4.60) 0.015
Extreme hypertrophy (MWT ≥ 30 mm) 10.23 (3.64-28.73) <0.001
Heart failure related mortality Genotype-positive status 6.33 (1.79-22.41) 0.004
Atrial fibrillation 12.66 (3.63-44.20) <0.001
SCD/aborted SCD analysis 1 Genotype-positive status 2.88 (1.23-6.71) 0.015
≥ 2 established risk factors (2003 
guidelines) 2.44 (0.99-6.01) 0.052
SCD/aborted SCD analysis 2 Genotype-positive status 2.88 (1.24-6.67) 0.014
≥1 established risk factors (2011 
guidelines) 2.32 (1.04-5.16) 0.039
Multivariate Cox proportional-hazards analysis was used. MWT = maximal wall thickness. SCD = sud-
den cardiac death. Established risk factors for sudden cardiac death according to the 2003 guidelines 
included: extreme hypertrophy (maximal wall thickness ≥ 30 mm), unexplained syncope, abnormal ex-
ercise blood pressure, non-sustained ventricular tachycardia, family history of sudden cardiac death. 
Established risk factors for sudden cardiac death according to the 2011 guidelines included: extreme 
hypertrophy (maximal wall thickness ≥ 30 mm), unexplained syncope and a family history of sudden 
cardiac death.
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Kaplan Meier curves for HF related mortality in carriers of different types of mutations 
are presented in figure 5. Thin filament mutation carriers had a greater probability of HF 
related death than thick filament mutation carriers (16% vs 5%, log rank p=0.06), and missense 
mutation carriers had a greater probability of HF related death than truncating mutation car-
riers (7% vs 4%, log rank p=0.03).
dIsCussION
This study compared the clinical outcome of G+ and G- patients with HC. During 12±9 years 
follow-up, multivariate analysis demonstrated that G+ status was an independent risk factor 
for all-cause mortality, CV mortality, HF related mortality, and SCD/aborted SCD.
figure 5 – Kaplan-Meier analysis comparing heart failure related death in (A; top) HC patients with 
thick filament associated gene mutations and HC patients with thin filament associated gene mutations, 
and (B; bottom) HC patients with truncating gene mutations and HC patients with missense gene muta-
tions.
Chapter 13
220
Several previous studies have evaluated the impact of sarcomere mutations on clinical 
outcome. Olivotto et al[8] studied 203 patients (G+: 62%), and found a greater probability 
of severe left ventricular systolic and diastolic dysfunction (HR 2.1; 95% CI 1.1-4.0;p=0.02), 
during a median follow up of 4.5 years. Li. et al[7] studied 558 patients (G+: 35%), and dem-
onstrated that G+ status was an independent predictor of HF events (HR 4.5; 95% CI 2.1-9.3; 
p<0.001), during a mean follow up of 6.6±6.3 years. Fujita et al.[5] studied 193 patients (G+: 
47%), and reported more CV events in G+ HC, during 1 year follow up. Lopes et al.[6] studied 
874 patients (G+: 44%), and reported a higher proportion of CV deaths and SCD events in 
G+ patients, during a mean follow up of 4.8±3.5 years. The mean follow-up period in these 
previous studies varied from 1 to 6.6 years. The present long-term follow-up study confirms 
and extends the findings from these previous studies.
G+ status in HC patients was an independent predictor of HF related mortality. The 
precise pathways through which sarcomere mutations lead to HF are unclear. In this study, 
47% of G+ HC was caused by MYBPC3 founder mutations. These mutations are respon-
sible for ~35% of HC cases in the Netherlands.[10] The pathophysiological consequences 
of MYBPC3 founder mutations have been investigated by van Dijk et al.[14] They reported 
a reduction of 33% in full-length cardiac MyBP-C protein, suggesting haploinsufficiency is 
part of the pathophysiology. In addition, the force generating capacity of cardiomyocytes was 
lower than myocardium from donor samples. This ‘’hypocontractile sarcomere phenotype’’ 
seemed to be a common feature of HC patients, suggesting it is rather part of the remodeling 
process.[14,15] This was investigated by correcting for a decrease in myofibril density.[16] 
After correction, values returned to normal for MYBPC3 mutations, but not for MYH7 muta-
tions[16]. And so, MYH7 mutations seem to cause hypocontractile sarcomeres directly. Other 
pathophysiological mechanisms may be a reduced phosphorylation of sarcomeric proteins, 
and enhanced Ca2+-sensitivity of the sarcomeres. Possibly, these early pathways involved in 
disease progression can be targets for future therapies.[3,17]
This study demonstrates a significant relationship between G+ status and SCD/aborted 
SCD. The risk of SCD/aborted SCD was low in G- probands and relatives. Lopes et al.[6] 
similarly reported an increased incidence of SCD/aborted SCD in G+ HC. However, other 
studies[7,8] did not show a relationship between G+ status and SCD, probably related to the 
low number of events, or relatively short follow-up duration. Ho et al.[18] demonstrated that 
myocardial collagen synthesis was increased in G+ individuals compared to control subjects. 
This suggests that sarcomere mutations lead to myocardial fibrosis, which is a substrate 
for SCD. Since myocardial fibrosis is believed to be visualized by cardiovascular magnetic 
resonance (CMR) with late gadolinium enhancement (LGE), it was shown that the extent of 
LGE on CMR was associated with an increased risk of SCD events.[19,20] Furthermore, an 
independent association between LGE and HF was reported.[21]
In this cohort, G- probands were older, more symptomatic, and had higher LVOT gra-
dients. During follow-up, 33% of G- probands underwent septal reduction therapy. Previous 
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data have shown excellent long-term outcomes after septal reduction therapy in symptomatic 
patients with HC and severe LVOT obstruction.[22] The survival disadvantage associated 
with LVOT obstruction can be substantially decreased by appropriate invasive therapy.[22] 
The G+ probands in this study had a more advanced cardiomyopathy, which is indicated by a 
higher MWT, higher incidence of AF, higher incidence of non-sustained ventricular tachycar-
dia, and more often a family history of SCD (table 1). Therefore, the G+ probands were at an 
increased risk of SCD and HF related death. Part of G- HC patients may have undiscovered 
pathogenic mutations. However, the additive genetic yield of next generation sequencing in 
HC seems limited.[23,24] Possibly, whole-exome and whole-genome sequencing will add 
more value to the discovery of new mutations.[3] However, such massive sequencing also 
generates many variants of unknown significance.[3,23] Determining of the clinical signifi-
cance of these variants is a major challenge.[23]
In this study, relatives with HC were younger and had a more benign phenotype than 
probands. This can be explained by the way of presentation. It seems that family screening 
leads to the detection of disease in an earlier phase.[25] Although this was not reflected in a 
significantly better clinical outcome, a trend was found for fewer cardiovascular deaths among 
relatives. The lack of difference between G+ and G- relatives can be explained by the small 
number of G- relatives.
The current findings demonstrate that G+ HC patients are at increased risk of progression 
towards HF and SCD/aborted SCD. Previous studies have demonstrated that genetic test 
results are predictive of medium-term outcome, and the current study demonstrates that this 
also holds for the long-term outcome of patients with HC. Due to the heterogeneous nature of 
HC, the therapeutic implications of a G+ status are currently limited. Phenotypic character-
ization is currently still the most important factor for determining prognosis in HC patients. 
The clinical challenge is to incorporate genetic test results in contemporary risk prediction 
models. Fundamental research on the pathophysiological consequences of sarcomere muta-
tions is crucial to develop genotype-specific risk-assessment and targeted therapies.
This study has several limitations. Patients who died and never presented to the clinic 
were missed in the analysis. Due to significant advances in DNA-sequencing methodology 
during the past decade, there was no homogenous genotyping over the whole period. The rate 
of complex genotype (1%) could be an underestimation of the real rate of complex genotype. 
Previous literature reported a rate of 5-7%[3].
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supplementary table 2 – Patients with hypertrophic cardiomyopathy that died from heart fail-
ure or sudden cardiac death, presented per gene affected and type of mutation.
Gene Mutation type
No. of patients
with mutation
Heart failure
related death
Sudden 
cardiac death
Total 327 17 (5%) 19 (6%)
MYBPC3 Truncating 179 7 (4%) 12 (7%)
Missense 27 2 (7%) 2 (7%)
Splicesite 33 1 (3%) 2 (6%)
Complex 1 0 0
MYH7 Missense 46 3 (7%) 2 (4%)
Splicesite 1 0 0
MYL2 missense 7 1 (14%) 0
splicesite 1 0 0
MYL3 missense 3 0 0
MYPN missense 1 0 0
TNNI3 truncating 1 0 0
missense 6 0 0
TNNT2 truncating 1
missense 9 1 (11%) 0
TPM1 missense 2 2 (100%) 0
CALR3 truncating 4 0 0
CSRP3 missense 2 0 0
Complex genotype 3 0 1 (33%)
All values are in number (%). CSRP3 = cysteine and glycine-rich protein 3, CALR3 = calreticulin 3, 
MYBPC3 = myosin binding protein C, MYH7 = myosin heavy chain 7, MYL2 = regulatory myosin light 
chain 2, MYL3 = regulatory myosin light chain 3, MYPN = myopalladin, TNNT2 = troponin T, TNNI3 
= troponin I, TPM1 = α-tropomyosin 1.
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ABstrACt
Purpose
Preclinical hypertrophic cardiomyopathy (HCM) is defined as the presence of a pathogenic 
mutation without left ventricular hypertrophy (LVH). The aim of this study was to assess the 
natural course of subjects with preclinical hypertrophic cardiomyopathy and to determine if 
there are predictors of disease occurrence.
methods
In this single center cohort of 136 subjects with preclinical HCM, 86 had > 1 echocardio-
graphic evaluation > 1 year apart, and were included in this study. At baseline and last 
follow-up, structural characteristics, systolic function and diastolic function were assessed 
by 2-D echocardiography. In addition speckle tracking echocardiography was performed to 
determine peak systolic longitudinal strain and strain rate. The endpoints of the study were 
the development of manifest HCM (LVH ≥ 15mm) and major adverse cardiac events.
results
During 4.5 ± 1.9 years (range 6.8 years) of follow-up, 1 patient developed manifest HCM(15 
mm, after 6.6y) and no cardiac events occurred. Maximal left ventricular wall thickness did 
not increase during follow-up. In subjects with progressive diastolic dysfunction during 
follow-up there was an increase of LV mass (+9g ±36 vs. -9g ± 28, p=0.04) and reduction of 
septal strain (-3.5% ±6 vs. -0.5% ± 6, p=0.08) and strain rate (-0.4 ± 0.5 vs. -0.1 ±0.4, p=0.03), 
compared with subjects with stable diastolic function.
Conclusion
During 4.5 year follow-up, manifest HCM occurred in one patient and there were no cardiac 
events. This suggests that preclinical HCM in adults is a relatively benign condition. We pro-
pose a 5-year interval between clinical evaluations in asymptomatic subjects with preclinical 
HCM unless a change in clinical status occurs.
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INtrOduCtION
Hypertrophic cardiomyopathy (HCM) is the most common inheritable myocardial disease, 
with a prevalence of 1:500 in the general population. In 1989 the first pathogenic mutation was 
identified in the myosin heavy chain gene by Seidman et al.[1] Subsequent research had led 
to the discovery of >1300 mutations in > 20 genes and has increased the understanding of the 
disease.[2] After identification of a pathogenic mutation in a HCM patient, presymptomatic 
DNA testing can be offered to relatives, which is currently recommended by both the 2011 
ACCF/AHA guidelines and the 2014 ESC guidelines.[3, 4]
The use of presymptomatic DNA testing in family screening introduced a new patient 
category to the field of HCM; namely genotype positive (G+) subjects without left ventricular 
hypertrophy (LVH). The natural course of these subjects with preclinical HCM remains 
unclear. But the reported risk of adverse cardiac events is low, and in a large multicenter 
registry no sudden cardiac death occurred.[5] Another problem is the difficulty to determine 
which of these subjects will develop manifest HCM (LVH ≥ 15mm), as currently no predic-
tors are known. It has been suggested that the presence of diastolic dysfunction may preclude 
to manifest HCM. [6, 7] Other potential predictors are subclinical abnormalities of systolic 
function which can be assessed by strain and strain rate echocardiography. The purpose of 
this study was to assess the natural course of subjects with preclinical HCM, and to determine 
if there are clinical or echocardiographic predictors for development to manifest HCM.
metHOds
study population
This single-center cohort study consists of 136 subjects with a pathogenic mutation with-
out left ventricular hypertrophy (LVH), who were identified through family screening at 
cardio-genetic outpatient clinic of the Thoraxcenter, Erasmus Medical Center, Rotterdam, 
the Netherlands between 2005-2014. Genetic testing was performed in family members 
after identification of the mutation in the index-patient. Subjects were included for further 
analysis if: (1) there was a confirmed pathogenic mutation; (2) LVH < 15mm; (3) there was 
>1 echocardiographic evaluation >1 year apart. Subjects with an unclassified genetic variant 
were excluded. Genetic testing was performed from 2006-2012 with classic Sanger technique 
for the following genes: cardiac myosin binding protein C (MYBPC3) and ß-cardiac myosin 
heavy chain (MYH7), cardiac myosin regulatory light polypeptide 2 (MYL2), cardiac troponin T 
(TNNT2), cardiac troponin I type 3 (TNNI3), cysteine and glycine-rich protein 3 (CSRP3), titin-
cap/telethonin (TCAP) and α-tropomyosin 1 (TPM1). From 2012 onwards, next-generation-
sequencing was performed, where a total of 48 genes were screened for mutations.
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The study conforms to the principles of the Helsinki Declaration. All subjects gave in-
formed consent and local institutional review board approval was obtained.
echocardiographic evaluation
Structural characteristics, systolic function and diastolic function were assessed by 2-D 
echocardiography at baseline and follow-up. The following data were acquired: LV septal and 
posterior wall thickness, LV end-diastolic and end-systolic diameters, left atrial dimensions, 
LV systolic function, and maximal LV outflow tract gradient. Doppler imaging was used to 
acquire early (E) and late (A) filling velocities, E/A ratio and E-velocity deceleration time. 
Tissue Doppler imaging (TDI) was used to acquire medial and lateral mitral annular systolic 
(S’), and early (E’) and late (A’) diastolic velocities. LA volume and LV mass were calculated 
and diastolic function was graded all according to current guidelines.[8, 9]
In addition, speckle tracking echocardiography (STE) was performed as previously de-
scribed, [10, 11] to measure peak systolic longitudinal strain, and peak systolic longitudinal 
strain rate (SR), in apical 4-chamber, 2-chamber and 3-chamber views (TomTEC Imaging 
Systems, Unterschleissheim, Germany). After manual tracing of the endocardial borders at 
end-systole, tracking was done automatically by the software. When necessary, manual read-
justment of the tracking was performed. For each segment longitudinal strain and SR curves 
were generated and peak values were documented. This data was analyzed by an observer, 
who was blinded for the clinical data.
Follow-up
Follow-up vital status and cause of death, if applicable, was obtained by reviewing the hospital 
records, from general practitioners and civil registries. Follow-up data were complete for all 
subjects. The primary endpoint of this study was the development of manifest HCM (LVH 
≥ 15mm). Secondary endpoints were major cardiac adverse events: including HCM-related 
death, sudden cardiac death or successful resuscitation after cardiac arrest, and hospital 
admissions related to HCM.
statistical Analysis
All statistics were performed using the SPSS 21 (IBM, Armonk, NY, USA) and Microsoft 
Excel 2010 (Microsoft Corporation, Redmond, WA, USA). Categorical variables were 
summarized as percentages. Normally distributed continuous data are expressed as mean ± 
standard deviation and non-normally distributed data are expressed as median (interquartile 
range). To compare continuous variables Student t test, Wilcoxon Signed Rank test or Mann-
Whitney U-test were used, and to compare categorical variables the χ2-test was used. All tests 
were 2-sided and a p-value <0.05 was considered statistically significant.
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resuLts
Baseline characteristics
The entire cohort consisted of 136 subjects with preclinical HCM, and 86 (56% female, age at 
baseline was 41 ±13 years) of those had >1 echocardiographic evaluation >1 year apart. Echo-
cardiographic data at baseline are listed in table 1. The distribution of pathogenic mutations 
is shown in figure 1. The majority of subjects (57%) had 1 of the 3 Dutch founder mutations 
in MYBPC3: c.2827C>T (n=20, 23%), c.2373dupG (n=18, 21%) and c.2864delCT (n=11, 13%). 
In none of the subjects, >1 mutation was identified.
Follow-up
Follow-up (4.5 ±1.9 years, range 6.8, 384 patient-years) was complete in all subjects. During 
follow-up one patient (female, age 51y, MYBPC3 c.2864_2865delCT) developed manifest 
HCM (from 13mm to 15mm) after 6.6 years. There were no major adverse cardiac events. 
There was no increase in maximal LV wall thickness or LV mass. Ejection fraction was stable 
table 1 – Echocardiographic characteristics at baseline and at last follow-up of 86 subjects with pre-
clinical HCM.
Baseline Follow-up P
Structural characteristics
- Ventricular septum, mm 10 ± 2 10 ± 2 0.002
- LV posterior wall, mm 9 ± 2 9 ± 1 0.02
- LV end diastolic diameter, mm 47 ± 5 46 ± 4 0.05
- LV end systolic diameter, mm 28 ± 5 27 ± 5 0.02
- LV mass, g 157 ± 45 152 ± 45 0.2
- Left atrial volume, ml 41 ± 18 41 ± 21 0.3
- LV outflow tract gradient, mmHg 6 ± 2 6 ± 6 0.5
Functional characteristics
- Ejection fraction, % 59 ± 8 58 ± 7 0.3
- Fractional shortening, % 40 ± 8 42 ± 8 0.1
- E/A ratio 1.3 ± 0.7 1.2 ± 0.8 0.02
- Deceleration time, ms 180 ± 53 209 ± 74 < 0.001
- TDI s’ velocity, cm/s 9.2 ± 2.8 8.4 ± 3.1 0.9
- TDI e’ velocity, cm/s 9.5 ± 2.6 8.2 ± 3.3 0.02
- TDI a’ velocity, cm/s 7.4 ± 1.9 10.0 ± 2.4 < 0.001
- E/e’ ratio 11.7 ± 3.8 8.5 ± 2.6 < 0.001
Data are displayed as mean ± SD or median ± IQR. LV: left ventricular; TDI: tissue Doppler imaging.
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during follow-up (59% ± 8 at baseline and 58% ± 7 at last visit, p=0.3). In 67 subjects (78%) dia-
stolic function was stable, and 16 subjects (19%) had progressive diastolic dysfunction during 
follow-up. In 3 subjects this could not be assessed. Other echocardiographic characteristics at 
follow-up are listed in table 1.
figure 1 – Distribution of pathogenic mutations.
table 2 – Global and regional systolic function in subjects with preclinical HCM, with stable diastolic 
function, and progressive diastolic dysfunction during follow-up. In 3 subjects diastolic function could 
not be determined.
Stable diastolic LVF Decrease in diastolic LVF
n = 67 16
Baseline Follow-up P Baseline Follow-up P
Ejection fraction, % 59 ± 8 58 ± 7 0.4 62 ± 7 61 ± 7 0.5
Systolic strain, % -20.1 ± 3.7 -19.8 ± 3.3 0.5 -21.3 ± 2.5 -19.7 ± 4.0 0.2
Septal strain, % -18.7 ± 5.0 -18.0 ± 4.2 0.5 -20.5 ± 4.3 -16.8 ± 4.7 0.04
Lateral strain, % -20.6 ± 6.0 -20.2 ± 5.2 0.7 -20.6 ± 3.9 -19.2 ± 5.3 0.5
Apical strain, % -21.2 ± 5.1 -21.2 ± 4.9 0.8 -23.5 ± 5.3 -23 .2 ± 5.0 0.9
Systolic strain 
rate,1/s
-1.29 ± 0.35 -1.17 ± 0.18 0.02 -1.39 ± 0.30 -1.15 ± 0.21 0.04
Septal strain rate, 
1/s
-1.20 ± 0.47 -1.07 ± 0.24 0.05 -1.41 ± 0.41 -1.01 ± 0.34 0.02
Lateral strain rate, 
1/s
-1.39 ± 0.52 -1.19 ± 0.30 0.01 -1.32 ± 0.40 -1.12 ±0.28 0.3
Apical strain rate. 
1/s
-1.34 ± 0.37 -1.27 ± 0.30 0.2 -1.53 ± 0.37 -1.38 ± 0.34 0.2
LVF: left ventricular function
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structural and functional characteristics
Subjects with progressive diastolic dysfunction during follow-up were older at last visit (51 ±12 
y) than subjects with stable diastolic LV function (44 ± 13y, p=0.07). Although no significant 
increase of maximal LV wall thickness was observed during follow-up in both groups (p=0.7), 
subjects with progressive diastolic dysfunction had an increase of LV mass (+9g ± 36), in 
contrast to subjects with stable diastolic LV function (-9g ± 28, p=0.04).
Regional systolic strain and peak systolic strain rate were assessed by STE. Global systolic 
strain was -20.3% ± 3.5 at baseline and -19.8% ± 3.3 at last visit (p=0.3), global systolic strain 
rate was -1.29 ± 0.3 and -1.17 ± 0.2 respectively (p=0.002). There were no regional differences 
in strain values at baseline or during follow-up; the only exception is the significant reduction 
of septal strain in subjects with progressive diastolic dysfunction (from -21% ± 4 to -17% ± 5, 
p=0.04). Global strain rate was reduced during follow-up, and in subjects with progressive 
diastolic dysfunction, there was also a reduction of septal strain rate (from -1.4 ± 0.4 to -1.0 ± 
0.3, p= 0.02; table 2).
Dutch founder mutations were present in 49 subjects. Subjects with the c.2827C>T and 
c.2373dupG mutations had a significant reduction in septal strain rate during follow-up. 
table 3 – Septal systolic function in subjects with Dutch founder mutations
Septal systolic strain (%)
Baseline Follow-up P
Dutch founder mutations (MYBPC3)
- c.2827C>T (n=20) -18.4 ± 4.5 -15.9 ± 4.3 0.08
- c.2373dupG (n=18) -19.1 ± 4.6 -18.3 ± 5.1 0.5
- c.2864_2865delCT (n=11) -16.5 ± 5.5 -17.9 ± 4.3 0.5
Other mutations
- MYBPC3 (n=21) -20.3 ± 4.9 -18.5 ± 3.4 0.2
- Other genes (n=16) -19.0 ± 3.7 -18.9 ± 3.6 0.9
Septal systolic strain rate (1/s)
Baseline Follow-up P
Dutch founder mutations (MYBPC3)
- c.2827C>T (n=20) -1.15 ± 0.30 -0.96 ± 0.21 0.03
- c.2373dupG (n=18) -1.31 ± 0.37 -1.06 ± 0.28 0.03
- c.2864_2865delCT (n=11) -1.02 ± 0.39 -1.05 ± 0.35 0.9
Other mutations
- MYBPC3 (n=21) -1.31 ± 0.42 -1.15 ± 0.18 0.2
- Other genes (n=16) -1.18 ± 0.32 -1.07 ± 0.27 0.2
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However regional strain or strain rate values could not be used to discriminate between the 
different mutations (table 3).
dIsCussION
The key finding of this study is that even a 4.5-year follow-up appears to be insufficient to 
determine which subjects with a pathogenic mutation will develop manifest HCM. Only one 
patient developed LVH of 15mm, and there were no adverse events during the study. This 
suggests that preclinical HCM in adults is a relatively benign condition, and this has several 
important implications.
Clinical recommendations
The 2014 ESC guidelines recommend a 1 or 2 yearly follow up for unaffected family members 
without known pathogenic mutation, but lacks practical recommendations of the follow-up of 
subjects with preclinical HCM.
Our study showed zero events in 384 patient years of follow-up, and this confirms the 
preliminary findings by Gray et al. They found that in a small cohort of adult preclinical HCM 
subjects (n=16, follow-up of ±4 years), none of these developed manifest HCM.[12] Also, the 
rate of SCD in subjects with preclinical HCM is very low; only incidental case reports have 
been published [13], but both in this study and the study by Christiaans et al.[5] there were 
no reported SCD or cardiac resuscitations in subjects with preclinical HCM. Furthermore, 
combined with the very low event rate in patients > 60 years of age with overt HCM[14], one 
could wonder if follow-up is necessary in asymptomatic subjects with preclinical HCM that 
are older than 60 years.
All considered, we conclude that (bi-)annual evaluation is not necessary in the majority of 
the subjects, and we propose a 5-year interval between clinical evaluations in these subjects, 
unless a change in clinical status occurs. Several signs of potential disease progression could 
lead to increased frequency of follow-up: most importantly, the presence of symptoms. If dur-
ing follow-up a progressive diastolic dysfunction or maximal LV wall thickness of 13-14mm 
is detected, more frequent evaluation is justifiable. In addition, in subjects without LVH but 
with apparent ECG abnormalities (such as the McKenna criteria [15]) further analysis with 
cardiac magnetic resonance imaging (CMR) is warranted; to determine the presence of myo-
cardial scarring or fibrosis, which increases the risk of life-threatening ventricular arrhythmias 
in these subjects.[13, 16]
Whether or not subjects with preclinical HCM should be excluded from sports is subject 
to debate, and current guidelines are ambiguous: “Mutation carriers without disease expres-
sion on ECG or echocardiography, who wish to participate in competitive sports, should be 
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advised on an individual basis, taking into account the local legal framework, the underlying 
mutation and the type of sporting activity.”[3]
Older European recommendations[17] advice to exclude these subject from sports 
activities, but the Bethesda Conference no. 36 consensus recommendations do not exclude 
preclinical HCM subjects from sports. Based on the findings of this study and the current 
literature describing the virtual absence of any cardiovascular events in subjects with preclini-
cal HCM, our HCM program usually allows them to enroll in competitive sport activities, 
but keeps them under close clinical surveillance with cardiac evaluations every year, as long 
as they participate in competitive sport. In addition, CMR can be used to fully exclude the 
phenotype.
It is important to note that these findings only consider the development of HCM in 
adults. In this study the minimum age was 17 years old at baseline. The progression of disease 
in children and adolescents needs to be investigated separately. Recently, Jensen et al. have 
demonstrated after 12 years of follow-up, a low (6%) penetrance of HCM in childhood and 
early adulthood. Also no cardiac events were seen in child relatives. The authors further state 
that: “this low penetrance challenges the general perception that HCM develops predomi-
nantly during the growth spurt in childhood or adolescence.”[18]
Identifying predictors of disease progression
The mechanisms of progression from preclinical to manifest HCM remain unclear. In a 
subset of these patients, cardiomyocytes start to remodel and this remodeling may lead to 
compensatory hypertrophy –locally at first – and more regional as disease progresses.[6, 7, 
19-22] But the slow progression of preclinical HCM limits the ability to identify potential 
predictors of disease progression. With only one patient that developed LVH ≥ 15mm, no 
further analysis could be performed to determine which subjects are at risk to develop HCM.
Progressive diastolic dysfunction could be a potential predictor for disease progression; 
but the relevance of it is unclear in this study. Only 16 subjects had progressive diastolic 
dysfunction, and the majority (9, 64%) was older than 50 years at the end of the study, and it 
is known that diastolic function also decreases with age.
On the other hand, in subjects with progressive diastolic dysfunction there was a signifi-
cant decrease in septal systolic strain and strain rate, which was not present in subjects with 
stable diastolic function.
Earlier studies have demonstrated that this regional systolic dysfunction, especially at the 
basal septum, is present in patients with manifest HCM.[23, 24] Although there was no clear 
reduction in systolic strain in subjects with preclinical HCM, compared with healthy con-
trols,[6] our findings show that the reduced regional contractility is only present in subjects 
with progressive diastolic dysfunction over time. Thus the remodeling of the cardiomyocytes 
could present itself as early local systolic and diastolic abnormalities, and progresses later to-
wards manifest HCM with asymmetrical hypertrophy and systolic and diastolic dysfunction 
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(figure 2). The finding that subjects with progressive diastolic dysfunction also appear to 
have impaired regional systolic function and increased LV mass may support this hypothesis. 
The favorable response to treatment with diltiazem in a recent study performed by Ho et al., 
which improves calcium handling, and removes one of the extrinsic factors that could trigger 
the remodeling of the cardiomyocyte, also supports this.[25]
Preventive strategies
Several strategies to prevent the development of LVH have been proposed. As mentioned 
above, Ho et al. randomized subjects with preclinical HCM between daily treatment with 
diltiazem or placebo. After ± 2 years of treatment there was no difference in the low number 
of patients who were diagnosed with HCM (2 in each group, all aged < 18y), but diltiazem 
was associated with improved diastolic function and LV wall thickness in MYBPC3 muta-
tion carriers.[25] This potential beneficial effect of diltiazem could be contributed to the 
improved calcium regulation on sarcomere level, observed in several preclinical studies.[26, 
27] Sarcomeric mutations are known to disturb calcium sensitivity, which is one of the factors 
that could lead to impairment of cardiomyocyte contractility and relaxation, and may lead to 
remodeling of the cardiomyocyte.[21, 28, 29]
Transgenic HCM models showed that angiotensin receptor blockers, such as losartan, 
may be effective in preventing of development of a clinical phenotype, and causing regression 
of disease,[30] but the results of recently published INHERIT trial did not demonstrate any 
disease regression in patients with manifest HCM.[31] The ongoing VANISH trial (Clinical-
Trials.gov Identifier: NCT01912534) is designed to determine whether losartan can reduce or 
halt disease progression. Future research could also focus on the possibility of preventing the 
disease by allele-specific silencing.[32]
The very limited occurrence of LVH in subjects with preclinical HCM could hamper the 
findings of these studies; especially because it is unclear which subjects with preclinical HCM 
are more prone to develop manifest HCM.
Limitations
The findings of this study are limited by the small sample size. STE is limited by the quality of 
echocardiographic images and in 3 subjects diastolic function could also not be assessed prop-
erly due to poor image quality. Genetic analysis was performed initially using classic Sanger 
technique. Next generation sequencing screening was not performed until and could lead to 
the identification of subjects with >1 mutation, and determine if this is a potential predictor 
for disease progression. Another important limitation is the distribution of the mutations in 
the study population; the majority of the subjects had a mutation in the MYBPC3 gene, due to 
the presence of three Dutch founder mutations. It is uncertain if the benign course of preclini-
cal HCM that was described in this study can be generalized to other populations. However 
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mutations in MYBPC3 gene are one of the most frequent causes of HCM, accounting for ± 
30% of the identified mutations worldwide.[33]
CONCLusION
During 4.5 year follow-up, manifest HCM occurred in one patient and there were no car-
diac events. This suggests that preclinical HCM in adults is a relatively benign condition. 
We propose a 5-year interval between clinical evaluations in asymptomatic subjects with 
preclinical HCM unless a change in clinical status occurs. It is unclear what the mechanisms 
of progression from preclinical to manifest HCM are, and the very limited occurrence of LVH 
in subjects with preclinical HCM could hamper the identification of preventive strategies.
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ABstrACt
Aims
Recent studies showed reduced maximal force generating capacity of cardiomyocytes from 
hypertrophic cardiomyopathy (HCM) patients with normal systolic function. In the present 
study we investigated if reduced maximal force at cellular level is associated with local systolic 
dysfunction in HCM patients.
methods and results
A total of 46 HCM patients (age 51 ±10 years, 64% male) underwent pre-operative trans-
thoracic echocardiography, and additionally, segmental systolic strain and strain-rate were 
measured from apical 4-, 2-, and 3-chamber views). Echocardiographic data were compared 
with age- and sex-matched controls. Maximal force development was measured in membrane-
permeabilized cardiomyocytes isolated from tissue obtained via surgical myectomy from 30 of 
these patients. Non-failing donors (n=10) served as control group. Ejection fraction of HCM 
patients was in the normal range. Peak systolic strain and strain rate were markedly lower 
in the septal wall of HCM patients compared with controls. A significantly lower maximal 
force generating capacity was found in cells from the HCM patients compared to non-failing 
donor hearts, and correlated with the reduction in systolic strain. In addition, systolic strain 
correlated negatively with septal thickness.
Conclusion
Systolic function in HCM patients is reduced at a regional level despite normal ejection frac-
tion. Impairment of regional systolic function, demonstrated by strain and strain rate analysis, 
may be explained by a reduction in force generating capacity at the level of sarcomeres. This 
could result in the development of asymmetric hypertrophy.
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INtrOduCtION
Hypertrophic cardiomyopathy (HCM) is the most prevalent inheritable myocardial disease, 
and is defined by the presence of left ventricular hypertrophy (LVH) of ≥15 mm, in absence of 
abnormal loading conditions.[1] Genotyping studies have identified a pathogenic mutation in 
± 70% of all patients with HCM.[2, 3] In total, >1300 mutations have been found in 13 genes, 
mostly coding for the sarcomeric proteins.[2] There is both genetic and clinical heterogeneity 
in HCM[4]: even when patients harbor the same mutation, the phenotype varies widely. The 
complex genotype-phenotype relationship remains unclear.
Recent studies [5-8] showed that, regardless of the disease-causing mutation, the 
force-generating capacity of the cardiomyocyte was reduced. Interestingly, this reduced 
force-generating capacity was found in patients with normal global systolic function.[7, 9] On 
the other hand, there is increasing evidence that regional myocardial dysfunction is present 
in HCM patients based on systolic strain analysis.[10-13] However it is unclear if there is a 
correlation between this regional myocardial dysfunction and the reduced force-generating 
capacity at sarcomere level of HCM cardiomyocytes.
In the present study we investigated whether reduced maximal force generating capacity 
at single cardiomyocyte level is associated with regional systolic dysfunction in HCM patients 
with and without sarcomeric gene mutations. In vitro force measurements were performed 
in single cardiomyocytes isolated from septal tissue obtained during myectomy surgery from 
HCM patients. These measurements were combined with the in vivo systolic function of 
these patients, which was assessed before surgery.
metHOds
study design and patient population
The initial study population consisted of 46 HCM patients who underwent surgical myec-
tomy at the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands. Each pa-
tient had an established diagnosis of HCM, based on unexplained LVH of ≥15 mm, assessed 
by echocardiography. Patients with HCM linked to Noonan’s syndrome, Fabry’s disease, 
mitochondrial disease or congenital heart defects were excluded. All patients were accepted 
for surgical myectomy or alcohol septal ablation (ASA) based on the presence of symptoms 
despite maximal medical therapy and LVOT gradients > 50 mmHg. In these patients tissue 
from the interventricular (IVS) septum was obtained directly during surgery, or as IVS biopsy, 
prior to the ablation procedure.
Genetic testing was performed in all patients; the following genes were screened: cardiac 
myosin binding protein C (MYBPC3), β-cardiac myosin heavy chain (MYH7), myosin regula-
tory light chain (MYL2), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), cardiac 
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troponin C (TNNC1), α-actin (ACTC1), and α-tropomyosin (TPM1). Next-generation se-
quencing was not systematically performed in all patients. Patients were divided in 2 groups: 
sarcomere mutation-positive HCM (HCMMUT), sarcomere mutation-negative HCM (HC-
MSMN), and controls.
Echocardiographic controls were obtained from age- and gender matched healthy subjects. 
Donors (n = 10, age 36 ± 5, 80% male) with no history of cardiac abnormalities, normal ECG 
and normal ventricular function on echocardiography within 24 hours of heart transplanta-
tion served as controls for the myocardial samples. The study conforms to the principles of 
the Helsinki Declaration. Informed consent of each patient was obtained in addition to local 
institutional review board approval.
Cardiomyocyte measurements
The septal tissue obtained during myectomy was used for single cardiomyocyte force mea-
surements using a previously described method [7, 14]. In short, single cardiomyocytes were 
mechanically isolated and treated with 0.5% Triton X-100 to permeabilize the membranes 
providing us with the opportunity to asses force generating capacity of the sarcomeres with-
out interference of Ca2+-handling proteins. A single cardiomyocyte was mounted between a 
force transducer and a piezoelectric motor and stretched to a sarcomere length of 2.2 μm. In 
an activating solution with a calcium concentration of 31.62 μmol/L (pCa 4.5), the myocyte 
started to generate force. After reaching the steady state force level the cardiomyocyte was 
mechanically shortened by 30% to determine total force development (Ftotal). Subsequently, 
the cardiomyocyte was transferred to relaxing solution with a calcium concentration of 10-6 
μmol/L (pCa 9.0) to measure passive force development (Fpas). Maximal force generating 
capacity (Fmax) was calculated by subtracting Fpas from Ftotal. (figure 1a).
figure 1 – Functional measurements of single cardiomyocytes. Single cardiomyocyte at a sarcomere 
length of 2.2μm in the experimental setup (A). Force recording of the cardiomyocyte (B).
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Force values were normalized to cross-sectional area (CSA), to obtain the tension, of the 
preparations calculated on the basis of cardiomyocyte/myofibril width and depth determined 
in the experimental set-ups (i.e. CSA = width x depth x π/4). Force signals were analyzed 
using Labview version 9.0 (National Instruments Corporation, Austin, TX).
echocardiography
All patients underwent comprehensive echocardiography using commercially available ultra-
sound machines (Philips Healthcare, Eindhoven, the Netherlands and Siemens Healthcare, 
Erlangen, Germany). All echocardiographic analyses were blinded from clinical character-
istics. The following data were acquired: end-diastolic IVS and posterior wall thickness, 
end-diastolic and end-systolic diameters, left atrial dimensions, and LV ejection fraction, all 
according to current guidelines.[15] The severity of the mitral valve regurgitation (MR) was 
graded on a 0 to 4 scale by color flow Doppler echocardiography [16]. The severity of the 
SAM of the anterior mitral valve leaflet was determined from the 2D images and was graded 
on a scale from 0 to 3 depending on the mitral-septal distance (grade 0 indicating no SAM 
and grade 3 indicating prolonged contact between mitral valve and septum) [17]. Peak LVOT 
gradient was estimated with continuous wave Doppler echocardiography by the modified 
Bernoulli equation (P = 4v2), where P is the pressure gradient and v is Doppler-determined 
blood velocity. LVOT gradient was measured at rest and during provocative maneuvers (such 
as Valsalva maneuver), and the highest gradient was considered the peak LVOT gradient.
Speckle tracking echocardiography (STE) was performed as previously described.[12, 
18] Peak systolic longitudinal strain, peak systolic longitudinal strain rate (SR), and early 
diastolic SR in apical 4-chamber, 2-chamber and 3-chamber views were measured and calcu-
lated.(TomTEC Imaging Systems, Unterschleissheim, Germany). After manual tracing of the 
endocardial borders at end-systole, tracking was done automatically by the software. When 
necessary, manual readjustment of the tracking was performed. For each segment longitudi-
nal strain and SR curves were generated and peak values were documented.
statistical Analysis
Regarding the clinical data SPSS version 20 (IBM, Armonk, NY, USA) and Microsoft Excel 
2010 (Microsoft Corporation, Redmond, WA, USA) were used for statistical analyses. Cat-
egorical variables were summarized as percentages. Normally distributed continuous data are 
expressed as mean ± standard deviation and non-normally distributed data are expressed as 
median (interquartile range). To compare continuous variables (such as EF, LV wall thick-
ness, LVOT gradient, segmental SS values) Student t test, ANOVA-tests or Mann-Whitney 
U-test were used, and to compare categorical variables the χ2-test was used. Correlation was 
determined using Spearman’s ρ.
Regarding the cardiomyocyte force measurements data analysis and statistics were per-
formed using Prism version 4.0 (Graphpad Software, Inc., La Jolla, CA). A one-way ANOVA 
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was used to gain insight in the differences in force development of the cardiomyocytes among 
the patient groups (HCMmut, HCMsmn and donor). All tests were 2-sided and a p-value <0.05 
was considered statistically significant.
resuLts
Clinical characteristics
Cardiomyocyte force measurements could not be performed in 13 of 46 patients due to tissue 
availability and lack of genetic data, and these were excluded from further analysis. The clini-
cal and echocardiographic characteristics of the remaining 33 patients (51 ± 13 years old, 12 
(36%) female) are listed in table 1. Myectomy was performed in 27 patients (81%), and ASA 
in 6 (18%). In 21 patients a pathogenic mutation was found: MYBPC3 in 15 (71%), MYH7 
in 3 (14%), TNNI3 in 2 (10%) and TMP1 in 1 patient (5%). The MYBPC3 mutations are all 
truncating mutations and the mutations in the other genes are missense mutations. In 12 pa-
tients genetic screening revealed no pathogenic mutation. These patients were older (57 ± 9.7 
years) than patients with a mutation (48 ± 14.7, p=0.05). Other clinical and echocardiographic 
characteristics did not differ significantly between the two groups: septal wall thickness was 
23 ± 5 mm in HCMMUT and 21±3 in HCMSMN (p=0.2); maximal LVOT gradient (either resting 
or after provocation) was 83 ± 25 mmHg in HCMMUT and 96 ±33 in HCMSMN(p=0.7); and 
LVEF was 63 ± 6 % in HCMMUT and 65 ± 8 % in HCMSMN (p=0.5, figure 2a).
table 1 – Clinical and echocardiographic characteristics of 33 HCM patients at the time of surgery.
Mutation Age
(y)
Sex NYHA LVWT
(mm)
LVOTG
(mmHg)
LVEF
(%)
Truncating mutations
MYBPC3
1 c.2373dupG 69 M 3 19 60 61
2 c.2373dupG 32 M 2 23 85 69
3 c.2373dupG 60 M 3 26 77 70
4 c.2827C>T 24 F 3 24 80 58
5 c.2827C>T 34 M 3 39 60 67
6 c.2827C>T 50 M 3 20 80 56
7 c.2864_2865delCT 62 F 3 19 110 61
8 c.927-2A>G 37 M 3 20 60 66
9 c.927-2A>G 58 F 3 25 75 63
10 c.927-2A>G 21 M 3 32 70 49
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table 1 – continued
Mutation Age
(y)
Sex NYHA LVWT
(mm)
LVOTG
(mmHg)
LVEF
(%)
11 c.1790G>A 47 F 2 20 85 55
12 c.2783C>T 71 M 3 22 75 66
13 c.3029delA 45 F 3 23 125 56
14 c.3407_3409del 55 M 3 19 95 68
15 c.772G>A 36 M 2 30 10 63
47±16 24±6 76±26 62±6
Missense mutations
MYH7
1 c.1291G>C 35 M 3 20 93 65
2 c.1816G>A 48 F 3 25 80 71
3 c.4130C>T 43 M 3 24 120 53
TNNI3
1 c.433C>T 46 M 2 20 100 74
2 c.433C>T 66 M 2 20 100 65
TMP1
1 c.850A>T 65 M 3 20 100 60
51±12 22±2 99±13 65±8
HCMsmn
1 - 74 F 3 21 137 61
2 - 58 M 3 26 115 51
3 - 73 F 3 24 90 62
4 - 49 M 3 18 60 63
5 - 65 F 2 17 85 78
6 - 52 M 3 22 170 72
7 - 44 M 2 20 85 64
8 - 60 M 2 20 100 64
9 - 46 F 3 20 90 66
10 - 56 F 2 15 75 76
11 - 52 M 3 17 45 55
12 - 60 F 2 17 100 59
57±10 20±3 96±33 64±8
LVEF: left ventricular ejection fraction; LVOTG: maximal left ventricular outflow tract gradient; 
LVWT: maximal left ventricular wall thickness; NYHA: New York Heart Association functional class;
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Force measurements
Single cardiomyocyte force measurements were performed at sarcomere length of 2.2μm 
to gain insight in Fmax. figure 1a shows a representative image of a single cardiomyocyte 
mounted in the experimental set-up. An example force recording is provided in figure 1b 
of an HCMMUT cardiomyocyte. Fmax was significantly lower (p=0.002) in the HCMMUT com-
pared to donor cardiomyocytes (figure 2d).
There was no significant difference in tension between cardiomyocytes with truncating 
(MYBPC3) and missense (MYH7, TNNI3 and TPM1) mutations. However, cardiomyocytes 
with missense mutations showed clearly a lower tension compared with cardiomyocytes from 
HCMSMN patients (table 2).
regional function and wall thickness
Ejection fraction was in the normal range in both the HCMMUT (63 ± 6%) and HCMSMN patients 
(65 ± 8%), and was similar to controls (63 ± 4%, p=1.0 and p=0.9 respectively, figure 2a). An 
figure 2 – In vivo and in vitro contractile dysfunction. Despite a normal ejection fraction (A) in the 3 
groups (control, HCMmut, HCMsmn) there is reduced peak systolic septal strain (B), reduced early dia-
stolic septal strain rate (C) and reduced maximal tension development at long (2.2 μm) sarcomere length 
(D) in HCM patients.
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overview of segmental strain per group is shown in figure 3. Global strain was reduced in 
both HCMMUT (-16.0 ± 3.2%) and HCMSMN (-15.1 ± 3.1%) compared with controls (-21.0 ± 
3.2%, p<0.001 and p<0.001 respectively). The biggest reduction in regional strain, compared 
with controls, was at basal segments of the anterior and inferior septum, both in HCMMUT 
and HCMSMN patients (table 3 and figure 2, 3). Decrease in septal strain was similar in 
HCMMUT and HCMSMN, and no differences were found between truncating and missense 
mutations (table 2, 3). Apical levels of strain were normal or slightly increased compared 
with controls. Peak septal systolic SR and early diastolic SR were clearly decreased compared 
with controls (figure 2c), but no difference was found between truncating and missense 
mutations (table 2, 3)
Although the maximal wall thickness was similar between the groups (see above), basal 
anterior wall thickness was increased in HCMMUT patients (22 ± 5 mm) compared with HC-
MSMN patients (18 ± 6 mm; p=0.02). Hypertrophy was most pronounced in the septal wall, 
with exception from the apical area (figure 4).
table 2 – Myocardial and cardiac mechanics of the basal septum in HCM patients with truncating 
and missense mutations.
HCMMYBPC3 HCMMissense HCMSMN
P
SMN
P
MYBPC3
P
missense
Fmax at 2.2μm, kN/m² 22.9 ± 10.4 0.4 13.7 ± 4.1 0.1 28.3 ± 9.5 0.01
Septal systolic strain, % -7.5 ± 3.8 1.0 -5.7 ± 5.4 1.0 -7.0 ± 4.8 1.0
Septal systolic SR, 1/s -0.60 ± 0.29 1.0 -0.73 ± 1.01 1.0 -0.62 ± 0.39 1.0
Septal early diastolic SR, 1/s 0.56 ± 0.30 1.0 0.29 ± 0.32 0.5 0.60 ± 0.48 0.4
SR: longitudinal strain rate. P values calculated with One-way ANOVA
table 3 – Myocardial and cardiac mechanics of the basal septum in HCMMUT patients, HCMSMN 
patients and healthy controls.
HCMMUT HCMSMN Control
P
control
P
MUT
P
SMN
Fmax at 2.2μm, kN/m² 20.3 ± 9.9 0.002 28.3 ± 9.5 0.09 35.3 ± 10.4 0.4
Septal systolic strain, % -7.0 ± 4.3 <0.001 -7.0 ± 4.8 1.0 -18.8 ± 7.4 <0.001
Septal systolic SR, 1/s -0.64 ± 0.58 0.007 -0.62 ± 0.39 1.0 -1.19 ± 0.64 0.03
Septal early diastolic SR, 1/s 0.47 ± 0.33 <0.001 0.60 ± 0.48 1.0 1.08 ± 0.54 0.02
SR: longitudinal strain rate. P values calculated with One-way ANOVA
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Basal septal peak longitudinal strain was plotted as a function of Fmax (figure 5a) and 
septal wall thickness (figure 5b) revealing a modest correlation with maximal force develop-
ment (Spearman’s ρ 0.46, p = 0.01) and a negative correlation with hypertrophy (Spearman’s 
ρ -0.38; p = 0.04).
figure 4 – Maximal wall thickness per segment. Measurements in HCMMUT and HCMSMN 
groups. A: anterior; AL: anterolateral; AS: anteroseptal; I: inferior; IL: inferolateral; IS: inferoseptal. 
Red segments have wall thickness ≥ 15 mm.
dIsCussION
This is the first study to compare myocardial function on a regional and cellular level. The 
most important finding of this study is that there is an association between the reduced 
maximal force development of the cardiomyocyte and impaired regional systolic function, 
especially of the septal wall, in patients with HCM.
figure 3 – Peak systolic longitudinal strain per segment. Measurements in HCMMUT group, HC-
MSMN group, and control group. A: anterior; AL: anterolateral; AS: anteroseptal; I: inferior; IL: infero-
lateral; IS: inferoseptal. Red segments have peak systolic strain < -15%.
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reduced force generating capacity at single cardiomyocyte level
A lower maximal force generating capacity was measured in HCM cardiomyocytes compared 
with non-failing donor cardiomyocytes (figure 2c), and this was in line with previous studies 
[5-8]. This drop in cellular performance can be can be explained by a combination of structural 
cellular remodeling and mutation-induced intrinsic sarcomeric defects.
Cellular remodeling exists of cardiomyocyte hypertrophy and a reduction in myofibril-
lar density. Previously we revealed a negative correlation between myofibrillar density and 
cardiomyocyte area. Interestingly, cellular remodeling and dysfunction was more evident in 
patients with a sarcomeric gene mutation compared to HCM patients without an identified 
mutation, suggesting a clear difference in genotype-positive and genotype-negative HCM 
disease [7]. Also in the present study maximal force generating capacity was less decreased in 
HCMSMN patients (figure 2c).
Depending on the type of mutation, the reduced force generating capacity is caused by 
the mutant protein itself or results from cellular remodeling. Most included patients harbored 
a truncating mutation in MYBPC3 (n=15) and the remainder missense mutations in MYH7, 
TNNI3 and TPM1 (n=6). Truncated proteins are not incorporated in the sarcomere and will 
be degraded, hence only the healthy protein is incorporated, albeit to a lesser extent. [5, 19, 20]
Missense mutations, however, potentially lead to poison peptides incorporated in the 
sarcomere [21, 22]. Previously, when maximal tension was corrected for myofibrillar density 
[7], maximal force generating capacity was normalized to donor level in absence of a muta-
tion or in presence of a truncating mutation in MYBPC3 or missense mutation in TNNI3. 
This was not the case when a missense mutation in MYH7 or TPM1 was present. Indeed, 
the present results confirm this previous observation as cardiomyocytes harboring missense 
mutations revealed even a lower tension compared with HCMSMN cardiomyocytes (table 2). 
This suggests a clear mutation-induced sarcomere defect leading to the reduction in tension, 
in addition to the cellular remodeling.
figure 5 – Correlations. Correlation between septal peak longitudinal strain and maximal tension 
development at long (2.2μm) sarcomere length (A) and septal peak longitudinal strain and maximal 
segmental wall thickness (B).
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regional systolic impairment and hypertrophy
Leaving the specific type sarcomeric gene mutation out of the equation, the observed reduc-
tion in maximal force generating capacity is typical for HCM, as in patients with idiopathic 
dilated cardiomyopathy and ischemic cardiomyopathy this reduction is not present[23]. 
This suggests the possibility that underlying HCM mutations trigger a common pathway of 
impaired contraction of the cardiomyocytes, and that this hypocontractility leads to regional 
dysfunction and asymmetrical hypertrophy. Classic echocardiographic assessment of HCM 
patients usually describes a hypercontractile heart, with normal or increased ejection fraction. 
However using deformation and strain analysis, it has become clear that there is regional sys-
tolic and diastolic dysfunction in HCM, especially in the basal septal wall.[11, 13] Indeed, in 
the present study the lower force generating capacity of the cardiomyocytes in HCM patients 
is accompanied with regional systolic and diastolic dysfunction, demonstrated by strain and 
SR analysis, and regional hypertrophy (figure 3 and 4, table 3).
Impaired cardiac mechanics appear to be an expression of the HCM phenotype: apical and 
classic HCM have different strain patterns [24]. Recently, it was demonstrated that strain was 
similarly reduced in HCM patients with and without pathogenic mutations.[11] In our study 
likewise no significant differences in regional strain values were found between HCMMUT 
and HCMSMN patients (figure 3 and table 3). On the other hand, there was a relationship 
between wall thickness and impaired regional function.
The reduced strain and SR (both systolic and diastolic) can be ascribed to several aspects 
of the myocardium of HCM patients. First, the presence of fibrosis is associated with reduced 
strain. Using cardiac magnetic resonance (CMR) imaging, Popovic et al. [25] demonstrated 
that the presence of myocardial fibrosis on CMR was correlated with reduced systolic strain, 
and Kobayashi et al.[13] showed that both systolic and diastolic septal SR were more decreased 
if more interstitial fibrosis was present on a cellular level. But both studies also demonstrated 
that the presence of hypertrophy itself was an independent predictor of reduced strain and 
strain rate. This is also confirmed by the negative correlation found in this study between wall 
thickness and septal strain (figure 5b).
Not only in patients with HCM is strain reduced. In patients with LVH caused by severe 
valvular aortic stenosis, longitudinal systolic strain was also reduced. However, after aortic 
valve replacement, strain would improve to normal values [26-28]. Strain analysis after surgi-
cal myectomy [29] and septal ablation [30] showed that despite improved NYHA class and 
reduced LVOT gradient and septal wall thickness, longitudinal strain remained impaired. 
This may suggest that the impaired cardiac mechanics in HCM also appear to be related to 
the intrinsic myocardial dysfunction, and not only to the loading conditions and LVH.
disease progression in HCm
The mechanisms of progression from preclinical HCM to the classic phenotype are largely 
unknown, and it has been suggested that diastolic dysfunction precedes the development of 
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hypertrophy. The findings in this study combined with other literature may hint at an alterna-
tive hypothesis for the development of HCM.
Patients with preclinical HCM appear to have a normal heart, but at a certain point 
remodeling of the cardiomyocyte starts. Several intrinsic and external factors could lead to 
the remodeling of the cardiomyocyte: impaired contractility (related to structural cellular 
remodeling and mutation-induced intrinsic sarcomeric defects, see above), microvascular 
dysfunction and energy depletion. Coronary microvascular dysfunction may lead to local 
ischemia, replacement fibrosis [31], and together with increased energetic costs of contrac-
tion,[32] possibly increased oxidative stress of the cardiomyocyte. In combination with a 
reduction in myofilament protein phosphorylation and higher Ca2+ -sensitivity, contractility 
might be further hampered leading to impairment of cardiomyocyte relaxation.[5] The re-
modeling of the hypocontractile cardiomyocyte may then lead to compensatory hypertrophy 
of the myocardium – initially locally – and more regional as disease progresses. This might 
present itself as initial diastolic dysfunction and later also clear (regional) systolic impairment.
Further studies that focus on the development of hypertrophy and the regression of 
systolic and diastolic function during follow-up of preclinical HCM patients could improve 
this hypothesis.
Clinical implications and limitations
The number of included patients with both STE and myocardial tissue analysis was relatively 
small. In addition, the study was performed in a referral center for patients with HCM, there-
fore selection and referral bias may have influenced the study results. All patients included 
were severely symptomatic due to important LVOT obstruction requiring septal reduction 
therapy. This is only a subset of the disease-spectrum of HCM. Nevertheless, to improve our 
understanding of the development of HCM, a longitudinal prospective study assessing strain 
and SR in a large cohort of HCM mutation carriers and overt HCM patients would be of 
interest to investigate the development of the HCM phenotype over time. In addition, further 
research is required to reveal possible therapy targets at cellular contractile level to possibly 
delay or even reverse the progression from pre-hypertrophic HCM to manifest HCM disease.
In conclusion, despite the preserved ejection fraction of HCM patients, regional systolic 
strain and SR was reduced. This correlated with the reduction in maximal force generating 
capacity at the cellular level and with septal wall thickness. Therefore, contractile dysfunction 
at the sarcomere might lead to regional systolic dysfunction, and eventually to asymmetrical 
hypertrophy.
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This thesis, as outlined in the introduction, seeks to approach the overall pathophysiology 
of hypertrophic cardiomyopathy (HCM) in a similar manner as we approach a patient with 
HCM (figure 1).
When a patient with HCM presents, the initial approach is threefold. Often patients will 
present with (invalidating) symptoms, the majority of which is related to left ventricular 
outflow tract (LVOT) obstruction. If medical therapy fails, an invasive approach is indicated. 
This invasive treatment of symptomatic LVOT obstruction is discussed in part II. Second, 
a subset of these patients is at increased risk of sudden cardiac death (SCD). In part III we 
discussed the prediction and prevention of SCD in patients with HCM. The final step is to 
realize that behind every HCM patient is a potential HCM family; clinical and genetic screen-
ing can be used to distinguish family members at risk. The clinical implications of sarcomeric 
mutations are discussed in part IV.
figure 1 – Assessment of the patient with hypertrophic cardiomyopathy (HCM). G: Genotype; LVH: 
left ventricular hypertrophy; SCD: sudden cardiac death.
INVAsIVe treAtmeNt OF symPtOmAtIC LeFt VeNtrICuLAr OutFLOw 
trACt OBstruCtION
septal myectomy versus alcohol septal ablation
Dynamic LVOT obstruction is present in the majority of the patients with HCM.[1] Not only 
is LVOT obstruction associated with symptoms such as dyspnea on exertion, fatigue, chest 
pain or syncope, but previous studies have also demonstrated that the presence of LVOT 
obstruction increases all-cause mortality and the occurrence of SCD in these patients.[2, 3] 
Substantial improvement in the quality-of-life of symptomatic patients with hypertrophic 
obstructive cardiomyopathy (HOCM) may be achieved by the use of a beta blocker, calci-
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umantagonist or disopyramide. Medical therapy-resistant obstructive HCM can be treated 
surgically, by performing septal myectomy, and percutaneously with alcohol septal ablation. 
During the last years there is an intense and polarizing debate to define the best strategy.[4-8]
In this debate, and current guidelines, most arguments and recommendations are based on 
short-term follow-up results or expert opinion. The long-term outcomes remain unclear, and 
this could be solved by a randomized controlled trial; but as outlined by Olivotto et al., this 
is not feasible. As we have demonstrated in chapter 1 and 2, event rates are relatively low, 
and this means that a very large cohort will be necessary; larger than all combined cohorts 
in North America, Asia and Europe. Alternatively a smaller study group could be used, but 
then we need a follow-up of 10-20 years, which is also not realistic.[9] The issue is further 
complicated by the specialization of the referral centers. Most hospitals that perform septal 
reduction therapy will do alcohol septal ablation or surgical myectomy; but only a minority is 
experienced in both [6, 10].
By combining data from multiple hospitals we could improve our current understanding. 
In chapter 1 we focused on the long-term outcomes of both invasive procedures, and com-
pared them with non-obstructive HCM patients. All procedures were performed in centers 
specialized in HCM care (Leuven, Nieuwegein, and Rotterdam). The most important finding 
was that after alcohol septal ablation and myectomy, both mortality and SCD risk were found 
to be similarly low, and comparable to patients with non-obstructive HCM (figure 2). This 
demonstrates that the survival disadvantage associated with symptomatic LVOT obstruc-
tion can be effectively annulled by appropriate invasive therapy and management in referral 
figure 2 – Kaplan Meier survival graph of 1047 patients with hypertrophic cardiomyopathy.
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centers for HCM care.[11] In the meta-analysis we performed in chapter 2, the long-term 
follow-up of more than 4500 patients confirmed the similarly low mortality (1.4% per year 
after myectomy and 1.5% per year after alcohol septal ablation, p = 0.8) and SCD rates (0.5% 
per year after myectomy and 0.4% per year after alcohol septal ablation, p = 0.5). The main 
difference between the two interventions was found in procedure related complications: 
patients who undergo alcohol septal ablation are at increased risk of pacemaker implantation 
due to periprocedural damage of the atrioventricular conduction system (10% versus 4.4%, p 
< 0.001). There was also a higher need for additional septal reduction therapy in patients who 
underwent alcohol septal ablation (7.7% versus 1.6%, p = 0.001).
Improvement of individual approaches
Surgical septal myectomy was introduced in the 1960s by Morrow[12] and became the pre-
ferred approach for septal reduction therapy, with excellent results in the original and extended 
technique [13-17]. Abnormalities of papillary muscles (hypertrophy, anterior and internal 
displacement, direct insertion into the anterior mitral valve leaflet) or elongated mitral leaflets 
may contribute to LVOT obstruction, and these remain untouched when solely a myectomy is 
performed. Concomitant mitral valve surgery could be beneficial in these patients, especially 
if there is limited septal thickness, but marked mitral leaflet elongation or mitral regurgita-
tion. The addition of anterior mitral leaflet extension, which stiffens the mid-segment of the 
anterior leaflet, to septal myectomy approaches these mitral valve abnormalities. Our results 
in chapter 3 show that in selected HCM patients, myectomy combined with anterior mitral 
leaflet extension is an effective procedure to abolish LVOT obstruction, and can be performed 
at the cost of acceptable morbidity and very low operative mortality (0% vs 2.5% respectively, 
as described in the myectomy cohorts in chapter 2).[18]
Periprocedural adverse arrhythmic events, such as sustained ventricular tachycardia or 
ventricular fibrillation, remain one of the potential concerns of alcohol septal ablation. The 
use of alcohol, with its inherent cardiotoxicity, and the risk of spillage in the left anterior 
descending coronary artery, has been blamed as the culprit of these life-threatening arrhyth-
mias. In chapter 6 we found that alcohol dosage did not predict the risk of arrhythmia. But 
in line with previous studies, infarct size – determined by CK-MB levels – did predict the risk 
of life-threatening ventricular arrhythmias. A higher dosage of alcohol was associated with 
a larger infarct size, as were a larger caliber of the septal perforator and LV wall thickness. 
Although infarct size may be hard to predict in the individual patient, the finding of high 
CK-MB levels post-procedure could warrant extended monitoring or even preventive ICD 
implantation, especially in the presence of other risk factors of SCD.
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PredICtION ANd PreVeNtION OF suddeN CArdIAC deAtH
SCD is a relatively rare but devastating clinical event in HCM with an incidence of 0.5-1%/
year in patients with HCM.[13] Originally, in the older 2003 ACC/ESC guidelines and 2011 
ACCF/AHA guidelines, the identification of high-risk patients was based on five clinical 
characteristics: a family history of SCD in first-degree relatives < 40 years of age, maximal 
left ventricular wall thickness (LVWT) of >30 mm, unexplainable syncope, non-sustained 
ventricular tachycardia (nsVT) and abnormal blood pressure response during exercise.[19, 
20] Although it was clear that the risk of SCD increases with increasing number of risk fac-
tors, both 2003 and 2011 guidelines distinguish high and low risk patients with only limited 
power (figure 3). [21]
figure 3 – Time-dependent receiver operating characteristic curves for the risk prediction models of 
the 2014 ESC guidelines (AUC=0.69), 2003 ACC/ESC guidelines (AUC=0.55), and 2011 ACCF/AHA 
guidelines (AUC=0.60), and the reference line (AUC=0.5). [24]
Identifying patients at high risk of sCd
In chapter 9 we validated the new risk prediction model for SCD that was proposed in the 
2014 ESC guidelines.[22] This model – the HCM Risk-SCD score – provides an individual-
ized 5 year SCD risk, and is based on some of the aforementioned risk factors, (abnormal 
blood pressure response during exercise was excluded) combined with LVOT gradient, left 
atrial diameter and age at evaluation. The model classifies patients based on their 5-year risk: 
low (<4%), intermediate (4-6%), and high (>6%); and is the basis of the 2014 ESC guidelines 
recommendation on ICD implantation.[13, 23]
In an independent setting, we found that the HCM Risk-SCD score discriminates better 
between patients with a high or low SCD risk, than the older models based on the 5 classic 
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risk factors.[24] Probably this model is a better predictor of outcome because the effects of 
cardiac remodeling are now considered. chapter 10 demonstrated that SCD risk increases 
significantly if factors of adverse LV remodeling are present.[25] Interestingly, an American 
examination of the prediction model found that the HCM Risk-SCD score is too insensitive 
to accurately identify high-risk patients. But these findings may be obscured by the inclusion 
of patients in the model that are not deemed eligible by the original authors, e.g. patients < 
18 years old or with septal thickness > 34 mm. These contradicting findings confirm that the 
HCM Risk-SCD score is not a replacement of clinical judgment. Another issue not addressed 
by the new risk model is the role of late gadolinium enhancement (LGE) on cardiac magnetic 
resonance imaging (MRI) as a possible predictor of SCD risk. The presence of LGE is associ-
ated with HCM-related mortality [26], but the relationship with SCD is ambiguous at best.
[26-28] A recent meta-analysis did not show any relationship with SCD.[29] This may be 
related to the fact that LGE can detect large areas of scar tissue and myocardial fibrosis; but 
interstitial fibrosis or disarray may not be detected. Another issue is the method of quantifica-
tion of LGE, and significant variation on LGE volume depending on the method.[30] Hope-
fully, these issues will be addressed in the HCMR study – in which we also participate – that 
is due for 2018. This NIH funded registry (clinicaltrials.gov identifier: NCT01915615) aims 
to identify novel risk predictors by using MRI.
ICd therapy in patients with HCm
If a patient is considered to be at increased risk of SCD, an ICD implantation should be 
considered. Chapter 11 and chapter 12 demonstrate that this protection of death due to 
malignant ventricular arrhythmias comes at the price of inappropriate shocks (4.8% per year) 
and device related complications (3.4% per year).[31, 32] Because HCM patients are young at 
implantation the risks should not be underestimated, because of the long period that young 
patients will live with the implanted device and leads.
Thus, the benefits and risk of ICD therapy in HCM patients should be carefully weighed. 
The improved discriminatory power of the new model implies that more high-risk patients 
are correctly identified and become eligible for ICD implantation, but also that unnecessary 
and potential harmful ICD implantations can be avoided in patients without increased SCD 
risk. However, the risk score is not a replacement of clinical judgment, but should be used as 
the authors state: “to complement clinical reasoning by providing objective individualized 
prognostic information.”[23] This is in line with the American 2011 guidelines: “The deci-
sion for placement of primary prevention ICD in HCM often involves a large measure of 
individual clinical judgment, particularly when evidence for risk is ambiguous. The potential 
for SCD needs to be discussed with each fully informed HCM patient and family member 
in the context of their concerns and anxieties and should be balanced against the risks and 
benefits of proposed prophylactic ICD strategy.”[20]
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CLINICAL ImPLICAtIONs OF sArCOmerIC mutAtIONs
When involved in the care of a patient with HCM, it is import to realize that behind this 
patient, there may be a family that consists of parents, siblings, and children. In all first-degree 
family members cardiologic evaluation should be offered. Genetic testing is recommended in 
the index patient, and if a pathogenic mutation is found, this can be used to further identify 
family members at risk.[13]
Identification of a pathogenic mutation not only helps to identify other family members. 
The results in chapter 13 demonstrated that patients with HCM and a pathogenic mutation 
have a greater probability of heart failure related death, compared with patients with HCM, 
without a mutation. This implies that patients with a pathogenic mutation should be followed 
up more closely to anticipate a change in clinical course. The adverse outcome associated 
with the presence of a pathogenic mutation is confirmed in a study that assessed the effect 
of triple mutations. These patients had marked adverse cardiac remodeling characterized 
by restrictive physiology, atrial dilation, and systolic dysfunction, and triple mutations were 
associated with a 14-fold higher risk to develop end-stage disease.[33] HCM patients with 
signs of adverse cardiac remodeling are considered at risk of further progression toward overt 
dysfunction and heart failure [34], and at increased risk of SCD as discussed in chapter 
10.[25] Aside from the clinical signs of adverse remodeling, our results favor incorporating 
genetic test results as a risk factor of adverse remodeling in patients with overt HCM.
The identification of a pathogenic mutation does not necessarily imply an adverse prog-
nosis. Individuals with a pathogenic mutation without any overt signs of HCM (maximal left 
ventricular (LV) wall thickness < 13mm), appear to have a favorable outcome. In chapter 
14 we have demonstrated that after 4.5 years of follow-up there were no adverse events in 
the group of preclinical HCM subjects. Only one patient developed manifest HCM, over the 
course of 6.6 years. These findings have several important clinical implications. First, based 
hereupon, we propose a 5-yearly follow-up of adult preclinical HCM subjects, unless a change 
in clinical status occurs. Second, the slow development of LVH in subjects with preclinical 
HCM also hampers the identification of predictors of disease progression, and the identifica-
tion of possible strategies to prevent the development of HCM in these subjects. For example, 
a recent study assessed the effect of diltiazem treatment in preclinical HCM subjects. After 
± 2 years of treatment there was no difference in the low number of patients (11% in both 
treatment and placebo group) who were diagnosed with HCM in each group, all aged < 18y).
[35] The NIH-funded VANISH trial (ClinicalTrials.gov Identifier: NCT01912534), in which 
we participate, is designed to determine whether losartan can reduce or halt disease progres-
sion. But both studies are limited by the slow disease progression and expected high number 
needed to treat.
Increasing the knowledge on the pathophysiology of how a specific mutation leads to 
HCM might increase the ability to prevent the development all together. In chapter 15 we 
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uncovered a small segment of the black box of genotype-phenotype relations. We assessed 
myocardial function on a regional level and a cellular level. This showed that in patients with 
HCM, there is an association between the reduced maximal force development of the cardio-
myocyte and impaired regional systolic function of the septal wall. This observed reduction 
in maximal force generating capacity is typical for HCM, and the impaired cardiac mechanics 
appears to be related to the intrinsic myocardial dysfunction, and not only to the altered load-
ing conditions and LVH.
These findings, combined with the results of chapter 14 and other literature may hint 
at a possible hypothesis for the disease progression of HCM in preclinical HCM subjects. 
Several intrinsic and extrinsic factors (e.g. haploinsufficiency or poison peptides caused by 
pathogenic mutations) could lead to remodeling of cardiomyocytes in an otherwise structur-
ally normal heart.[36-40] The remodeling hampers both maximal force generating capacity 
and cardiomyocyte relaxation, and may lead to compensatory hypertrophy of the myocar-
dium – initially locally – and more regional as disease progresses. This could present itself as 
initial diastolic and regional systolic dysfunction, and eventually to the typical asymmetrical 
hypertrophy (figure 4).
In conclusion, the presence of a pathogenic sarcomeric mutation does imply a greater 
risk of adverse outcome, especially heart failure related events. However, in preclinical HCM 
subjects, it remains a benign condition. Finally, the association of regional and myocardial 
dysfunction could advance our understanding of disease progression, in both preclinical HCM 
and overt HCM patients.
figure 4 – Intrinsic effects (of the pathogenic mutation) and extrinsic factors lead to remodeling of 
the sarcomere and a hypocontractile cardiomyocyte. Regional systolic and diastolic impairment may 
lead to overt HCM.[41]
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Future dIreCtIONs
Both surgical myectomy and alcohol septal ablation are now established in the armamentarium 
of invasive therapies to reduce the symptoms related to symptomatic LVOT obstruction. 
An individual approach is required to determine the preferred method of septal reduction 
therapy. This decision should be based on patient co-morbidities, anatomical features (e.g. 
mitral valve abnormalities, septal anatomy), and patient preference. The first step is to discuss 
the symptomatic patient in an experienced multidisciplinary heart team (consisting of at least 
one cardiothoracic surgeon, an interventional cardiologist, and a cardiologist specializing in 
the care of patients with HCM). Preferably, and as stated in current guidelines, both the sur-
geon and the interventional cardiologist should be experienced in respectively myectomy and 
alcohol septal ablation. Therefore, we recommend early referral of patients with symptomatic 
LVOT obstruction to centers with substantial and specific expertise in HCM care.[13]
Future research in percutaneous septal reduction therapy may need to focus on reduction 
of procedural related atrioventricular disturbances and life-threatening arrhythmias. Current 
guidelines state that alcohol septal ablation should be reserved for elderly patients, but as 
demonstrated in chapter 7, these patients are at increased risk for atrioventricular distur-
bances post-procedure. In younger patients (± 43 years) the risk for pacemaker implantation 
(5%) is comparable with patients in a similar age group post-myectomy (1-6%), but the very 
long-term follow-up (> 20 years) is still unclear, and a relevant issue in younger patients. 
Secondly, the use of an alternative for alcohol could also reduce the risk of procedure related 
arrhythmias. Septal microsphere embolization uses microspheres instead of alcohol to create 
a more controlled infarction. chapter 8 describes the first clinical experience in the Neth-
erlands using septal microsphere embolization as an alternative for alcohol septal ablation. 
Although in both cases it resulted in immediate improvement in hemodynamics, without any 
procedure-related arrhythmic events, future research, with a substantial cohort and longer 
follow-up will have to demonstrate whether septal microsphere embolization will be a viable 
alternative to alcohol septal ablation.[42]
The aforementioned multidisciplinary approach should also be considered in the preven-
tion of SCD. Implantation of an ICD protects against SCD, but this protection comes at the 
price of potential inappropriate shocks and device-related complications. These risks are 
particularly relevant when the device is implanted in a younger population, as is the case 
in HCM. In this group it is important to implant a device as simple as sufficient, such as a 
single ventricular lead, or even a total subcutaneous device. The drawback of the latter is 
the dependency on screening vectors, and especially high-risk HCM patients are not eligible 
for subcutaneous ICD implantation.[43] This also means we should continue to strive for 
improved risk stratification. Aside from quantification of LGE on cardiac MRI (as discussed 
above), genetic information might contribute to further improvement of the risk stratification 
and identification of high-risk patients. Our current understanding of genetics and its role in 
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SCD is limited. The rise of referral centers for HCM and the participation of these centers in 
large international registries, such as HCMR and SHARE (www.theshareregistry.org), could 
clarify this relationship.
Finally, these large international collaborations could also improve our further under-
standing of the development of the disease, and the progression from a pathogenic mutation 
towards overt HCM. Currently, a pathogenic mutation is not a separate criterion for disease, 
but it raises the chance to obtain the disease. If we understand the progression of disease 
on a cellular level, targeting these mechanisms might also provide a strategy to halt disease 
progression. Gramlich et al.[44] demonstrated that the disruption of the titin reading frame 
due to truncating DCM mutation can be restored by exon skipping in both human and mouse 
models. This antisense mediated exon-skipping leads to improved cardiomyocyte function 
and normalized sarcomeric protein expression in vitro.[44] If, and when, these novel strate-
gies will be available for HCM patients remains very uncertain, and we need to expand our 
knowledge on genotype-phenotype relations.
CONCLusIONs
This thesis demonstrated with the excellent long-term results of myectomy and alcohol 
septal ablation, that both are safe and effective procedures to reduce symptoms in therapy 
refractory LVOT obstruction, but that for each patient an individual and multidisciplinary 
approach should be pursued. Also, by further improving the SCD risk prediction models and 
the indications of ICD implantation, we found that the prognosis of patients with HCM is 
now almost comparable to the general population. Finally, improving our understanding of 
phenotype-genotype relations could be the pathway to preventive strategies. The road ahead 
could lead to an effective curative therapy for HCM, and this road ahead is going to be bumpy. 
At least it will be an exciting ride.
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Dit proefschrift streeft ernaar om de pathofysiologie van hypertrofische cardiomyopathie 
(HCM) op dezelfde manier te benaderen zoals wij naar een patiënt met HCM kijken 
(figuur 1). Als een patiënt met HCM zich presenteert op de polikliniek, bestaat deze initiële 
benadering uit 3 aspecten. Vaak is het zo dat een patiënt komt met symptomen zoals dyspnoe 
d’effort, of thoracale pijnklachten. Het overgrote deel hiervan is gerelateerd aan obstructie 
van de uitstroombaan van de linker ventrikel. De eerste stap in de behandeling van deze 
klachten is middels medicatie, maar als maximaal medicamenteus beleid niet toereikend is, 
moet invasieve behandeling overwogen worden. Deze invasieve benadering wordt besproken 
in deel II. Ten tweede is het zo dat een deel van de patiënten met HCM een verhoogd risico 
heeft op plotse dood. deel III bespreekt dan ook het voorspellen en voorkomen van plotse 
dood in patiënten met HCM. Tenslotte moeten we niet vergeten dat bij elke patiënt met 
HCM er ook een potentiele HCM-familie hoort; klinische en genetische screening kunnen 
dan gebruikt worden om familieleden die de ziekte hebben of een verhoogd risico erop op te 
sporen. De klinische implicaties van een positieve gen mutatie worden besproken in deel IV.
figuur 1 – Benadering van de patient met hypertrofische cardiomyopathie (HCM). G: genotype; 
LVH: linker ventrikel hypertrofie; SCD: plotse dood.
INVAsIeVe BeHANdeLING VAN OBstruCtIeVe HCm
septale myectomie versus alcohol septum ablatie
In de meerderheid van patiënten met HCM is dynamische linker ventrikel (LV)-uitstroombaan 
obstructie aanwezig. [1] Deze obstructie is niet alleen geassocieerd met symptomen zoals 
dyspnoe d’effort, vermoeidheid, thoracale pijnklachten of syncope, maar diverse studies heb-
ben ook aangetoond dat de aanwezigheid van een significante LV-uitstroombaan obstructie de 
kans verhoogd op overlijden, en ook het optreden van levensgevaarlijke ritmestoornissen en 
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plotse dood. [2,3] In een deel van de patiënten kan aanzienlijke verbetering van kwaliteit van 
leven bereikt worden met medicamenteuze therapie. Hierin spelen bètablokkers, calcium-
antagonisten en disopyramide de belangrijkste rol. In patiënten met obstructieve HCM, die 
klachten blijven houden ondanks optimale medicamenteuze therapie, kan invasief ingegrepen 
worden. Dit kan chirurgisch door middel van septale myectomie, of percutaan door middel 
van alcohol septum ablatie. Zeker in de laatste jaren is er een intense en polariserend debat 
gaande in internationale literatuur om de beste behandelstrategie te omschrijven. [4-8]
Het probleem van dit debat, en ook de huidige richtlijnen, is dat de meeste argumenten en 
aanbevelingen gebaseerd zijn op de korte termijn uitkomsten, of op basis van de zogenaamde 
‘expert opinion’. Langetermijnresultaten zijn minder duidelijk, en een gerandomiseerde 
studie zou helderheid kunnen bieden. Echter, Olivotto et al. hebben aangetoond dat dit niet 
mogelijk is. In hoofdstuk 1 en 2 tonen we aan dat de event rates zeldzaam zijn, en dit betekent 
dat een zeer groot cohort nodig is – groter dan een combinatie van Europese, Amerikaanse 
en Aziatische cohorten - om uitspraken over de 2 interventies te kunnen doen. Indien we 
een kleinere studiepopulatie nemen, moet de follow-up meer dan 10-20 jaar lang zijn, wat 
eveneens niet realistisch is. [9] Een losstaand probleem is dat de verwijzingscentra meestal 
gespecialiseerd zijn in slechts een van de interventies: of alcohol septum ablatie of chirurgi-
sche myectomie, maar slechts een minderheid heeft ervaring met beide technieken. [6,10]
Omdat een gerandomiseerde studie dus niet realistisch is hebben wij besloten de gegevens 
van meerdere centra te combineren. In hoofdstuk 1 hebben we de langetermijnresultaten van 
beide invasieve procedures naast elkaar gelegd, en dit vergeleken met niet-obstructieve HCM-
patiënten. Alle ingrepen zijn verricht in tertiaire verwijzingscentra (UZ Leuven, St. Antonius 
Ziekenhuis Nieuwegein en Erasmus MC Rotterdam), gespecialiseerd in de behandeling van 
HCM-patiënten. De belangrijkste bevinding was dat zowel na alcohol septum ablatie als 
myectomie, de gehele mortaliteit en het risico op plotse dood, zeer laag waren; vergelijkbaar 
met patiënten zonder LV-uitstroombaan obstructie (figuur 2). Dit toont dan ook aan dat de 
verhoogde kans op overlijden, geassocieerd met obstructieve HCM, weggenomen kan worden 
na geïndiceerde invasief ingrijpen en behandeling door een team gespecialiseerd in de behan-
deling van HCM. [11] In hoofdstuk 2 hebben we een meta-analyse verricht die in meer dan 
4500 patiënten naar de langetermijnresultaten kijkt, en hierin werden eveneens de lage gehele 
mortaliteit (1,4% na myectomie en 1,5% na alcohol septum ablatie, p=0.8) en het lage risico op 
plotse dood (0,5% na myectomie en 0,4% na alcohol septum ablatie, p=0.5). Het belangrijkste 
verschil tussen beide procedures was met name terug te vinden in de complicaties gerelateerd 
aan de ingreep: na alcohol septum ablatie was het risico op permanente pacemakerimplantatie 
duidelijk verhoogd (10% versus 4,4% na myectomie, p<0,001). Bovendien was er na alcohol 
septum ablatie vaker een 2e ingreep nodig om gewenst effect te bereiken (7,7% versus 1,6%, 
p=0,001).
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Individuele verbeteringen van beide technieken
Chirurgische septale myectomie is in de jaren zestig geïntroduceerd door Morrow [12] en 
is snel de gouden standaard geworden, met goede resultaten bij de originele en de gemo-
dificeerde (verlengde myectomie) techniek. [13-17]. Een beperking van deze techniek is dat 
afwijkingen van het papillair spieren (hypertrofie, malpositie en directe insertie op het voorste 
mitralisklepblad) of van de mitraalklepbladen zelf niet behandeld worden, als er enkel een 
myectomie verricht wordt. Gelijktijdige mitraalklepchirurgie kan dan ook van toegevoegde 
waarde zijn in bepaalde patiënten, zeker als er beperkte septale hypertrofie aanwezig is, maar 
wel verlengde klepbladen of ernstige mitralisklepinsufficiëntie. De combinatie van myectomie 
met anterieur klepblad extensie zorgt voor versteviging van dit klepblad, en behandeld dus ook 
de mitraalklep problematiek. Onze resultaten in hoofdstuk 3 laten zien dat in geselecteerde 
patiënten met obstructieve HCM de combinatie van myectomy en mitraalklepblad extensie 
een effectieve ingreep is die de gradiënt over LV-uitstroombaan doet verdwijnen en dit met 
zeer lage mortaliteit (0% in ons cohort versus 2,5% in de myectomie cohorten in hoofdstuk 
2). [18]
In patiënten die alcohol septum ablatie ondergaan, is het optreden van procedure-
gerelateerde aritmieën, met name ventriculaire tachycardie of fibrillatie, een punt van 
bezorgdheid. Alcohol, dat inherent cardiotoxisch is, wordt vaak als de schuldige geduid van 
deze levensbedreigende ritmestoornissen. In hoofdstuk 6 tonen we aan dat alcohol dosering 
op zich geen invloed had op het risico op ritmestoornissen. Wel was het zo, vergelijkbaar 
figuur 2 – Kaplan Meier grafiek die de overleving toont van 1047 patiënten met hypertrofische car-
diomyopathie.
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met eerdere studies, dat een groot infarct – bepaald door serum concentratie van CK-MB, 
een voorspeller was van optreden van ritmestoornissen. Factoren die leiden tot een grotere 
infarcering waren LV-septum dikte, diameter van de septaaltak en alcoholdosering. Het is 
dus duidelijk dat in de individuele patiënt het van tevoren moeilijk te voorspellen is wie een 
verhoogde kans op levensbedreigende ritmestoornissen heeft. Wel is het zo dat patiënten 
met fors verhoogde cardiale enzymen na de ingreep zeker recht hebben op monitoring, of 
dat zelfs preventieve ICD-implantatie overwegen kan worden, zeker als patiënt nog andere 
risicofactoren voor plotse dood heeft.
VOOrsPeLLeN eN VOOrkOmeN VAN PLOtse dOOd
Plotse dood is relatieve zeldzaam maar natuurlijk zeer ernstige complicatie van HCM, met een 
gemiddelde incidentie van 0,5-1,0% per jaar. [13] Om te bepalen welke patiënten een verhoogd 
risico hebben op plotse dood werd in de 2003 ACC/ESC en 2011 ACCF/AHA richtlijnen 
gebruikt gemaakt van 5 klinische kenmerken: positieve familie anamnese voor plotse dood 
in 1e graad familieleden < 40 jaar oud, maximale LV wanddikte van > 30mm, onverklaarde 
syncope, non-sustained ventriculaire tachycardie en abnormale bloeddruk response tijdens 
inspannig(stest). [19,20] Hoewel er wel een verband was tussen het aantal aanwezige risico-
factoren en de kans op plotse dood, kon het verschil tussen hoog en laag risico patiënten maar 
beperkt gemaakt worden (figuur 3). [21]
figuur 3 – Tijdsafhankelijke ROC-curve voor de risico predictie modellen van de 2014 ESC richtlijn 
(AUC=0.69), 2003 ACC/ESC richtlijn (AUC=0.55), en 2011 ACCF/AHA richtlijn (AUC=0.60), en de 
referentielijn (AUC=0.50). [24]
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Identificatie van hoog risico patiënten
In hoofdstuk 9 hebben wij als eerste het nieuwe risico voorspellend model van de in 2014 
geïntroduceerde ESC-richtlijnen gevalideerd. Dit model dat gebaseerd is op de HCM Risk-
SCD score, maakt gebruikt van een individuele 5-jaars risico, en is gebaseerd op enkele van de 
bovengenoemde risicofactoren (maar abnormale bloeddruk respons was hier buiten gelaten), 
in combinatie met LV uitstroombaan gradiënt, linker atrium diameter en leeftijd. Het model 
maakt vervolgens onderscheid op basis van het 5-jaars risico: laag (<4%), gemiddeld (4-6%) en 
hoog (>6%). Dit onderscheid is ook de basis voor de aanbevelingen voor ICD-implantatie in 
de Europese richtlijnen. [13,23]
Hoewel het model wel intern gevalideerd is geweest, hebben wij als eerste in een onaf-
hankelijk cohort gevonden dat het HCM Risk-SCD model beter onderscheid kan maken 
tussen patiënten met een hoog en een laag risico op plotse dood, dan oudere modellen 
gebaseerd op de vijf klassieke risicofactoren. [24] Een mogelijke verklaring hiervoor is dat 
het effect van cardiale remodelleren betrokken wordt. Hoofdstuk 10 laat zien dat indien 
er sprake is van ongunstige remodeling, het risico op plotse dood significant verhoogd is. 
[25] Interessant is dat een Amerikaanse analyse het HCM Risk-SCD model als inaccuraat 
bestempeld, en als onvoldoende gevoelig om onderscheid te maken tussen patiënten met 
hoog en laag risico. Wel is het zo dat deze bevindingen vertroebeld worden door inclusie 
van patiënten die niet in aanmerking komen volgens de auteurs van de originele HCM Risk 
studie, bijvoorbeeld patiënten < 18 jaar, of met LV wanddikte van > 35mm. In ieder geval 
laten deze tegenstrijdige bevindingen wel zien dat het gebruik van een risico model geen 
vervanging moet zijn van het klinische oordeel van de specialist. Een ander probleem dat 
niet aan de orde komt in het nieuwe model is de rol van late gadolinium aankleuring op 
MRI in het voorspellen van plotse dood. Hoewel de aanwezigheid van deze late aankleuring 
geassocieerd is met HCM-gerelateerde mortaliteit, is de relatie met plotse dood dubbelzin-
nig op z’n best. [26-28] Een recente meta-analyse liet eveneens geen verband zien tussen 
plotse dood en aanwezigheid van late aankleuring. [29] Dit kan te maken hebben met het 
feit dat deze aankleuring wel myocardiale fibrose en verlittekening kan aantonen, maar 
geen interstitiële fibrose of myocardiale disarray. Bovendien is het zo dat de kwantificatie 
van deze aankleuring erg methodiek afhankelijk is. [30] Momenteel loopt de HCMR studie 
(clinicaltrials.gov nummer: NCT01915615), waar wij ook aan meedoen, die deze problemen 
en beperkingen in de rol van MRI in het voorspellen van plotse dood systematisch benadert, 
en hopelijk meer helderheid kan scheppen.
Gebruik van ICd’s in patiënten met HCm
Indien een patiënt met HCM als een hoog risico patiënt voor plotse dood beschouwd wordt, 
moet ICD implantatie overwogen worden. In hoofdstuk 11 en 12 tonen wij aan dat de effectieve 
bescherming tegen plotse dood, wel ten koste gaat van onjuist toegediende schokken (4.8%/
jaar)en complicaties gerelateerd aan het apparaat zelf (3.4%/jaar). Omdat de gemiddelde 
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HCM patiënt jong is als de ICD geplaatst wordt, kunnen deze risico’s niet genegeerd worden, 
juist omdat deze patiënten veel langer met geplaatste elektroden en batterij moeten doen.
Al met al moeten de voor- en nadelen van ICD behandeling zorgvuldig afgewogen wor-
den. Het gebruik van het nieuwe risico model, met een verbeterd onderscheidend vermogen 
tussen hoog en laag risicopatiënten, impliceert dat niet alleen meer hoog risico patiënten juist 
geïdentificeerd worden, maar ook minder patiënten met laag risico voor plotse dood onnodig 
behandeld worden met een ICD, en alle nadelen van dien. Zoals eerder beschreven is, is 
een risico score geen vervanging van het klinisch oordeel, maar moet gebruikt worden “als 
aanvulling op de kliniek door objectieve individuele prognostische informatie te bieden.” [23] 
Dit sluit mooi aan bij de opmerking in de Amerikaanse richtlijnen uit 2011: “de beslissing om 
een ICD te implanteren in het kader van primaire preventie in patiënten met HCM is vaak ge-
baseerd op individuele klinische inschatting, zeker als het risico op plotse dood dubbelzinnig 
is. Dit risico moet met de volledig geïnformeerde patiënt besproken worden, en uiteindelijk 
een afweging zijn van de risico’s en voordelen van preventieve ICD implantatie.” [20]
kLINIsCHe ImPLICAtIes VAN sArCOmeer mutAtIes
Bij het behandelen van een patiënt met HCM is het belangrijk om niet uit het oog te verliezen 
dat achter deze patiënt ook een familie staat, bestaande uit ouders, broers en zussen, en kin-
deren. Bij alle nieuw gediagnosticeerde patiënten met HCM moeten alle 1e graad familieleden 
ook geëvalueerd worden. Genetisch onderzoek wordt in de index-patiënt aangeraden, en in-
dien een pathogene mutatie gevonden wordt kan dit gebruikt worden om andere familieleden 
te identificeren die het risico hebben op het ontwikkelen van HCM. [13]
Maar het vinden van een pathogene mutatie zegt ook iets over de individuele patiënt. In 
hoofdstuk 13 hebben we aangetoond dat patiënten met HCM en de aanwezigheid van een 
pathogene mutatie een groter risico hebben om te overlijden als gevolg van hartfalen, dan 
patiënten zonder een mutatie. Dit impliceert dat patiënten met een mutatie recht hebben op 
striktere follow-up, zodat makkelijker op een verandering in klinisch beloop gereageerd kan 
worden. Dat de aanwezigheid van een sarcomeer mutatie een negatieve invloed heeft blijkt uit 
ook uit een eerdere studie waarin gekeken wordt naar het effect van dubbele en triple mutaties. 
Want deze patiënten hadden duidelijk meer cardiale remodeling, met restrictieve fysiologie, 
atriale dilatatie en systolische dysfunctie. De aanwezigheid van drievoudige mutaties was 
zelfs geassocieerd met een 14-voudig verhoogd risico op eindstadium ziekte te ontwikkelen. 
[33] HCM-patiënten met aanwijzingen voor negatieve cardiale remodeling hebben dus een 
verhoogd risico op hartfalen en, zoals aangetoond in hoofdstuk 10 ook een hoger risico op 
plotse dood. [25] Wij adviseren dan ook naar aanleiding van onze resultaten om genetisch 
onderzoek mee te laten wegen, naast de klinische tekens, om in te schatten welke patiënten 
een hoger risico op negatieve remodeling hebben.
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Maar de aanwezigheid van een pathogene mutatie is niet altijd een teken van slechte 
prognose. Volwassenen met een pathogene mutatie, maar zonder aanwijzingen voor HCM, 
dus met een LV-wanddikte < 13mm, lijken hier geen beperkingen van te ondervinden. In 
hoofdstuk 14 hebben wij aangetoond dat er in een groep van deze ‘patiënten’ er in 4,5 geen 
ongunstige voorvallen plaatsvinden. Bovendien was er maar 1 patiënt die echte HCM ontwik-
kelde, en dat na 6,6 jaar. Deze bevindingen hebben enkele belangrijke klinische consequenties. 
Ten eerste, gebaseerd op bovenstaande resultaten, adviseren wij deze volwassen personen 
niet 1- of 2-jaarlijks maar om de 5 jaar te evalueren, tenzij er klinische veranderingen zijn. 
Ten tweede is deze trage ziekteprogressie en ontwikkeling tot echte HCM een belangrijke 
beperking in onderzoek naar voorspellers van ziekteprogressie, en beperkt het ook de iden-
tificatie van potentiele behandelstrategieën om ziekteprogressie te voorkomen. Bijvoorbeeld 
is er recent een studie gepubliceerd die het effect van diltiazem op personen met pathogene 
mutatie onderzocht heeft. Na +-2 jaar behandeling was er geen verschil tussen het (lage) 
aantal patiënten dat HCM ontwikkelde in de placebogroep en behandelgroep. Bovendien 
waren alle patiënten die HCM ontwikkelden < 18 jaar. Momenteel doen wij mee met de 
NIH-gesponsorde VANISH-studie, en hierin wordt bekeken of losartan ziekteprogressie kan 
vertragen of tot stilstaan brengen. Dat de ziekte uit zichzelf een trage progressie heeft blijft 
een beperking, en zal naar verwachting leiden tot een hoog ‘number needed to treat’.
Wel kan het zo zijn dat een beter begrip van hoe een specifieke mutatie in het contractiel 
apparaat kan leiden tot de (asymmetrische) hypertrofie, kan bijdragen om mogelijkheden deze 
progressie tegen te houden. In hoofdstuk 15 hebben een tipje van de sluier gelicht, die over 
de genotype-fenotype relatie ligt. We beoordeelden de myocardfunctie op regionaal niveau 
en op cellulair niveau. Hieruit bleek dat bij patiënten met HCM, er een verband tussen de 
verminderde maximale krachtontwikkeling van de cardiomyocyt is en verminderde regionale 
systolische functie van de septale wand. Deze verlaging van maximale krachtontwikkeling is 
typisch voor HCM, en de verminderde cardiale mechanica blijkt gerelateerd aan de intrin-
sieke myocardiale disfunctie, en niet alleen aan de gewijzigde belasting en linker ventrikel 
hypertrofie.
Deze bevindingen, in combinatie met de resultaten van hoofdstuk 14 en andere literatuur 
kunnen wijzen op een mogelijke hypothese voor de progressie van de ziekte van HCM in 
gezonde mutatiedragers. Verschillende intrinsieke en extrinsieke factoren (bv haploinsuffici-
entie of zogenaamde poison-peptides, veroorzaakt door pathogene mutaties) zouden kunnen 
leiden tot remodeling van hartspiercellen in een verder structureel normaal hart. [36-40] De 
remodeling belemmert zowel maximale kracht genererende capaciteit en relaxatie van de car-
diomyocyten, en kan leiden tot compenserende hypertrofie van de hartspier - eerst lokaal - en 
later ook regionaal als de ziekte vordert. Dit kan zich uiten als eerst regionale diastolische en 
systolische disfunctie en uiteindelijk als de typische asymmetrische hypertrofie (figuur 4).
Concluderend impliceert de aanwezigheid van een pathogene sarcomeer mutatie een 
groter risico op negatieve uitkomst, vooral hartfalen gerelateerde gebeurtenissen. In gezonde 
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mutatiedragers blijft het een goedaardige aandoening. Ten slotte zou de associatie van re-
gionale functie en myocarddysfunctie ons begrip van de progressie van de ziekte kunnen 
bevorderen, zowel in mutatiedragers als echte HCM-patiënten.
tOekOmstPersPeCtIeVeN
Zowel chirurgische myectomie als alcohol septum ablatie zijn nu gevestigd in het arsenaal 
van invasieve behandelingen om symptomen die verband houden met symptomatische LV-
uitstroombaan obstructie te verminderen. Een individuele aanpak is nodig om de optimale 
therapie te bepalen. Deze beslissing moet worden toegespitst worden op de patiënt: como-
rbiditeiten, anatomische kenmerken (bijv. mitralisklepafwijkingen, vasculaire anatomie van 
het septum), en de voorkeur van de patiënt zelf. De eerste stap is dat de symptomatische 
patiënt door een ervaren multidisciplinair hartteam (idealiter bestaande uit ten minste één 
cardiothoracale chirurg, een interventiecardioloog en een cardioloog gespecialiseerd in de 
behandeling van patiënten met HCM). Bij voorkeur, en zoals vermeld in de huidige richt-
lijnen, moeten zowel de chirurg als de interventiecardioloog ervaren zijn in respectievelijk 
myectomie en alcohol septum ablatie. Daarom adviseren wij vroegtijdige verwijzing van 
patiënten met symptomatische obstructieve HCM naar centra met specifieke expertise op 
het vlak van HCM. [13]
Toekomstig onderzoek in percutane septum reductie therapie zal zich moeten concen-
treren op de vermindering van de procedure-gerelateerde complicaties: atrioventriculaire 
geleidingsstoornissen en levensbedreigende hartritmestoornissen. In de huidige richtlijnen 
staat dat alcohol septum ablatie moet worden gereserveerd voor oudere patiënten, maar 
zoals aangetoond in hoofdstuk 7, hebben juist deze patiënten een verhoogd risico voor 
figuur 4 – Intrinsieke effecten (van de pathogene mutatie) en extrinsieke factoren leiden tot remodel-
leren van de sarcomeer en tot een hypocontractiele cardiomyocyt. Regionale systolische en diastolische 
dysfunctie kunnen uiteindelijk leiden tot manifeste HCM. [41]
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atrioventriculaire geleidingsstoornissen na de procedure. Bij jongere patiënten (± 43 jaar) is 
het risico voor de implantatie van een pacemaker (5%) conform met patiënten in een ver-
gelijkbare leeftijdsgroep post-myectomy (1-6%). De zeer lange termijn follow-up (> 20 jaar) 
is nog onduidelijk, en wel een relevante kwestie bij jongere patiënten. Ten tweede kan het 
gebruik van een alternatief voor alcohol ook het risico van procedure gerelateerde aritmieën 
verminderen. Septale embolisatie dat microsferen gebruikt in plaats van alcohol zou een meer 
gecontroleerde infarct kunnen maken. Hoofdstuk 8 beschrijft de eerste klinische ervaringen 
in Nederland met septale microsfeer embolisatie als alternatief voor alcohol septum ablatie. 
Hoewel beide gevallen resulteerde in onmiddellijke verbetering in de hemodynamica, zonder 
procedure gerelateerde aritmische gebeurtenissen, zal toekomstig onderzoek met een groter 
cohort en langere follow-up moeten aantonen of septale microsfeer embolisatie een levensvat-
baar alternatief voor alcohol septum ablatie is. [42]
De bovengenoemde multidisciplinaire aanpak moet ook worden overwogen in de preven-
tie van SCD. Implantatie van een ICD beschermt tegen plotse dood, maar deze bescherming 
heeft een prijs van onterechte schokken en apparaat-gerelateerde complicaties. Deze risico’s 
zijn met name belangrijk wanneer in een jongere patiëntengroep geïmplanteerd wordt, zoals 
het geval is in HCM. In deze groep is het belangrijk om een zo eenvoudig mogelijk apparaat te 
implanteren, zoals een enkele ventriculaire elektrode, of zelfs een volledig subcutaan apparaat. 
Het nadeel van dit laatste alternatief is de afhankelijkheid van de juiste elektrische vectoren, 
en er is reeds aangetoond dat de hoog-risico patiënten met HCM niet in aanmerking komen 
voor subcutane ICD implantatie. [43] Dit betekent ook dat we moeten blijven streven naar een 
betere risicoanalyse. Naast kwantificering van late aankleuring op cardiale MRI (zoals hierbo-
ven besproken), kan de genetische informatie ook leiden tot een verdere verbetering van de 
risicostratificatie en identificatie van risicopatiënten. Onze huidige kennis van de genetica en 
haar rol in plotse dood is beperkt. De opkomst van tertiaire referentiecentra voor HCM en de 
deelname van deze centra in grote internationale registers, zoals HCMR en SHARE (www.
theshareregistry.org), kan deze relatie verduidelijken.
Tenslotte kunnen deze grote internationale samenwerkingsverbanden ook leiden tot een 
verbetering van ons begrip van de ontwikkeling van de ziekte, en de overgang van mutatie-
drager naar echte HCM-patiënt. Momenteel beschouwen wij een pathogene mutatie niet 
als afzonderlijk criterium voor de ziekte, maar een factor die de kans verhoogt om de ziekte 
te krijgen. Als we de progressie van de ziekte kunnen begrijpen op cellulair niveau, is het 
stoppen van deze mechanismen ook een strategie om de ziekteprogressie te stoppen, zoals 
bijvoorbeeld gerichte gentherapie. [44] Wanneer deze nieuwe strategieën beschikbaar zijn 
voor HCM-patiënten blijft erg onzeker, en we moeten dan ook onze kennis over genotype-
fenotype relaties blijven uitbreiden.
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CONCLusIe
Dit proefschrift toonde aan dat myectomie en alcohol septum ablatie veilige en effectieve pro-
cedures zijn in de behandeling van obstructieve HCM, met uitstekende resultaten op lange 
termijn, maar dat voor elke individuele patiënt een multidisciplinaire aanpak moet worden 
ingezet. Ook de verbetering van de risicoanalyse voor plotse dood en indicatiestelling voor 
ICD-implantatie, heeft geleid dat de prognose van patiënten met HCM nu bijna vergelijkbaar 
met de algemene bevolking is. Tot slot, het verbeteren van ons begrip van fenotype-genotype 
relaties kan de weg vrijmaken voor preventieve strategieën. Dit zou kunnen leiden tot een ef-
fectieve curatieve therapie voor HCM, maar voor het zover is, is er nog een lange en hobbelige 
weg te gaan. Het zal in ieder geval een spannende rit worden.
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Bij het schrijven van het dankwoord begrijp je opeens hoe tegenstrijdig de term ‘mijn proef-
schrift’ is. Want als je iets niet alleen doet dan is het een proefschrift schrijven. Zonder de 
hulp en steun van jullie was dit er niet gekomen. Toch wil ik graag een aantal mensen in het 
bijzonder bedanken. Ik ben mij ervan bewust dat dit een risico is, omdat je altijd mensen kan 
vergeten; hiervoor bied ik alvast mijn excuses aan.
Ten eerste wil ik mijn promotor, prof.dr. Felix Zijlstra bedanken. Beste Felix, niet alleen wist 
je alles van een afstand in goede banen te leiden, maar ik weet nog goed hoe ik, vers uit de 
schoolbanken, een gesprek met je had over het wel of niet ingaan van een promotietraject. 
Een advies dat je me toen gaf was het volgende: “je moet alleen maar gaan promoveren als het 
onderwerp je kan boeien en je bereid bent je er helemaal op te storten. Je moet het niet doen 
voor een opleidingsplek, je ego, of druk van anderen, want dan worden het lange jaren.” Ik 
ben blij dat ik dat advies ter harte genomen heb, want lang hebben deze jaren nooit gevoeld, 
ze zijn eerder voorbij gevlogen.
Dan natuurlijk mij co-promotoren: dr. Michelle Michels en dr. Arend Schinkel. Beste Mi-
chelle, dank je wel om, samen met Arend mijn co-promotoren te zijn. Ik bewonder enorm hoe 
jij alles weet te combineren: een drukke HCM-poli, het instandhouden en verder uitbouwen 
van het (inter)nationaal onderzoeksnetwerk, onderwijs, supervisie, een actief gezinsleven, 
en nog veel meer. Dat ik ook nog eens altijd bij je terecht kon voor vragen, adviezen, tips 
en strategieën is voor mij heel waardevol geweest. Dank je wel voor het vertrouwen om je 
eerste promovendus te mogen zijn, ik had geen betere supervisor kunnen wensen. Beste 
Arend, doordat jij in de kamer naast mij zat was het ideaal om even binnen te schieten en 
te overleggen. Jouw feedback op de manuscripten waren voor mij heel belangrijk, en ik heb 
daar heel veel van geleerd. Jouw rust en pragmatisme waren een belangrijke steun als ik het 
na de zoveelste afwijzing even niet meer zag zitten. Jij en Michelle waren een ideaal team om 
mijn enthousiasme in goede banen te leiden, en de juiste richting op te sturen als ik mezelf 
voorbijschoot.
Dr. Folkert ten Cate, beste Folkert, zonder jou was ik hier waarschijnlijk niet terecht 
gekomen. Jouw gedrevenheid om Rotterdam op de HCM-kaart te zetten kan alleen maar ge-
evenaard worden door jouw enthousiasme. Ik ben blij dat je mij een kans gegeven hebt in het 
Thoraxcenter, eerst als ANIOS, en enkele maanden later door mij het onderzoek in te duwen. 
Bovendien zag je altijd heel goed waar de controversiële onderwerpen en lacunes in de HCM-
literatuur zaten, en die ideeën hebben een belangrijke bijdrage aan de totstandkoming van dit 
proefschrift geleverd.
Prof.dr. Robert-jan van Geuns, en prof.dr. Ad Bogers, dank voor het willen plaatsnemen in 
de kleine commissie. Prof.dr. Jolanda van der Velden, beste Jolanda, eveneens dank voor het 
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plaats willen nemen in de kleine commissie, maar vooral ook inde goede samenwerking, en 
het voor mij inzichtelijker maken van HCM op een cellulair niveau.
Prof.dr. Rik Willems en prof.dr. Johan van Cleemput, beste Rik, dank je wel voor de zeer 
goede samenwerking. Ik ben blij dat jij mij destijds geadviseerd hebt om mijn horizon naar 
Rotterdam te verleggen, want zie alle goeds dat het gebracht heeft. Beste Johan, vanaf het 
begin van mijn co-schappen in UZL heb je mij kunnen overtuigen van dat ik met cardiologie 
goed gekozen had. Ik weet nog dat je mij een lijst met onderwerpen voor mijn stagewerk gaf, 
en daar stond toen bij: alternatieven voor alcohol ablatie. Ik wist niet dat ik er 6 jaar later nog 
steeds mee bezig zou zijn.
Mijn paranimfen, Admir Dedic en Max Liebregts; Admir, vanaf het begin in Rotterdam heb 
ik veel aan je gehad. Samen de congressen afstruinen was natuurlijk fantastisch, maar weet 
dat jij mij als een van de eerste de voordelen van het promoveren hebt laten zien. Ik kijk al 
uit naar jouw eigen promotie binnenkort. Max, dat we vanuit Leuven al een hechte vriend-
schap hebben, maakt het alleen maar mooier dat je destijds geprikkeld genoeg was om mee 
te helpen met het eerste project. Door jou is de samenwerking Rotterdam-Leuven uitgebreid 
met Nieuwegein, en dat heeft ons zeker geen windeieren gelegd, zoals de oplettende lezer wel 
gemerkt heeft. Mooi dat jouw proefschrift ook bijna klaar is.
Mijn kamergenoten: Jackie, Rene, Lotte, Claire en Stijn. Twee jaar lang hebben jullie mij goed 
geholpen, of het nu met echobeelden maken of importeren was, de eerste stappen in speckle 
tracking en onderzoek in het algemeen. Bedankt voor de fijne samenwerking. Later kwam 
Hannah daar ook bij, jij hebt het vaandel overgenomen van mij in Rotterdam, en dat doe je 
met verve. Heel veel succes!
Dank aan al mijn (oud-)collega’s in het Erasmus MC. In het bijzonder: Sing, je hebt mijn 
in het prille begin onder je hoede genomen en wegwijs gemaakt in de wereld van klinische 
wetenschap. Dank je wel. Nicolas, met dezelfde alma mater en muzieksmaak moest onze sa-
menwerking wel goed gaan. Ik heb veel van je geleerd en jouw drive en ambitie is besmettelijk. 
Verder nog Ken, Sakir, Marcel, Olivier, Jannet, Tamas, Maarten, Joost, Anne Mijn, Floris, 
Crista, Joella, Jonathan, Julio, Jin, Osama, Lara, Matthijs: thank you for your support and the 
good conversations we had! Ron van Domburg, bedankt voor alle hulp met de statistische 
problematiek, geniet van je pensioen binnenkort. Prof.dr. Jaap Deckers, dank je wel om deel 
te nemen aan de grote commissie, en dank je wel om mijn jaar in het MCL mogelijk te maken.
Onderzoek is ook samenwerken met andere centra; Jur ten Berg en Marcel Kofflard, dank 
je wel hiervoor. Jur, bedankt om ook deel te nemen aan de grote commissie.
Mijn collega’s van de interne geneeskunde, intensive care en cardiologie in het Maasstad 
ziekenhuis, dank voor de goede samenwerking en flexibiliteit als ik wat meer aandacht aan het 
afronden van mijn onderzoek wilde geven. Ik heb er twee mooie jaren gehad, en veel geleerd.
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Mijn vrienden: Bram, Gijs, Guus, Huib, Max, Kristof, Roeland, Steven, Steven en Wout, 
mannen van idefix, jullie zijn me heel dierbaar. We zien elkaar minder dan in Leuven, maar de 
kwaliteit van die momenten neemt enkel toe. Gijs, koffiepartner in crime; binnenkort jij ook 
in deze schoenen?
Een hele hele belangrijke rol in alle ondersteuning is natuurlijk weggelegd voor mijn familie, 
en dan in de eerste plek voor mijn ouders: Papa, Mama en Nen, jullie steun kan ik ècht niet 
in een dankwoord uitdrukken, want dat doet het sowieso te kort. Dankzij jullie heb ik altijd 
de mogelijkheid en vertrouwen gekregen om te doen wat ik wilde; maar af en toe was het 
heerlijk om naar Tilburg of Amersfoort te vluchten, of juist samen te sparren over van alles. 
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